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ABSTRACT 
 
 
The RecQ family of helicases has been termed the “Caretakers of the Genome,” 
and rightfully so. These proteins are highly conserved from bacteria to humans and 
have been implicated in functions from homologous recombinatorial repair to damage 
checkpoint response to telomere maintenance and more. Mutant genes of three of the 
human RecQ helicases lead to syndromes characterized by a high incidence of cancer, 
premature aging and early death. Despite their implications in several biological 
functions and importance to the integrity of the human genome and suppression of 
cancer, many aspects of the RecQ family structure and function remain unknown. To 
date, much is known about the catalytic function of the helicase domain and 
accompanying domains, but considerably less is known about the non-catalytic N-
terminus in these proteins, which, in many cases, including those human orthologs 
involved in disease, can make up about half of the total protein length. While 
experiments have been able to identify protein partners that interact with the N-terminal 
region, few are able to narrow the binding sites to minimally functional parts and fewer 
still describe any detail regarding the structural features of these binding areas. In fact, 
some reviews have generally described the N-terminus as “featureless,” a concept we 
challenge in our studies. 
Many of the N-termini of these RecQs have long been known to contain large 
stretches of acidic residues, a feature of intrinsically disordered regions. These 
xiii 
 
regions/proteins are rich in charged and polar residues, lack compactness that makes 
crystallography possible, and have flexible and dynamic conformations that are 
prevalent in “high specificity, low affinity” interactions. Disordered proteins are well-
known to be hot spots for protein/protein interactions and post-translational 
modifications, amongst other functions. Considering these facts, and recognizing the 
ties between these and what we know about the N-termini of the RecQs, we 
hypothesized that these proteins likely have long disordered termini. In Chapter 3, we 
confirm the presence of disorder at the Top3/Rmi1 binding site on Sgs1, the 
Saccharomyces cerevisiae RecQ helicase. We show that even in a disordered state, 
this binding region is not “featureless,” but in fact contains a transient alpha-helical 
molecular recognition element that is necessary to facilitate complex formation between 
Sgs1, Top3 and Rmi1. Loss of helical structure at this site leads to increased genomic 
instability and sensitivity to DNA damaging agents. Based on these results, we suggest 
that there are likely many more such elements in the N-terminus that that are important 
for other Sgs1 protein/protein interactions and provide an estimate for the number of 
interactions in this region.  
In Chapter 4, we evaluate the prevalence of disorder in a set of Chromatin 
Processes proteins in an effort to establish a role for disorder with regards to 
maintaining chromatin integrity. In our bioinformatics study, we found that disorder is 
overrepresented in the Chromatin Processes proteins, and that a major driving force for 
disorder in these proteins is protein/protein interaction and post-translational 
modification. We also show a biological connection to disorder and increased 
protein/protein interaction by investigating these parameters in the context of the DNA 
xiv 
 
damage checkpoint response and in complex formations. Mediators between highly 
structured kinases in the checkpoint were the most interactive proteins and over half of 
all predicted interaction sites occurred in disordered areas. Complexed proteins often 
contained one protein with a high number of disordered sites and a high number of 
predicted interactions, while the rest were considerably more ordered. 
Chapter 5 explores a Sgs1 interaction partner, Rmi1 and uses bioinformatics to 
design structurally-based point mutations in an effort to further elucidate Rmi1 function 
in yeast, which remains largely unknown outside of its enhancement of Top3/Sgs1 
catalytic function. Using AGADIR, which predicts alpha-helical structure and is 
particularly useful in our hands for guided-mutagenesis in disordered regions, we 
identified several point mutations that lead to Δrmi1 phenotypes or intermediate growth 
on hydroxyurea. We hypothesize that these mutants are important in maintaining Rmi1 
stability.  
Together, these studies suggest an important change in how the field 
approaches further studies into the RecQ helicases; traditional methods of primary 
sequence comparisons and crystal structures limit the study of disordered regions that 
are still functionally important. Future care should be given to consider the conservation 
of structure or structural elements in the RecQs over strict alignments when comparing 
functional regions between orthologs. Our studies also suggest that it is highly likely that 
structural motifs for important protein interactions in RecQs are being overlooked 
because they are not readily obvious using traditional methods. By understanding these 
motifs and the interactions they facilitate, we may be able to more easily identify 
polymorphisms in patients with genomically unstable conditions like cancer and, having 
xv 
 
better understood the biological process these structures facilitate, design drugs to 
counteract detrimental effects. 
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CHAPTER ONE: 
INTRODUCTION  
 
The RecQ family of helicases is highly conserved from bacteria to humans and 
functions at the interface of DNA replication and repair [1]. It is instrumental in 
maintaining genomic stability by directing homologous recombinatorial repair and 
preventing crossover events with non-sister chromatids during repair [2]. Some 
organisms like Saccharomyces cerevisiae and Schizosaccharomyces pombe contain 
only one RecQ helicase, while others can contain many--like the human WRN, BLM, 
RecQL4, RecQL1, and RecQL5 homologs--with a maximum of seven homologs 
discovered in Arabidopsis [3]. Homology arises from the similarity of the catalytic 
domains [4]; differences in protein primary sequence usually arises in extended N-
terminal regions of the protein, most of which are predicted to have an appreciable 
degree of protein disorder. 
 
Founding Member of the RecQ Family of Helicases 
 RecQ was first identified in E. coli as a mutated gene in the RecF pathway that 
imparts death-resistance in thymineless media, but makes the organism more sensitive 
to UV damage and results in a deficiency in recombination [5].  Purification efforts of the 
gene product found that the gene produces a helicase with 3’ to 5’ unwinding activity 
and DNA-dependent ATPase activity [6]. This activity is sensitive to ATP and Mg+2 
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levels, to the presence of single-stranded DNA (ssDNA) and is facilitated by the 
presence of single stranded DNA binding (SSB) protein and [7]. RecQ promotes and 
disrupts recombinatorial events, and thus is an important mediator in preventing 
aberrant recombination events (i.e. Between homeologous sequences) [8]. 
 
RecQ Helicase Structure and Function 
 Structurally, all RecQ family members contain a C-terminal helicase region with a 
DEAD/H motif that spans about 400 residues with seven sequence motifs common in 
most DNA and RNA helicases, including the Walker-A motif, which is required for the 
binding and hydrolysis of ATP [9]. Crystallography has revealed that the helicase region 
of RecQ consists of two lobes separated by a cleft lined with highly conserved amino 
acid residues that bind ATP and potentially ssDNA [10]. Single point mutations in and 
around this cleft in the human RecQ variant, BLM, have been found to lead to either full- 
or partial-loss-of-function of the helicase [11].  
 Many RecQ helicases also contain domains that are essential for the protein’s 
catalytic activity including a RecQ conserved (RQC) domain and a helicase and 
RNaseD C-terminal (HRDC) domain [12]. The RQC domain, while not present in all 
members, is exclusive to the RecQ family. The function of this domain is not fully 
understood, but it has been implicated as an important region for DNA binding and 
processing. Crystallography reveals that the region has two subdomains. One 
subdomain is crucial for Zn+2 binding via a set of four conserved cysteines; this domain 
was also found to be essential for proper BLM core folding and ATPase activity [13]. 
The second subdomain is a winged-helix domain, which has been shown to bind DNA 
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in the human WRN homolog [10, 14]. NMR structural analysis of this region in the 
human BLM protein reveals that it is comprised of 4 alpha helices and 4 beta strands 
with a flexible loop between the first and second helices not present in other RecQs, 
implying that the full functionality of this winged helix domain may vary between 
orthologs [15]. In WRN, this domain also contains a nucleolar targeting sequence [16].  
The functionality of the HRDC domain has been implicated through biophysical 
studies; the structure of this domain has been resolved via NMR and crystallography, 
and has been shown to resemble DNA binding domains from other helicase and DNA-
binding proteins [17, 18]. This domain in the S. cerevisiae ortholog was found to be 
comprised of 5 helices, and, since the hydrophobic residues responsible for packing 
these helices into a functional core are conserved, it is hypothesized that the structure is 
likely similar in other orthologs with this domain.  On the surface of this core are a series 
of positively-charged residues that can facilitate binding to negatively-charged DNA [17].  
The HRDC domain is required for dissolution of double Holliday junctions (dHJs) in BLM 
protein, and can bind DNA in the RecQ protein [18, 19]. 
A study has suggested that the RecQ helicases be divided into two classes, 
depending on the length of the protein and overall structure (Figure 1.1) [9].  One class, 
called the ‘long-form’ RecQ helicases, contains a large N-terminal stretches of acidic 
amino acids and/or extended C-terminal regions of poorly described function, or, in the 
case of WRN, an exonuclease domain.  Members of the RecQ family included in this 
class include BLM, WRN, Sgs1, D.m.BLM, and RecQL4.  The ‘short-form’ of RecQ 
helicases is missing this long N-terminal region but still contains the typical helicase 
domain and may contain the RQC and HRDC domains. An example of this class 
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includes E. coli RecQ.  Opresko et al suggests that the presence or absence of this 
additional protein sequence on either the N- or C-terminal end may reflect the nature of 
DNA substrate-binding specificities in the RecQ family; in general, E. coli RecQ is the 
least structurally complex member but preferentially binds the broadest number of DNA 
duplex types.  Sgs1, BLM and WRN, with their long stretches of additional sequence on 
both the N- and C-termini, tend to unwind mostly those DNA duplexes containing 
junctions, such as Y-structures and HJs [20]. It is probably more likely that the extended 
domains in the N-terminus are to serve as protein/protein interaction sites and 
modifications sites, as discussed at length below. 
 
 
Figure 1.1: Domain comparison of long- and short-form RecQ helicases. Data for 
H. sapiens sand S. cerevisiae come from genetic studies; C. albicans domains are 
estimated by a CD search on NCBI BLASTp. 
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RecQ Helicase in S. cerevisiae, Sgs1 
 Sgs1 is the only RecQ helicase in the budding yeast Saccharomyces cerevisiae; 
it contains 1447 amino acid residues with a helicase domain (residues 674-1017), an 
RQC domain (residues 1017-1085) and an HRDC domain (residues 1272-1351) [21]. 
Purification of residues 400-1268 (including the helicase and RQC domain) showed a 
protein able to hydrolyze ATP, but only in the presence of DNA substrates of various 
forms [22]. This fragment is able to bind DNA, with a preference for ssDNA over dsDNA, 
particularly forked substrates. This same fragment is capable of unwinding G4 
quadruplex structures [23]. Full-length Sgs1 is capable of binding Y-structure, ssDNA, 3’ 
overhang, 5’ overhang, HJs, and dsDNA. The binding of substrates with 5’ and 3’ 
overhangs was found to be similar, unlike the results found in the 400-1268 fragment. 
This implies that the N-terminal and C-terminal domains of the protein, including the 
HRDC and mostly undefined N-terminus, may facilitate the binding of a wider array of 
substrates  [24]. Like the founding family member, Sgs1 unwinds DNA in a 3’-5’ 
direction and requires ATP (and preferably, Mg+2) [22]. The rate of ATPase activity of 
Sgs1 is approximately 10 fold greater than RecQ and is inhibited by the presence of 
RPA, possibly as a function of competition between the two proteins for ssDNA [24]. 
The first 674 amino acids lack any well-defined or well-conserved domains, but do 
contain two extended regions of acidic residues (residues 400-474 and 510-596; [12]) 
that are present in other yeast homologs and in human BLM. Deletion of these regions 
can suppress Δtop3 slow growth like a Δsgs1 mutant, but are mostly like wildtype 
growth on hydroxyurea (HU) and methylmethanesulfonate (MMS), implying that there is 
6 
 
a separation of function in this region, though the specific function of these regions 
remains to be discovered [12]. 
  
Characterization of the Δsgs1 Phenotype 
Sgs1 was first classified by Gangloff et al. in 1994 during a search for 
suppressors of the slow-growth phenotype common to strains lacking Topoisomerase 3 
(Top3). The importance of Sgs1 in maintaining genomic stability is apparent as cells 
lacking Sgs1 show an increase in mitotic recombination in the form of interchromosomal 
homologous recombination, intrachromosomal excision recombination, and ectopic 
recombination [25, 26]. This recombination has been found to be improperly induced 
and concluded in Δsgs1 cell lines, as cells lacking Sgs1 have been found to have an 
increase in gross chromosomal rearrangements (GCRs), most notably in the form of 
translocation/deletions and telomere additions [27]. Meiotically, Δsgs1 cells are also 
abnormal, as an increased number of multichromatid molecules and an increase in 
homeologous recombination between non-identical sequences (though not homologous 
recombination) have been observed [25, 28, 29]. Cells lacking Sgs1 were found to 
undergo more synapsis in meiosis and have an increased number of crossing over 
events over wildtype cells [30].  Exposure of Δsgs1 cells to a diverse range of DNA 
damage has revealed several sensitivities, including UV light, hydroxyurea and MMS 
[31-33]. In addition to being sensitive to damage, sgs1Δ cells are overall unhealthy 
under normal conditions, and have an average life span only 40% that of wildtype cells.  
In older Δsgs1 cells, the nucleoli appear to age faster than wildtype cells as well [34]. 
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Role of Sgs1 in DNA Repair 
Catalytically, Sgs1 acts in many steps in DNA repair (Figure 2). At the beginning 
of double strand break processing, Sgs1 works in tandem with Dna2 and Exo1 to resect 
the ends of the break beyond the actions of the MRX complex, which is needed to 
produce a length of ssDNA long enough for Sgs1 to work on [35, 36]. Sgs1 is needed in 
order to achieve resection efficiency needed for further steps in the repair process; in 
cells missing Sgs1, only a fraction of cells are able to achieve the same degree of 
resection as wildtype cells [37]. The ends produced by Sgs1 and partners are then 
acted upon by Rad51, which is able to invade a homologous sequence and use it as a 
template for error-free recombinatorial repair. Sgs1 later works in conjunction with the 
topoisomerase Top3 and accessory protein Rmi1 to dissolve double dHJs in a non-
crossover event [38]. The result is a repaired gap that is error-free.  Loss of Sgs1 results 
in a greater percentage of these breaks being repaired in an alternative pathway that 
promotes crossing over by allowing HR to occur between homologous chromosomes 
rather than sister chromatids [39]. This may result in a loss of heterozygosity (LOH). In 
addition to properly processing ends in the first steps and resolving branched structures 
in the last steps of recombination, Sgs1 has been found to be instrumental in preventing 
homeologous recombination by acting as an anti-recombinase [27]. Because there is an 
increase in recombination between sequences of less than perfect homology in cells 
lacking Sgs1, it is hypothesized that Sgs1 plays a role in dismantling the d-loop created 
by Rad51 during strand invasion if the site of recombination on the donor strand is not 
homologous.  Though the method of divergent strand rejection is not fully known, it has 
been shown that mismatch repair proteins often drive the suppression of homeologous 
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recombination, and that helicase activity is likely a necessary addition to the proteins 
that mediate the dissolution [27, 29, 40]. 
Sgs1 has also been shown to be required in the intra-S-phase checkpoint that 
activates in response to stalled DNA replication.  This checkpoint is activated in part by 
the phosphorylation of Rad53, and cells that were lacking Sgs1 were found to have 
substantially lower amounts of phosphorylated Rad53 in S-phase under damaging 
conditions [41].  This implies that, in addition to its role in the physical repair of DNA 
damage, Sgs1 has been found to promote genome integrity by activating replication 
checkpoints that allow for sound repair of DNA damage and by stabilizing DNA 
polymerase ε at these stalled forks along with Mec1 [42-44]. Sgs1 has also been 
implicated in the phosphorylation of Rad53 in conjunction with Exo1 in G1 cells, and 
both are needed to induce a checkpoint delay at G1 in the presence of irradiating 
damage [45]. Sgs1 interaction with Rad53 has been confirmed via mutagenic co-
immunoprecipitation and is believed to be reliant on the phosphorylation of Sgs1 at 
residue T451; this gives support to Sgs1 working as an upstream element of Rad53 in 
the checkpoint cascade, a theory supported by the experiments in G1 cells described 
above [46]. 
Sgs1 has also been implicated in telomere maintenance, since in cells that lack 
telomerase (Δtlc1, the gene for telomerase RNA) loss of Sgs1 results in more rapid 
aging, an increased rate of telomere shortening, and arrest in G2/M phase. Though the 
exact nature of Sgs1’s role in telomere maintenance is still unknown, it is hypothesized 
that the phenotypes observed in Δtlc Δsgs1 cells may be the result of a) formation of 
DNA quadruplex structures at shortened telomere ends that require Sgs1 to be 
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resolved, b) the loss of S-phase checkpoint ability that results in the delayed G2/M 
arrest seen in these cells, c) Sgs1 playing an active, yet unknown role in telomerase-
independent repair pathways (ALT pathway) as it was shown to co-localize with a few 
proteins in this pathway, or a combination of the above [47]. Deletion of SGS1 in a 
Δest2 background (a catalytic subunit of telomerase) also saw rapid senescence 
beyond the deletion of EST2 alone. The double mutant also exhibited the increased rate 
of telomere loss found in the Δtlc1 Δsgs1 strain, and this loss was further exacerbated 
by the loss of another protein in the recombination pathway, Rad52. When senescent 
cells were allowed to recover via recombination-mediated telomere lengthening, Δsgs1 
Δest2 cells were unable to recover wildtype growth rates like the Δest2 mutant, implying 
a role for recombination and, subsequently, Sgs1 in telomere lengthening as a means of 
maintenance. Indeed, evaluation of the telomere structure of Δest2 versus Δest2 Δsgs1 
cells found that the former contained longer type II structures with Y’ elements followed 
by extended tracts of C1-3A/TG1-3 repeats, while the latter contained shorter type I 
structures, which contains tandem Y’ elements followed by a short tract of repeats [48].   
It has been shown that cells with type II structures tend to eventually reach a wildtype 
growth rate, while type I cells never recover wildtype growth. The findings imply a role 
for Sgs1 in suppressing preference for type I structure formation in the absence of 
telomerase [49, 50]. Part of Sgs1’s role in maintaining type II telomere structure  is due 
to a sumoylation event at K621, as mutation of this residue to an arginine incapable of 
being sumoylated shows the increase in type I telomere structure found in strains 
lacking telomerase and full-length Sgs1 [51]. 
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Recently, Sgs1 has also been implicated in single strand annealing (SSA) and 
strand exchange (SE) activities [52]. The region in the N-terminus spanning residues 
103-322 has been identified as the minimum domain for SSA and SE. In vivo assays 
have shown that in a sgs1 mutant lacking this region, recombination rates are elevated 
on par with a Δsgs1 strain, implicating this region in suppressing hyperrecombination, 
though the mechanism, and whether or not deletion of the domain inactivates the whole 
protein, is unknown. Loss of this region also leads to a greater amount of homeologous 
annealing in vivo, implying that the region is needed in order to reject duplex DNA 
formation between mismatched sequences. In vitro, a peptide containing this region can 
perform SA with homeologous DNA, but not SE, implying that the SE function of this 
region in Sgs1 is what is used to prevent aberrant recombination between 
nonhomologous sequences in vivo [52].  
 
               
Figure 1.2: Roles for STR complex in yeast. 
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N-Terminal and Putative N-terminal Sgs1 Protein/Protein Interactions 
While the catalytic core serves as the driver for the catalytic functions of Sgs1, 
only half of the protein is actually dedicated to helicase and helicase-related activities. 
The entire N-terminus of Sgs1 has no known activity outside of SE/SSA, but has been 
implicated in several protein/protein interactions; the diversity of these interacting 
proteins illustrates the numerous pathways and steps Sgs1 has been implicated in with 
regards to DNA repair (Figure 1.3). 
 
 
Figure 1.3: Putative domains of Sgs1 binding partners. Domains of selected 
partners important in DNA repair are present over whole protein, but are preferentially 
located in the N-terminus. 
 
 
Topoisomerase 2 (Top2) is a type II topoisomerase responsible for DNA 
decatenation events in both mitosis and meiosis; loss of Top2 can result in failure to 
complete mitosis and meiosis [53].   Because of this, Top2 has been described as the 
only essential topoisomerase in yeast.  Top2 has been shown to interact with full-length 
Sgs1 via co-immunoprecipitation, and yeast-two-hybrid assays have narrowed down the 
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minimal binding area for Top2 on Sgs1 from residues 466-746 and for Sgs1 on Top2 to 
residues 1109-1163, a potential leucine zipper [53, 54].   
Rad16 was also discovered via yeast two-hybrid to bind with the N-terminal 
region between residues 421-792 [55].    This region overlaps the Top2 binding domain. 
Rad 16 has been implicated in nucleotide excision repair (NER) in conjunction with 
Rad7; the two form the NEF4 complex, which is an ATP-dependent DNA damage 
sensor [56]. It is instrumental in repairing UV damage, specifically pyrimidine dimers 
induced in transcriptionally inactive DNA.  Yeast cells lacking Rad16 cannot perform 
NER but retain transcription-coupled repair [55].  Loss of Sgs1 in a Δrad16 background 
leads to increased sensitivity to UV damage, implying that the two proteins may work in 
redundant repair pathways, despite the fact that they interact physically. Because of this 
evidence of physical interaction, the authors of the primary study of the Sgs1/Rad16 
interaction suggest that in addition to the several functions of Sgs1 outlined above, it 
may also play a role in repairing specific DNA damage with Rad16, thus making Sgs1 
an important protein in the absence of Rad16 [55].  
Srs2 is a second 3’-5’ helicase present in S. cerevisiae. It has similarities to 
bacterial UvrD/Rep helicases and is implicated in early-stage recombinatorial regulation 
[57, 58]. Though Srs2 and Sgs1 have been shown to physically interact [59], the double 
mutant is inviable unless upstream recombination elements are also knocked out, 
implying that in the absence of these helicases, lethal recombination events occur. The 
area mapped to Sgs1 for Srs2 binding spans residues 422-722, an overlap with both the 
proposed domains for Top2 and Rad16 binding. It should be considered, also, that 
Sgs1, Srs2 and Mre11 form a complex, though the interaction between Sgs1 and Mre11 
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alone has not been elaborated on; it is possible that the binding region for Srs2 also 
houses a binding domain for Mre11 [59]. 
Deletion of Sgs1 contributes to a decrease in Rad53 phosphorylation [41]. 
Interaction with Sgs1 via Rad53’s FHA1 domain has been localized to Sgs1 residues 
292-661 [44, 60]. Mutagenesis of four phosphorylation sites in this regions to 
unphosphorylatable residues shows an approximately 50% reduction in Rad53 
activation [60]. The authors of the study suggest that interaction between Rad53 and 
Sgs1 at these sites in the acidic region is necessary for Rad53 recruitment and 
activation. 
Rpa70 binding to the acidic region of the N-terminus was recently identified using 
beta-galactosidase binding assays; the binding area is between residues 292-661 on 
Sgs1--the same binding site proposed for Rad53. Isothermal titration calorimetry further 
narrowed this region to residues 404-560 [46]. Interestingly, the presence of Rpa70 
controls the nuclease/helicase functions of another Sgs1 binding partner, Dna2. Dna2 
and Sgs1 work together in conjunction with Exo1 to resect DNA at double strand breaks 
[61]. The authors of the study found that the presence of RPA enhances 5’-3’ Dna2 
resection, and impairs 3’-5’ resection. It is possible, then, that the Rpa70 interaction on 
Sgs1 serves, in part, to regulate strand selection of the Dna2/Sgs1 interaction at breaks. 
Physical interaction between Sgs1 and Dna2 has been confirmed [61], but it is yet 
unknown where the interaction occurs on Sgs1. Considering the role of Rpa70 in 
resection activity of Sgs1/Dna2, and considering where Rpa70 has been confirmed to 
interact, it is plausible that the N-terminus contains a binding site for Dna2 as well. 
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The RTR Complex: RecQ Interaction with Top3 and Rmi1 
 The most well-studied interaction with Sgs1 involves the formation of a 
RecQ/Topoisomerase/Rmi protein (RTR) complex, an assembly that is conserved in 
many of the other RecQ homologs. In S.cerevisiae, Top3 and Rmi1 partner with Sgs1 to 
perform the catalytic functions necessary to facilitate early and late stage DNA repair. 
 
Role and Interaction of Topoisomerase III (Top3) in the RTR complex 
 Top3 was first purified and classified in a 1992 study as a type IA topoisomerase 
[62]. Strains lacking Top3 suffer from a slow-growth phenotype under normal conditions, 
hyperrecombination, inability to form asci, and an increased GCR rate [27, 63, 64]. 
Structurally, the yeast Top3 has not been solved, but as the human variety, Top3α,  is 
said to closely resemble the canonical topoisomerase IA structure, it stands to reason 
that S. cerevisiae Top3 likely contains the domains I-IV, Toprim, and acidic cluster 
found in other orthologs [65, 66].   Top3 is responsible for resolving negatively 
supercoiled DNA structures in the cell, and has been implicated in resolving 
recombination-dependent X-shaped molecules (HJs) in an Sgs1-dependent manner 
[67]. This topoisomerase dependency on RecQ function has also been seen in bacterial 
systems, as E. coli RecQ has been found to stimulate catenation of dsDNA via TopoIII 
[68].  The first yeast two-hybrid study implicated the first 282 amino acids of Sgs1 in 
Top3 binding [54], and the minimum functional binding area has been further narrowed 
down to the first 158 amino acid residues via co-immunoprecipitation and ELISA assay 
[69].  Yeast mutants lacking the N-terminal 158 residues of Sgs1 demonstrate 
hyperrecombination and a greater DNA damage sensitivity as compared to a Δtop3 
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mutant.  It has been hypothesized that the loss of the N-terminus results in a 
“hyperactive” Sgs1 helicase which introduces more chromosomal instability than a 
wildtype Sgs1 in this same background [70]. This effect is described by the authors as a 
“toxic effect” that is specific to a Sgs1 lacking the interaction domain for Top3 but still 
catalytically active. The nature of this toxic effect, however, is still unknown. The 
phenotype observed in these mutants can be overcome by increasing the concentration 
of Top3 in the cell or by fusing the Top3 open reading frame to the N-terminus of Sgs1 
[69, 71]; as Sgs1/Top3 interaction has been shown to be independent of DNA binding, it 
has been implied that Sgs1 may be responsible for recruiting Top3 to areas of DNA it 
needs to act upon [72].    
   
Role and Interaction of Rmi1 in the RTR Complex 
 Rmi1 was first discovered in a screen for genes that, like Sgs1, were required for 
viability of cells that lacked Mus81, with hopes that this would lead them to other 
candidates for genes in the Sgs1-Top3 pathway [73]. RMI1 deletion produced a 
synthetically lethal phenotype in a Δmus81 mutant that could be rescued when RAD51 
was also deleted; as this lethality could also be repeated in conjunction with deletion of 
several other genes with roles in replication fork restarting (RRM3, SLX1, SLX4, etc.), 
and that this lethality could also be rescued when genes responsible for homologous 
recombination were also deleted (RAD51, RAD52, RAD54), a role for Rmi1 in 
homologous recombination was proposed [74]. Strains lacking Rmi1 are slow-growing 
and sensitive to HU and MMS; these phenotypes could be suppressed by also deleting 
SGS1, similar to Δtop3.  Rmi1 strains are also genetically unstable; Δrmi1 strains have 
16 
 
an increased recombination rate over both wildtype and Δsgs1 cells. Rad52 foci are 
increased in response to a loss of Rmi1, implying that there is an increased rate of 
spontaneous damage in Δrmi1 cells that likely explains the elevated GCR rates [73, 74]. 
A role for Rmi1 in checkpoint response has been suggested as well, as Rad53 
phosphorylation is incomplete in the presence of HU or MMS when Rmi1 is absent [74].  
Rmi1 has been co-precipitated with both Top3 and Sgs1, but Sgs1/Rmi1 and 
Sgs1/Top3 interaction appears to require the third partner to bind stably [73, 75].   Rmi1 
has no known catalytic function, but has been implicated in binding  small amounts of 
DNA, particularly dHJs [76].  Rmi1 is a known enhancer of Top3 DNA relaxation and 
has been found to stimulate the decatenation of dHJs by Sgs1 and Top3, particularly at 
late stages of junction dissolution, a function retained in the human complex [24, 76, 
77]. Interestingly, yeast cells lacking Sgs1, Top3, or Sgs1 and Top3 have been found to 
retain DNA resection ability (albeit slow and inefficient compared to wildtype), but 
strains lacking Rmi1 lack the ability to resect at all, perhaps suggesting an important 
supporting role for Rmi1 in resection function both in the presence and absence of Sgs1 
[37].  Rmi1 may also play a role in sister chromatid cohesion in conjunction with Top3, 
as cells lacking either of these proteins show an increase in separated chromatids over 
wildtype cells [78]. Notably, Δsgs1 mutants did not appear to have a cohesion defect; 
the authors suggest that, because Δrad51 and Δsgs1 in conjunction with Δrmi1 and 
Δtop3 alleviated the cohesion defect, Rad51 and Sgs1 act upstream in a pathway that 
drives Top3 and Rmi1 to facilitate cohesion. 
 The structure of the yeast ortholog of Rmi1 is still unknown, but alignment of the 
human N-terminal portion of the protein best approximates the yeast structure. Human 
17 
 
Rmi1 contains a cluster of three alpha helices at the far N-terminus that are predicted to 
stabilize a central β-barrel structure containing an OB-fold [79]. This barrel affixes to 
Top3α in domain II, with the alpha helices facing away from the domain. From this 
barrel extends a 23-residue loop with no appreciable structure; this loop is believed to 
be a functional region for modulating Top3α activity by controlling the mechanistics of 
the catalytic “gate” of the topoisomerase, and is necessary for Top3α/Rmi1 interaction 
[65, 79]. Studies with the human Rmi1/Top3α found that this loop is needed for the 
enhancement of Top3α dissolution of dHJs and helps facilitate interaction between the 
two proteins, lending support to the gatekeeper model [79]. In human RTR, this process 
may be more complicated, as the Rmi1 protein is double the size of the yeast variety 
and the complex contains a fourth member, Rmi2, which binds to the C-terminal portion 
of the human Rmi1 protein and to RPA [79, 80]. Rmi1-/- models in mammalian systems 
reveal similar phenotypes to those found in yeast, as rmi1-/- mice stop developing in the 
embryonic stage due to a decrease in cell proliferation and decrease in replication and 
accumulate genomic instability in the form of aneuploidy and fragmented chromosomes 
[81].  
 
 RTR Complex Member in Humans: Rmi2 
 The human RTR complex contains a fourth member in Rmi2, a protein with no 
known homolog in yeast. Considering the fact that Rmi2 interaction in the complex is 
due at least in part to interaction with the C-terminal OB fold of Rmi1, which has no 
equivalent in yeast, it is unlikely that this protein exists at all in yeast, and could be a 
function of the more complex RecQ network in humans  [82]. Disrupting the interface 
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that is responsible for Rmi1/Rmi2 binding contributes to an increase in sister chromatid 
exchange (SCE) in human cells, a sign of genomic instability [82]. Deleting Rmi2 leads 
to an overall decrease in both Top3α and Rmi1 levels, sensitivity to MMS, and an 
increase in chromosome breaks [83]. The role for Rmi2, like the role for Rmi1, is still 
being fully discovered, but it has been suggested that Rmi2 is responsible for proper 
Rmi1 folding, RTR complex stability, and enhancement of dHJ dissolution via RTR [82, 
83]. 
 
RecQ Orthologs in Humans  
 Unlike yeast, humans have five known RecQs, [84], all with activity in different 
pathways, interactions with different proteins, and, in the case of three of the five, 
different syndromes that result from mutation in one of the RecQ genes. This part of the 
introduction will discuss the five human homologs, starting with the two not known to 
cause syndromes, and following with the clinically-relevant homologs. 
 
RecQL1 
 RecQL1 is the most robustly expressed of all of the RecQs in humans, and is 
most prevalent in the heart, lungs, skeletal muscles and kidney [85]. It is capable of 
unwinding forked substrates in an ATP-dependent manner and of single strand 
annealing in the absence of ATP [86]. Deficiency in RecQL1 has no known disease 
phenotype, but cells lacking the protein have decreased replication origin firing and 
replication fork rates. Since RecQL1 is recruited to origins at the G1/S border, it is 
reasonable to assume that the protein plays some role in modulating proper DNA 
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replication in vivo [87]. RecQL1 interacts with PARP1 [88], a protein implicated in 
responding to replication stress, and mutants lacking RecQL1 are sensitive to agents 
that impair replication via inhibition of topoisomerase activity. RecQL1 has the capability 
of restoring synthetically-created replication fork structures from regressed “chicken-
foot” structures, implying that the protein is needed to restore forks undergoing repair 
and restart proper replication [89]. Mouse fibroblast cells lacking RecQL1 also have 
increased sensitivity to IR damage, an increase in spontaneous γH2AX foci (an 
indicator of DNA damage), aneuploidy, and an increase in SCEs, all indicators of 
genomic instability [90]. 
  
RecQL5 
 The human RecQL5 gene locus encodes for three isomers, generated via 
alternative splicing. The α- and γ-isoforms are largely understudied, but a study into one 
of the Drosophila small-form isomers shows that it shares the catalytic characteristics of 
the other RecQs [91]. The small isomers, however, lack any nuclear localization signal, 
and are thus not present in the nucleus [92]. The sub-cellular localization of these 
isoforms and specific function has yet to be explained.  The most commonly-studied 
variant is RecQL5β, a 991 amino acid protein present in both the nucleus and 
cytoplasm. It is expressed in many different tissue types in appreciable amounts, with 
strong expression in the testis [92, 93]. Cells lines lacking RecQL5 are enriched in 
γH2AX and Rad51 foci, have an increased number of broken chromatids/chromosomes, 
tri- and quadriradials, and other aberrations, and are associated with an increase in HR-
mediated DSB repair [94]. While deletion of RecQL5 does not lead to an increase in 
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spontaneous SCEs, the deficient cells are campothecin (CPT)-sensitive and have an 
increase in SCEs when treated versus wildtype cell lines [95]. It is suggested that the 
cause of  RecQL5 CPT sensitivity is due to the inability of the cells to restart forks post-
treatment, leading to apoptosis [96]. RecQL5 is a 3’-5’ helicase found to interact with the 
MRN complex in vivo and in vitro. RecQL5 co-localizes with the complex at the site of 
DNA double strand breaks, and requires the complex in vivo for recruitment to damage. 
RecQL5 has been implicated in regulating MRN exonuclease activity by impeding 
resection of break ends [97]. The helicase also interacts with RNA polymerase II via its 
RPBI subunit; because the interaction occurs only when the mapped interaction site on 
RPBI is phosphorylated, and because this phosphorylation is indicative of transcript 
elongation, it has been proposed that RecQL5 also plays a role in transcription [98]. The 
most fully studied interaction is between Rad51 and RecQL5, where the interaction site 
of RecQL5 on Rad51 at the stretch between residues 654-725 is needed for RecQL5 
prevention of d-loop formation by displacing Rad51 on ssDNA [94, 99]. This prevention 
is believed to be an active mechanism for regulating Rad51 activity preventing HR in 
wildtype cells, a parallel function to the anti-recombinase function seen in Sgs1. While 
no known human disease is connected to RecQL5 mutation, RecQL5 deficient mice 
were found to be more prone to cancer than their wildtype counterparts, with 46% of 
those tested developing a cancer by 22 months of age [94]. The most common cancers 
in this study were lymphomas, and the most common solid tumor was lung 
adenocarcinoma. In a study of RecQ homolog levels in primary colorectal cancer, 
RecQL5 mRNA expression and protein levels were found to be reduced in tumors, 
particularly in those tissues described to be microsatellite instable [100]. Overall, this 
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implies that RecQL5 may be tumor-suppressing in the colon, so while there may not be 
a specific syndrome equated to mutant RecQL5, it is feasible that the protein levels are 
misregulated in other cancer types as well. 
 
RecQL4 
 RecQL4 displays the same ATPase and single strand annealing properties as 
other RecQs, but compared to some of the other human members, it is not particularly 
robust as a helicase since it is unable to efficiently unwind the diversity of DNA 
structures found from BLM or WRN protein [101, 102]. Unlike these other helicases, 
however, RecQL4 seems to be adept at unwinding long duplex DNA, suggesting a 
specialized biological function [103]. Structurally, RecQL4 is also remarkably different 
from other “long” human RecQs in that it does not contain the RQC or HRDC accessory 
domains typical of this family of proteins. Instead, it is the only member to feature a 
domain with similarities to S. cerevisiae Sld2, a protein necessary for proper DNA 
replication [104, 105].  The ortholog in Xenopus laevis, xRTS, has been found to be 
recruited to DNA early in replication initiation and deficient cells are delayed in DNA 
replication [104]. Drosophila RecQ4 also has replication defects, including loss of DNA 
polymerase alpha on chromatin and S-phase arrest; the Sld2 domain has been found to 
be necessary to rescue RecQ4 deficient cells from replication defects [106]. These 
findings suggest a role for RecQL4 in maintaining proper replication fidelity in the cell. 
Interestingly, RecQL4 has also been detected in the mitochondria and is necessary for 
proper mtDNA replication [106, 107]. RecQL4-deficient fibroblasts are sensitive to HU, 
CPT, and doxorubicin (DOX), but are not significantly sensitive to UV, IR, and cisplatin 
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damage. Since HU, CPT, and DOX are primarily harmful during S-phase, this further 
strengthens the suggestion that RecQL4 plays a functional role in replication (Figure 
1.4) [108] . A role for RecQL4 in telomere maintenance has also been proposed, since 
interaction with TRF2, a protein in this process, has been confirmed [109]. The authors 
of this study also found that RecQL4 associates with TRF1 foci at telomeres during S-
phase and deficient cell lines display greater telomere fragility than wildtype cells. What 
role RecQL4 actively plays at the telomeres, however, has yet to be discovered.  
 
 
Figure 1.4: Proposed roles for RecQL4. 
 
RecQL4 is predominantly expressed in the thymus and testis, with low-level 
expression also detected in the heart, brain, placenta, pancreas, small intestine, and 
colon; peak expression is detected in G1/S, consistent with a role in early replication 
[110]. Given the pattern of expression, it is unsurprising that RecQL4 deficient mice 
models have been found to have hypoplasia of the thymus; this finding perhaps 
explains the frequency of infections some patients of RecQL4-deficient syndromes 
incur. The same mice are also prone to embryonic growth retardation and death, low 
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birth weight, hair loss, skin lesions, sclerotic tails and premature greying, symptoms of 
aging, growth and skin problems similar to those seen in some human patients [111].  
Perhaps suggestive of the diversity of its suggested roles, humans deficient in RecQL4 
suffer from one of three syndromes: Rothmund-Thomson Syndrome (RTS), 
RAPADILINO syndrome, or Baller-Gerold syndrome. 
 Rothmund-Thomson syndrome was first described in 1868, by an 
ophthalmologist who observed children with poikiloderma and cataracts [112]. Patients 
with RTS can exhibit any of a myriad of symptoms, including short stature, bone 
deformations, poikiloderma, early aging, photosensitivity and neoplasia predisposition, 
particularly lymphomas and osteosarcomas; variability of symptoms between patients is 
often great, as indicated in several patient case studies where no two patients showed 
the same phenotype and no patient showed all of the possible symptoms associated 
with the syndrome (Figure 1.5) [112-115]. The mutation responsible for the disease 
varies from patient to patient, but all known mutations are exclusive to the helicase core 
and C-terminus of the protein [115]. RAPADILINO syndrome is characterized by radial 
deformations, patellae malformation/lack of formation, diarrhea, skeletal abnormalities 
including high or cleft palates, and short stature [116].  There are fewer than 20 reported 
cases of the syndrome as of 2009, but they are overwhelmingly occurring in Finland, 
implying the presence of a founder mutation. Cancer status is as high as 40% in 
patients with RAPADILINO, with osteosarcomas and lymphomas being the most 
common cancer types in the populations studied, particularly in those with dual A420 
and A463 deletion genotypes [115].  Baller-Gerold syndrome patients exhibit bone 
deformities similar to those seen in RAPADILINO, and have anomalies including cranial 
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malformations, imperforate anus, rectovaginal fistulas, poor prenatal growth, and mental 
retardation [117]. 
 
 
Figure 1.5: Rothmund-Thomson patients. The patient on the left shows the 
poikiloderma and bone malformations characteristic of the syndrome. The patient on the 
right shows a closer look at poikiloderma [118, 119]. 
 
 
WRN 
 The Werner’s helicase is much like other RecQ homologs in that it easily 
unwinds a diverse spectrum of DNA structures, including G4 quadruplex, bubbled 
duplex, 3’-overhang, synthetic x-junction, and forked duplexes; long-range unwinding is 
stimulated by the presence of RPA, which physically interacts with WRN [120, 121].  
However, it presents another original case with regards to human “long form” RecQs in 
that it contains a 3’-5’ exonuclease domain in the far N-terminus of the protein that is 
active particularly on forked DNA [122, 123]. Roles for WRN are summarized below 
(Figure 1.6). Phenotypically, cells which lack a functional WRN protein have a growth 
deficit, decreased survival rate, and sensitivity to HU, MMS, CPT and crosslinking 
agents [124-128]. A study with WRN-deficient mice found that embryos have a 
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decreased rate of survival versus wildtype mice; mice that survive embryogenesis show 
early evidence of myocardial fibrosis and higher incidence of cancer than mice that are 
wildtype or heterozygous at the WRN locus [129].  Cell lines derived from patients 
lacking WRN exhibit an increase in mutation rates over normal cell lines, especially in 
deletions [130]. Cells have an increased number of chromosome aberrations, including 
chromatid breaks and gaps in general and at fragile sites, both spontaneously and when 
treated with DNA-damaging agents.  These cells have an increase in DSBs as 
evidenced by an increased level in γH2AX phosphorylation, both in untreated cells and 
in cells arrested in replication by HU [131];  the authors of the study suggest that this 
may be due to increased PCNA dissociation from chromatin at stalled forks in these cell 
lines and subsequent fork collapse, as PCNA levels in chromatin fractions are reduced 
in HU-treated Werner’s syndrome cell lines. Whether this mechanism is true, however, 
remains unknown. WRN-deficient cells also have an increase in Rad51 foci, suggesting 
an increase in HR in these cell lines, possibly as a result of increased DSBs [131, 132].  
 Wildtype WRN protein interacts with a bevy of proteins from different biological 
pathways, suggesting a diverse role for both of its catalytic domains. The C-terminus of 
WRN interacts with the C-terminus of the oncoprotein p53, and WRN-deficient cells 
have been found to have a decrease in p53-mediated apoptosis and increase in 
senescence, implying a regulatory role for p53 with regards to WRN function [133, 134]. 
Indeed, p53 has been found to inhibit WRN exonuclease function, as well as helicase 
function on X-shaped junctions [135, 136].  
WRN co-localizes with Mre11 after replication fork arrest in mid- to late- S phase 
and syndromes that are deficient in members of the MRN (Mre11/Rad50/Nbs1) 
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complex, including Nijmegen breakage syndrome, have a decrease in WRN 
relocalization to nuclear foci, suggesting that WRN may be recruited to breaks via MRN 
and this recruitment is needed for proper DNA repair via HR [137]. Physical interaction 
with Nbs1 and WRN has been confirmed, and the two proteins co-localize in response 
to IR and mitomycin C [138]. In addition to possibly recruiting WRN to the site of breaks 
being initially processed by MRN, the complex has also been found to enhance the 
activity of WRN helicase function in vitro [138]. In support of WRN’s role in DSB repair 
via HR, WRN has also been found to co-localize with Rad51, Rad54, and Rad54b at 
sites of mitomycin C-induced damage [139]. 
In addition to being needed in HR-mediated DSB repair, WRN has been found to 
interact with, and unwind DNA intermediates from base excision repair (BER) [140]. 
This unwinding activity is regulated by Ape1, a protein active in BER that WRN 
physically interacts with. Ape1 inhibits the helicase function of WRN unless the complex 
is acted on by polβ; the suggested model for WRN’s role in BER is that Ape1 binds a 
lesion that requires BER, and recruits WRN to the lesion. Polβ “takes” the DNA from 
WRN-bound Ape1, and the now catalytically-active WRN helps stimulate polβ-driven 
DNA repair of the lesion. Though this model is yet unconfirmed, it is clear that WRN 
plays some role in efficient BER repair. 
WRN may also play a role in nucleotide-excision repair (NER) and base-excision 
repair (BER) as co-IPs have shown that the RQC domain of WRN interacts with NEIL1, 
a protein that repairs bases damaged by oxidation, and this interaction is most strong 
under conditions of oxidative stress. NEIL1 interaction inhibits both the exonuclease and 
helicase function of WRN, while WRN stimulates the glycosylase activity of NEIL1. The 
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exact role of WRN in NER is still unknown, but there is a significant increase in oxidative 
damage-derived base modifications in cells lacking WRN, and no additive increase in 
modification in cells lacking both NEIL1 and WRN, implying that NEIL1 and WRN work 
in the same NER pathway to prevent the persistence of damaged bases [141]. 
WRN’s role in non-homologous end-joining (NHEJ) has also been described, 
though no further investigation into this role has been conducted in the last decade.  It 
had been found that the N-terminus of WRN interacts physically with NHEJ protein 
Ku70, and the C-terminus interacts with Ku80 [142]. This interaction stimulates WRN 
exonuclease, but not helicase activity [142-144]. WRN also interacts with DNA-PKcs, 
which phosphorylates WRN in an unclear role and inhibits WRN helicase function in a 
manner that can be blocked by the Ku complex. It is suggested that WRN and DNA-
PKcs form a complex where WRN is inactive until it binds Ku-bound DNA, after which 
WRN’s helicase activity becomes active and helps process broken DNA ends for NHEJ 
[145]. The authors of this study also found interaction between DNA-PKcs and WRN is 
important at telomeric D-loops, as DNA-PKcs actually stimulates WRN helicase activity 
at telomeric D-loops. In vitro, DNA-PKcs also stimulates WRN D-loop dissolution in non-
telomeric regions, though it cannot stimulate WRN-mediated dissolution of forked DNA, 
HJs, or G-tailed substrates. In agreement with this role at telomeric D-loops, WRN 
deficient cells have shorter telomeric G-tails [146].  
A study in mice deficient for both WRN and Terc, which codes for telomerase 
RNA, also supports a role for WRN in telomere maintenance.  Mutant mice exhibited 
aging symptoms more readily than mice expressing WRN in a Terc deficient 
background.  Affected mice appeared to be normal in young adulthood, but began to 
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rapidly age shortly thereafter; these symptoms became more severe as subsequent 
generations ended up with shorter telomeres, implying that symptoms are due at least 
in part to insufficient telomere maintenance [147]. 
 
                              
 Figure 1.6: Proposed roles for WRN protein. 
 
The WRN protein is prone to modification, the most-studied of which is 
phosphorylation. Phosphorylation of the protein occurs in response to replication fork 
blocks, and both ATR and ATM kinases have been implicated in modification of the 
protein in the presence of HU-stalled forks [148]. Interaction with the Abl kinase, which 
is active in response to genotoxic stress, has been detected in peptides containing the 
exonuclease and helicase domains. Abl phosphorylates tyrosine on WRN in response 
to bleomycin, and this phosphorylation inhibits exonuclease and helicase activities  
[149]. Phosphorylation by an unknown kinase also occurs at residues S440 and S467 in 
response to bleomycin. These residues are not in a catalytic region, and thus have not 
yet been found to influence the catalytic activity of the protein, but phosphomutants at 
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these sites are unable to relocalize WRN to the nucleoli post-damage, and repair DSBs 
more slowly following etoposide treatment [146]. 
 
 
Figure 1.7: Werner's syndrome patient at various ages. Tracking of a Werner's 
patient show the normal aging to age 21, followed by rapid aging characteristic of the 
disease. Image from University of Washington. 
 
 
Given the wide range of pathways and modifications of WRN, it is perhaps 
unsurprising those patients with Werner’s Syndrome (WS) --who lack WRN-- have a 
range of symptoms that are the result of increased cell senescence and cancer-
susceptibility. WS patients are different from sufferers of other RecQ-related syndromes 
in that they live relatively healthy lives for approximately the first 20 years of life, but age 
quickly thereafter and become more prone to age-related disease at a younger-than-
expected ages, including bilateral cataracts, dermatological problems, premature 
greying/hair thinning, diabetes mellitus, hypogonadism, osteoporosis, premature 
atherosclerosis, and neoplasms (Figure 1.7) [150]. The mean age of first neoplasm in 
WS patients is 43 years, and patients have an excess in rare cancer types versus the 
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normal population, with an increase in soft-tissue sarcomas, osteosarcomas, and 
follicular thyroid carcinoma, amongst others [151]. These rare neoplasms are some of 
the most commonly encountered in the small patient pool, along with melanoma, 
meningioma and leukemia. The gross diversity of cancer types is perhaps reflective of 
the multiple pathways in which WRN is implicated. 
 
BLM 
 BLM was first identified as a RecQ Helicase in 1995, when cDNA mapping 
verified that it contained the motifs common to the RecQ family [152]. Analysis of the 
gene product of this cDNA also confirmed its ATP and 3’-5’ helicase activity present in 
the other family members [153]. Since then, many in vitro and in vivo studies of human 
BLM and other mammalian orthologs have tried to establish the role of BLM in 
maintaining genomic stability (Figure 1.8). Human and other mammalian cells lacking 
BLM have reduced survival in response to crosslinking agents, sensitivity to HU, MMS, 
etoposide, CPT, 4-NQO and UV-C irradiation, increased rates of homologous 
recombination resulting in non-crossovers, reduced NHEJ repair, and an increased 
numbers of SCEs [154-158].  Mice with mutant BLM have an increased rate in 
spontaneous tumor incidence, and this occurrence appears to be dosage-dependent, as 
homozygous mutants suffer they greatest occurrence, and heterozygous mice have a 
slightly elevated rate over wildtype mice [156]. Mitotic recombination in BLM-deficient 
mice was found to be increased in a separate study, and, as a result, an 18-fold 
increase in loss of heterozygosity (LOH) [159]. The effect of LOH became apparent in 
combination with APC-/+ mice, which become prone to intestinal cancer if they become 
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APC-/- through aberrant crossing over between homologous chromosomes rather than 
sister chromatids. These mutants lose the tumor-suppressing effects of APC; mice 
lacking BLM in this background accumulated cancers at a greater rate than mice with 
WT BLM [159]. Embryogenesis of BLM-deficient mice is also impaired, as these 
embryos are developmentally delayed and small compared to their WT counterparts. 
Red cell production in these mutants is also impaired, and mutant fibroblasts incur an 
increased number of SCEs compared to fibroblasts from WT embryos [160].  
 Protein levels of BLM peak in S-phase and persist through G2/M before 
decreasing dramatically in G1, where repair by NHEJ takes over [161-163]. BLM protein 
can be found all over the nucleus, but form foci in response to damage and has been 
shown to co-localize with RPA, PMLs, and the nucleolus [163]. BLM catalyzes the 
branch migration of recombination intermediates, including dHJs, and has affinity for X-
shaped DNA junctions, 3’-tailed duplex DNA, ssDNA, and G4 quadruplexes [153, 164-
166]. It is also capable of resecting DNA in concert with Dna2, a function which requires 
helicase ability, is regulated by RPA, and enhanced by MRN, which acts upstream of 
BLM to resect short tracts of DNA at breaks [167, 168]. BLM catalysis is perhaps the 
most closely related to S. cerevisiae Sgs1 as it also harbors an interaction with Top3(α) 
and Rmi1 in the far N-terminus and is found to co-localize with these proteins in vivo 
[169, 170]. This interaction enhances BLM unwinding of dHJs, but does not affect the 
rate of ATP hydrolysis by BLM. Even in the presence of synthetic substrates that do not 
require the DNA-relaxing activity of Top3α, BLM unwinding activity of this DNA is 
enhanced, implying that the binding event between proteins itself may have some sort 
of effect on BLM processivity [170, 171]. 
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 Like WRN and other long-form RecQ helicases, BLM has been shown to interact 
with a bevy of different proteins acting in different pathways, implying a diverse cellular 
role. BLM has been shown to localize to the telomeres in cells lacking telomerase, and 
FRET analysis confirms interaction between BLM and telomeric protein Trf2 [172].  The 
same study found that overexpression of BLM in telomerase-deficient cells has been 
shown to increase telomere DNA synthesis, dampening the telomere-shortening effect 
seen in the telomerase-defective strains. This result, paired with the fact that telomere 
defects and shortened telomeres increase in BLM-deficient cells, suggests a role for 
BLM in the alternative lengthening of telomeres (ALT) pathway and general telomere 
maintenance [161, 172]. 
 BLM has been detected in two large proteins complexes. The BRCA1-associated 
genome surveillance complex (BASC) contains Msh2, Msh6, Mlh1, ATM, BLM and the 
MRN complex proteins [173]. Co-localization between BRCA1 and BLM after HU 
exposure and partial co-localization after IR damage has been observed, implying this 
complex of proteins is needed to respond to DNA damage, but the functionality of this 
complex is yet unknown. BLM has also been found to work in complex with Top3α, 
RPA, Mlh1 and the Fanconi Anemia proteins FANCG, FANCC, FANCE, FANCF, and 
FANCA, and has been shown to co-localize and co-immunoprecipitate with FANCD2 
[157]. Cells lacking the Fanconi core complex show a decrease in subnuclear 
relocalization of BLM to γH2AX foci following interstrand crosslink damage; this co-
localization is driven by BLM phosphorylation, which is abolished when the FANC 
complex is absent. Cells derived from mice deficient in FANCD2 and both FANCD2 and 
BLM show equivalent sensitivity to crosslinking agents, suggesting a pathway overlap 
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for the proteins with regards to crosslink repair [174]. Deletion of both genes is not 
epistatic with regards to SCEs, however, suggesting that the overlap in FANC and BLM 
repair pathways are limited to certain types of regulation [174]. BLM has also been 
known to localize at ultrafine anaphase bridges and is proposed to be necessary for 
dissolving these bridges in anaphase to prevent chromosome fragmentation [175]. 
FANCD2 has also been detected on chromosomes during anaphase, and these 
ultrafine bridges were found to associate with FANCD2 spots, suggesting a role for the 
two proteins in faithful chromosome segregation [176]. While the exact relation between 
BLM and the FANC proteins has yet to be elucidated, it is clear that the interaction of 
these proteins is necessary for proper BLM response to DNA damage [157, 173]. 
 Protein-protein interactions have also been detected with other singular proteins. 
SPIDR, a scaffolding protein that co-localizes and binds to BLM in response to DNA 
damage is required to formation of BLM foci [177]. The oncoprotein p53 physically 
interacts with BLM residues 1-431 between its own residues 155-393, and the 
localization of BLM to PML bodies in the nucleus has been found to be dependent on 
p53 [178, 179].  BLM and p53 have also been shown to co-localize at the site of stalled 
DNA replication forks and cells lacking BLM have a decrease in p53 recruited to these 
forks, implying that BLM is needed for p53 transport to these stalls. Thus, both play a 
role in regulating the location of the other in the cell [180]. Yeast-two-hybrid analysis has 
mapped an interaction between BLM and MLH1 to the BLM C-terminus, but cells 
lacking BLM have no difference in mismatch repair versus WT cells, suggesting that the 
interaction is not due to a role in mismatch repair, but rather a yet undescribed more 
specific repair [181]. Co-localization of BLM, Top3α, and Rmi1 with the PICH helicase 
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on ultrafine anaphase DNA bridges has been detected, and these bridges, indicative of 
defective sister chromatid separation, are increased in cell lines lacking BLM. The role 
of BLM at these bridges is unknown, but may reflect the need for the protein at 
unresolved DNA replication structures [175]. 
 
                                   
                  Figure 1.8: Proposed roles for BLM protein. 
 
 
 Like WRN, BLM is subject to extensive post-translational modification. BLM has 
been found to be phosphorylated by ATM in response to IR damage and by Chk1 and 
Chk2 in response to HU damage [154, 182]. Phosphorylation of residue T99 is 
increased in response to CPT and HU-induced damage, and occurs in a DNA 
replication-dependent manner by ATM and ATR. It is believed that this phosphorylation 
regulates the association of BLM with Top3α; when phosphorylated, BLM association 
with Top3α and PML bodies decreases, and association with γH2AX at breaks 
increases. This function suggests a potential role for BLM as a signaling molecule 
independent of its function with Top3α [183]. Residue S144 is phosphorylated by SAC 
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kinase MPS1; modification peaks in G2/M, suggesting a role for this modification in 
mitosis. Indeed, mutant S144A cells do not properly delay in mitosis in response to 
nocodazole and have an increase in multinucleated cells. S144A cells also have an 
increase in chromosome instability as illustrated by a broad distribution of chromosome 
number/cell vs. WT [184]. In S-phase, S338 is phosphorylated in an effort to enhance 
interaction with the protein TopBP1, which maintains BLM levels in the cell through 
G2/M before residue K3 is ubiquitinated by Mib1 in G1 to facilitate degradation of BLM 
in an effort to favor NHEJ DNA repair over HR [185]. A second study suggests that not 
S338, but S304 mediates this interaction [186]. In either case, a phosphorylation event 
is necessary to mediate at least one protein/protein interaction in BLM. 
 In humans, deficiency in BLM protein results in Bloom’s syndrome, first described 
by dermatologist Dr. David Bloom when he described several patients with symptoms 
including telangiectatic erythema on the cheeks, nose, eyelid margins, lips, forehead, 
and ears, sun sensitivity, and stunted growth (Figure 1.9). Considering that some 
patients were related, he suggested that the disease has a genetic component [187, 
188]. Case studies into patients listed in the Bloom’s Syndrome Registry reveal that low 
birth weight at full term, café au lait spots, bone abnormalities, underdeveloped testes in 
males, irregular menses and early menopause in females, early onset diabetes (median 
age 24.8 years), high-pitched voices, and learning disabilities are also common 
symptoms [189, 190]. Of the 150 persons in the 1993 study, 118 had incidence of 
neoplasms; 86 of these were malignant, and mean age onset of these neoplasias was 
24.4 years. Leukemias tended to predominate in children, and carcinomas in adults; 
lymphomas were prevalent in both age groups. Immune deficiency is also reported in 
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most patients [190]. In a survey of 134 persons with Bloom’s Syndrome, 64 different 
mutations were found in 125 of them; 54 of these are premature stops, and 10 are 
missense mutations. Premature stops exist over the length of the protein from residue 
104 to 1283.  While there is no single mutation responsible for the disease, the most 
common mutation is the BLMAsh mutation, a frame shift mutation at tyrosine 736 and 
prevalent in the Ashkenazi Jewish population [191]. Bloom’s Syndrome is an autosomal 
recessive disease, suggesting a ¼ chance in inheritance from two carrier parents, but 
the observed rate in afflicted families is actually lower than this; the prevailing 
hypothesis is that BLM recessive homozygotes are prone to greater loss in 
embryogenesis, thus making the disease yet more rare and restricted to the 265 
reported registered cases as of 2009 [189]. While heterozygotes do not have Bloom’s 
Syndrome, it has been suggested that this genetic status results in an increased risk of 
cancer; a study of heterozygotes for BLMAsh found that they were twice as prone to 
colorectal cancer than those without the mutant allele [192]. However, a human study of 
Jewish individuals with colorectal cancer found no significant relationship between 
cancer incidence and BLMAsh heterozygosity [193]. A study in a functional BLM chimera 
in diploid yeast shows that non-Bloom’s causing loss-of-function mutants in 
heterozygotic carriers have HU sensitivity intermediate to the wildtype and loss-of-
function homozygotes [11]. This finding suggests that combination of a non-functional 
allele with a wildtype BLM allele could in fact impact cell survival in the presence of 
chronic DNA damage. This could have potential consequences for human patients with 
a heterozygotic loss-of-function BLM status, particularly with regards to long-term DNA 
damage (e.g. chemotherapy).   A frameshift mutation in a polyadenine tract in BLM in 
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genetically unstable cancers prone to microsatellite instability was also discovered 
[194], and intronic SNPs in Rmi1, Top3α, and BLM have all been found to be associated 
with increased risk of acute myelogenous leukemia/myelodysplastic syndrome and 
melanoma (Rmi1 and Top3α) and bladder cancer (BLM) [194, 195]. This suggests an 
importance for BLM in maintaining genomic stability in the body, and that a degree of 
haploinsuffciency may exist with regards to certain kinds of cancer. 
 
 
Figure 1.9: Patients with Bloom's syndrome. Patient on the left exhibits the classic 
facial telangiectasias of the disease. The middle and right patients exhibit the short 
stature of the disease. The middle patient grew to 138 cm in adulthood and the patient 
in the right photograph (147 cm) is next to his brother (183 cm), who does not have the 
disease. Photographs from Bloom’s syndrome registry, Weill Cornell Medical College.  
 
 
Intrinsically Disordered Proteins/Regions (IDP/Rs) 
As the RecQ helicases participate in a wide range of functions, and, as shown in 
the case of Sgs1, many of the protein/protein interactions that regulate these functions 
are N-terminal, it is perhaps striking that little research has been done in defining the 
structure of the first half of these proteins as has been done for the catalytic regions. It 
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is well-known that the N-termini of many of the long-form RecQs contain acidic domains 
and that they are home to both protein interaction and modification sites, but the termini 
have been described as being “featureless [196].” Classically, shape and folding was 
believed to be the cornerstone in understanding protein function, and the so-called 
"lock-and-key" models were used to describe the biochemistry behind most protein-
substrate interactions.  While secondary and tertiary structures are still indicators of 
protein function for many proteins, this somewhat stringent view of structural science is 
moot for a rising class of proteins and protein domains.  For many important proteins, 
including those used in cell cycle control, transcriptional and translational regulation, 
and protein phosphorylation, a low degree of even secondary structure is evident.  
These proteins are called "intrinsically disordered proteins (IDP)" or "natively unfolded" 
proteins [197]. 
 
Characteristics of IDPs 
Many IDPs are characterized by a high degree of flexibility, low hydrophobicity, 
little sequence complexity, a low degree of compactness, and a large net charge.  IDPs 
are generally rich in polar molecules (R, G, Q, E, S, P, K), two of which (P and G) have 
been shown to break secondary structures like alpha helices and beta sheets [197, 
198].  In general, they tend to lack large hydrophobic or aromatic residues, as well as 
residues that promote tertiary structure (i.e. through disulfide bonds). These proteins 
therefore lack the sequence complexity of a more structured protein as they are 
depleted in several amino acids (I, L, V, W, Y, F, C, N). Because of this specialized 
composition, disordered proteins tend to be highly soluble in water and are generally 
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more heat-soluble than ordered proteins [199]. Even within the disordered proteins, 
there are proposed “flavors” of protein, and the composition of the different flavors (V, 
C, and S) vary slightly from one another [200]; type C are more enriched in H, M, and A 
than the others, type S has the least amount of H, and type V contain the greatest 
percentage of inflexible residues C, F, I, and Y versus the other types of disordered 
proteins. Interestingly, the role of these classes tend to differ as well, with C-type 
containing the most protein modification sites,  S-type proteins being mostly protein-
protein interactors, and V-type being mostly ribosomal proteins, thus implying a role for 
primary structure in protein function [200, 201].  Secondary structure in these proteins is 
typically confined to short segments, often helical and transient.  As a whole, the 
“shape” of these proteins is classified as an ensemble of conformations which vary in 
their degree of transient secondary and tertiary structure.  The protein will continuously 
shift between different conformations, and it is from these conformations that protein 
function(s) can arise [202-206]. In general, these disordered regions and proteins are 
believed to exist within a “structural continuum” along with folded proteins, and can 
generally be described as being “molten globules,” collapsed structure with no firm 
tertiary structure but developed secondary structure that is in a relatively fixed position; 
“multi-domain proteins,” which have ordered domains tied together by disordered linkers 
(also referred to as “beads on a string”), and “intrinsic coils,” which are mostly unfolded 
and have little secondary structure, if any [202, 207]. For disordered regions within 
proteins that have clusters of defined, folded structure, functionally disordered regions 
may be very short, such as 4-8 residue linkers and transient helices; they could also be 
large, being 10% of the protein in consecutive residues or longer [200].  Given depletion 
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in aromatic and hydrophobic residues that result in the lack of a folded structure, 
traditional techniques like X-ray crystallography are not available to IDPs. As such, 
alternative techniques, including NMR spectroscopy, small angle x-ray scattering 
(SAXS), circular dichroism, infared spectroscopy and atomic force microscopy are 
employed in order to determine the ensemble-averaged structures obtained from 
disordered proteins.  
 
Prevalence of IDPs 
A high percentage of eukaryotic proteins contain regions that are predicted to 
have a long stretch (greater than 30 residues) of disorder; in S. cerevisiae, 50-60% of 
the proteome is predicted to have these disordered domains, nearly three times as 
many disordered regions as predicted in E. coli  [208]. Within the three kingdoms, these 
long stretches are predicted in 2% of Archea, 4.2% of Eubacteria, and 33% of 
Eukaryotic proteins.  In mammals, up to 25% of the total number of proteins is predicted 
to be composed of completely unfolded proteins, such as Securin, Calpastatin, and Tau 
[209, 210], which makes study of IDP function and characteristics an important topic  
[200].   
 
Thermodynamic Characteristics of IDPs 
If one were to visualize the energy profile of a folded protein graphically, it could 
generally be described as an energy landscape ranging from conformations with high 
energy, to an energy minimum of the folded state in the pit of the graphical 
representation (Figure 1.10). Unfolded proteins represent a dense population of 
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conformational possibilities--transition from one disordered conformation to another 
incurs little energy penalty [211]. In ordered proteins, however, the transition from 
unfolded to folded protein is stepwise, and the energy landscape is “funnel-like.” As the 
protein reaches conformations of ever decreasing free energy, the conformational 
possibilities become less dense, as reversal from a lower energy state incurs an 
entropic penalty much greater than those seen in the disordered ensemble. Thus, the 
structural possibilities for a folded protein decrease as the folds approach the local 
energy minima. Upon binding, disordered proteins lose a degree of entropy, particularly 
if they undergo an induced-folding event; appropriate enthalpy compensation from 
modifications like phosphorylation can also counteract entropy loss from folding. It has 
also been inferred through experiments with the disordered interaction between pKID 
and KIX proteins that IDPs may have a lower energy barrier to overcome than an 
order/order interaction, as it is easier for disordered proteins to reach transitional states 
in the binding reaction; this also lowers the need for high entropy loss compensation 
[197, 212-214].    
 
Functional Advantage of IDPs 
IDPs are great for transient interactions, but given their high prevalence, 
particularly in higher eukaryotes, benefits beyond the transient nature likely exist. 
Indeed, there are several theories to the benefits of a fully- or largely-disordered protein. 
One potential scenario is that an ordered protein of importance in several protein 
pathways (i.e. kinases) has several downstream partners with disordered regions [213]; 
this allows the kinase to bind several partners with one single structure. On the other 
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hand, a disordered protein/region may have many ordered partners that it can support 
along the length of the disorder. The shape of the protein may change differently based 
on the partner being bound (or may even stay disordered, forming a “fuzzy complex 
[215]”). Beyond this, even these same proteins can bind different partners in the same 
region, using small molecular recognition motifs (MoRFs) as docking points to 
specifically recognize each different partner. By nature of its extended conformation, 
disordered proteins may also allow for a much larger interaction area with its partner 
than a folded partner affords; indeed, a disordered protein may well surround some or 
all of an ordered protein [213, 216, 217]. Beyond this variety of binding events, termed 
“promiscuous binding [210],” disordered proteins/regions also provide open access to 
post-translational modification of residues, can serve as flexible linkers that modulate 
the distance/position between two ordered domains, can be a stimulus for protein 
degradation (for transient protein expression), can contribute to molecular assemblies of 
proteins into large complexes, and can act as an area of rapid evolution that will not 
disrupt a protein’s catalytic or structural function (Figure 1.11)  [200, 217-219]. A study 
into the putative roles and advantages of IDPs in yeast Chromatin Processes proteins 
can be found in chapter 4 of this dissertation. 
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Figure 1.10: Free energy of proteins. Unfolded proteins tend to have high free energy 
that reaches no minimum energy conformation, while ordered proteins have a low-
energy conformation termed "native." Proteins with small degrees of secondary 
structure vary between the energy extremes [220]. 
 
 
 
 
Figure 1.11: Potential roles of disorder in protein binding. Adapted from Dunker et 
al, 2002 [219]. 
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Evolutionary Advantage of IDPs 
IDPs present an interesting case in the study of the evolution of proteins. There 
are three definitions of structural conservation with regards to IDPs: flexible disorder, 
which conserves the disorder in orthologs but not the primary sequence, constrained 
disorder, which conserves both the disorder and the primary sequence, and non-
conserved disorder [221]. Specific examples of flexible disorder evolution have been 
investigated where dynamic properties of disordered regions like linkers are conserved 
between orthologs, but primary sequence alignment is poor [222].  As such, it is 
important to consider evaluation beyond primary sequence alignments with regards to 
these regions; the different levels of disorder conservation are prevalent in different cell 
functions, with flexible disorder being most enriched in cell signaling and regulatory 
proteins and constrained disorder being most prevalent in proteins involving ribosome 
biogenesis, RNA binding, and protein folding [221]. Thus, the degree of primary 
sequence conservation may or may not be an important tool depending on the function 
of a group of orthologs. Also, while primary sequence in a great deal of IDPs tends to be 
poorly conserved in comparison to ordered proteins, a large percentage of them tend to 
conserve overall chemical composition; this allows a certain degree of flexibility in these 
regions with regards to acquisition of mutations and indels in these regions; function of 
these regions may still be retained if the mutagenesis does not affect overall chemistry 
[223, 224]. Indeed, long indels in homologous eukaryotic proteins have been confined 
mostly to the termini and disordered regions of the protein, and further disorder usually 
arises from disordered areas, which can more easily tolerate the modification of 
sequence [225, 226]. Conservation of disordered regions is particularly important with 
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regards to areas of post-translational modification, and the density of phosphosites in a 
protein highly correlates with disorder conservation (and less so with amino acid 
conservation) [221].  
With regards to evolutionary time,  it has been suggested that disorder tends to 
evolve more quickly than ordered regions [227]. An investigation into the evolution of 
disordered and ordered protein sets found that disordered proteins are generally more 
tolerant of evolution than ordered proteins, and evolution of individual residues tolerates 
a broader range of substitutions. Interestingly, this is not true of all residues in disorder; 
glutamine and asparagine are more prone to change in order than disorder, and 
tryptophan and tyrosine are often highly conserved in disordered domains [228]. 
Because protein/protein interaction events are also often driven by MoRFs that are not 
large, folded structures, interactions between partner proteins can be conserved so long 
as the MoRF remains, allowing for greater evolutionary change in the areas surrounding 
the MoRF [223]. It should be unsurprising, then, that disorder is more prevalent in 
eukaryotes than prokaryotes; over evolutionary time, disorder present in prokaryotes 
can add on more disorder to accommodate for further protein function in higher 
organisms. Indeed, length of disorder very closely correlates with the super-kingdoms, 
with eukaryota exhibiting much larger percentages of proteins with 80 or more 
consecutive residues in a disordered region than prokaryota and archea [229]. 
 
Examples of Intrinsic Disorder 
The oncoprotein p53 has been shown to have disordered N- and C-termini that 
modulate several protein-protein interactions and house the majority of the protein’s 
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PTMs, including acetylation, phosphorylation, and methylation events [230]. p53 is 
modulated by Mdm2 via its disordered transcription activation domain; binding regulates 
p53 interaction with transcriptional factors and targets p53 for destruction. As proper 
p53 function is important for suppressing cancer, the impact of mutated disordered 
regions on the ability of p53 to regulate downstream elements is in ongoing 
investigation [231]. Mutation of the disordered domain in the p53 transactivation domain 
showed that a simple P27A substitution increased binding to E3 ligase Mdm2, a result 
that lead to lowered expression of p53 target genes; this clearly exhibits the need for a 
degree of conserved disorder in proteins like p53 [232]. 
Tau protein in mammalian brain cells is a microtubule-associated protein that has 
been detected in neurofibrillary tangles in the brains of Alzheimer’s Disease (AD) 
patients. In the normal brain, Tau protein is mostly a random coil; Tau has been found 
to be abnormally hyperphosphorylated in AD cases, and this modified protein is more 
prone to a stiffer, more partially folded conformation that tends to form the observed 
tangles [233-235]. Though it is currently unknown what mechanism this aggregation 
plays in AD onset and progression (if any), it remains a hallmark sign of the disease and 
the advancement of dementia in AD has been highly correlated with the degree of 
tangles present [236]. 
In yeast, ADR1, a regulator of alcohol dehydrogenase ADH2, contains a DNA-
binding domain with an N-terminal disordered accessory domain and two zinc finger 
domains; overall, the unbound protein resembles a “beads on a string” model, where 
the two structured zinc finger domains lie on the disordered “string” that makes up the 
rest of the domain. Upon DNA binding, the region undergoes more extensive folding, 
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and the whole domain becomes structured. It is hypothesized that this increased folding 
around the fingers may increase the affinity of the region for DNA and is a good 
example of functional disorder in transcriptional regulation [237]. 
 
Disorder in S. cerevisiae 
Studies in the S. cerevisiae proteome have estimated the percentage of proteins 
containing at least 30 consecutive disordered residues is between 31-54%, at least 50 
consecutive disordered residues is between 19-30%, and wholly disordered proteins are 
up to 6% of the total proteome [209, 238]. With regards to the types of protein in the 
yeast genome that contain disorder, proteins are often found in the nucleus and are 
associated with transcription, protein modification (kinases), and binding activity, 
including DNA binding [238]. Disorder was also found to be a characteristic of “hub” 
proteins in yeast--proteins that act as a docker of several different partner proteins. 
Yeast hubs are enriched in wholly disordered proteins and depleted in ordered proteins, 
with hubs involved in protein binding being most strongly associated with predicted 
disorder, supporting the hypothesis that they are acting as “promiscuous binders” of 
several downstream protein elements; a study in promiscuous transcriptional hubs show 
that this specific class of protein reflects this model [239, 240].  
 
Disorder in RecQ Helicases 
Though there has been talk about the acidic domains of Sgs1 and BLM, implying 
consideration of the role of disorder in the RecQ family, the topic remains overall 
understudied. Using IUPRED prediction software [241], it is evident that the long-form 
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RecQs in humans and the yeast Sgs1 all contain a degree of long disorder in the N-
terminus (Figure 1.12). Given that the RecQ helicases function in several different 
pathways as described above, and are subject to a wide array of protein/protein 
interactions and post-translational modifications in these N-termini, and, since these are 
major function of disordered proteins, disorder and other structural study in the RecQ 
helicases require more attention going forward. Thinking about the RecQs with regard 
to disorder, both flexible and non-conserved rather than traditional primary sequence 
alignments could potentially help elucidate some of the questions still surrounding these 
proteins. Chapter 3 reports a study we conducted on the N-terminal region of Sgs1 at 
the Top3 binding site, confirming predictions that this area is in fact, disordered. It is 
suggested, then, that disorder be taken into consideration when studying the RecQ 
proteins and their binding partner interactions. While NMR is the basis for study of 
disorder in that chapter, chapter 5 suggests a method for using site-directed 
mutagenesis as a means for targeting MoRFs in otherwise disordered regions. This can 
allow for the identification of important small/transient structure in these areas that may 
help mediate protein function and stability. Indeed, helical prediction of the first 250 
residues of BLM using a bioinformatics tool for predicting alpha-helical structure,  Agadir 
[242], reveals several putative helical regions that, based on our findings with Sgs1, 
may be transient helices facilitating the interaction of BLM with Top3α, Rmi1 and Rmi2 
(Figure 1.13). Further study into this region may highlight areas of interest to look for 
SNPs in the general population that may contribute to an understanding of increased 
cancer risk.  
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Figure 1.12: IUPRED predictions for BLM, WRN, RECQL4, and Sgs1. IUPRED [241] 
profiles show that long-form RecQs in humans have some degree of predicted disorder, 
particularly in protein/protein interaction domains. 
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Figure 1.13: Agadir profile of BLM protein. The Agadir [242] profile of the first 250 
residues of the BLM protein (Top3/Rmi1/Rmi2 interaction) reveals several putative 
areas of predicted alpha-helical structure for site-directed mutagenesis-based structural 
studies. 
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CHAPTER 2: 
MATERIALS AND METHODS 
 
Note to the reader: Experiment-specific methods are included in the chapter they apply 
to. Please refer to those chapters for these protocols. Below are detailed protocols for 
techniques used for several different experiments or for protocols only briefly outlined in 
publications. 
 
Site-Directed Mutagenesis 
          Protocol was adapted from the Agilent Technologies protocol manual for Quick 
Change Mutagenesis. Primer numbers used in all site-directed mutagenesis 
experiments in the table 2.1 below and were designed as 35-mers with the mutation of 
interest in the center of the primer; the codon choice was determined by the least 
amount of nucleotide changes that could be made from original sequence to mutant, 
with consideration for codon commonality. All mutagenesis was conducted with a twelve 
and a half minute extension time at 68°C 
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Table 2.1: Site-Directed Mutagenesis Primer List  
Primer Name Gene Mutation Sequence 
1877-sgs1-F30P-F SGS1 F30P AGACAAAGATTTCGTACCCCA
GGCTATCCAAAAGC 
1878-sgs1-F30P-R SGS1 F30P GCTTTTGGATAGCCTGGGGTA
CGAAATCTTTGTCT 
1879-sgs1-N80STOP-F SGS1 Stop at residue 
80 
TGCTACGAAACAACATTAAGT
CATGCAAACTTTGT 
1880-sgs1-N80STOP-R SGS1 Stop at residue 
80 
ACAAAGTTTGCATGACTTAATG
TTGTTTCGTAGCA 
1881-sgs1-L93P-F SGS1 L93P GAACGATACAGAATGGCTCTC
GTACACTGCCACAT 
1882-sgs1-L93P-R SGS1 L93P ATGTGGCAGTGTACGAGGGC
CATTCTGTATCGTTC 
1923-W92PF SGS1 W92P GTCGAACGATACAGAACCGCC
CTCGTACACTGCCA 
1924-W92PR SGS1 W92P TGGCAGTGTACGAGGGCGGT
TCTGTATCGTTCGAC 
1987-K26P-F  SGS1 K26P GACTTTACAGGAAGACCCAGA
TTTCGTATTCCAGG 
1988-K26P-R  SGS1 K26P CCTGGAATACGAAATCTGGGT
CTTCCTGTAAAGTC 
1989-Q34P-F  SGS1 Q34P CGTATTCCAGGCTATCCCAAA
GCACATCGCGAACA 
1990-Q34P-R  SGS1 Q34P TGTTCGCGATGTGCTTTGGGA
TAGCCTGGAATACG 
2014-Sgs1V29PF SGS1 V29P GGAAGACAAAGATTTCCCATT
CCAGGCTATCCAAA 
2015-Sgs1V29PR SGS1 V29P TTTGGATAGCCTGGAATGGGA
AATCTTTGTCTTCC 
2016-Sgs1I33PF SGS1 I33P TTTCGTATTCCAGGCTCCCCA
AAAGCACATCGCGA 
2017-Sgs1I33PR SGS1 I33P TCGCGATGTGCTTTTGGGGAG
CCTGGAATACGAAA 
2061- Sgs1K17P F SGS1 K17P GGAGCACAAATGGTTAccGGA
AACGGCGACTTTAC 
2062- Sgs1K17P R SGS1 K17P GTAAAGTCGCCGTTTCCggTAA
CCATTTGTGCTCC 
2063- Sgs1 T21P F SGS1 T21P GTTAAAGGAAACGGCGcCTTT
ACAGGAAGACAAAG 
2064-Sgs1 T21P R SGS1 T21P CTTTGTCTTCCTGTAAAGgCGC
CGTTTCCTTTAAC 
2065-Sgs1 D25P F SGS1 D25P GGCGACTTTACAGGAAccCAA
AGATTTCGTATTCC 
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Table 2.1: Site-Directed Mutagenesis Primer List (continued) 
    
Primer Name Gene Mutation Sequence 
2066-Sgs1D25P R SGS1 D25P GGAATACGAAATCTTTGggTTC
CTGTAAAGTCGCC 
2067-Sgs1 I37P F SGS1 I37P GGCTATCCAAAAGCACccCGC
GAACAAAAGGCCTA 
2068-Sgs1 I37P R SGS1 I37P TAGGCCTTTTGTTCGCGggGT
GCTTTTGGATAGCC 
2069-Sgs1T61P F SGS1 T61P ATGTGGACCAGGAACAcCAAA
CTTTATAACCAGCA 
2070-Sgs1T61P R SGS1 T61P TGCTGGTTATAAAGTTTGgTGT
TCCTGGTCCACAT 
2098-Sgs1D25A F SGS1 D25A GGCGACTTTACAGGAAGcCAA
AGATTTCGTATTCC 
2099-Sgs1D25A R SGS1 D25A GGAATACGAAATCTTTGgCTTC
CTGTAAAGTCGCC 
2100-Sgs1D25K F SGS1 D25K GGCGACTTTACAGGAAaAgAA
AGATTTCGTATTCC 
2101-Sgs1D25K R SGS1 D25K GGAATACGAAATCTTTcTtTTCC
TGTAAAGTCGCC 
2102-Sgs1I33A F SGS1 I33A TTTCGTATTCCAGGCTgcCCAA
AAGCACATCGCGA 
2103-Sgs1I33A R SGS1 I33A TCGCGATGTGCTTTTGGgcAG
CCTGGAATACGAAA 
2104-Sgs1I33K F SGS1 I33K TTTCGTATTCCAGGCTAAACAA
AAGCACATCGCGA 
2105-Sgs1I33K R SGS1 I33K TCGCGATGTGCTTTTGTTTAG
CCTGGAATACGAAA 
2273-Sgs1 L9P F SGS1 L9P GAAGCCGTCACATAACccAAG
AAGGGAGCACAAAT 
2274-Sgs1 L9P R SGS1 L9P ATTTGTGCTCCCTTCTTggGTT
ATGTGACGGCTTC 
2275-Sgs1H13P F SGS1 H13P TAACTTAAGAAGGGAGCcCAA
ATGGTTAAAGGAAA 
2276-Sgs1H13P R SGS1 H13P TTTCCTTTAACCATTTGgGCTC
CCTTCTTAAGTTA 
2307-W15P F Sgs1 SGS1 W15P AAGAAGGGAGCACAAAccgTTA
AAGGAAACGGCGA 
2308-W15P R Sgs1 SGS1 W15P TCGCCGTTTCCTTTAAcggTTT
GTGCTCCCTTCTT 
2607-Rmi1 F63P F RMI1 F63P AGACAGAGAACTGTTGccCCA
GGTGTTGATGGTAG 
2608-Rmi1 F63P R RMI1 F63P CTACCATCAACACCTGGggCA
ACAGTTCTCTGTCT 
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Table 2.1: Site-Directed Mutagenesis Primer List (continued) 
Primer Name Gene Mutation Sequence 
2610-Rmi1 P88A R RMI1 P88A CCACTTTCTGTTTTTTCGcATC
CAGCTTGGTTTTT 
2611-Rmi1 E220P F RMI1 E220P ATTTTGTGATTATTTGccATCTA
AATTACAACGTG 
2612-Rmi1 E220P R RMI1 E220P CACGTTGTAATTTAGATggCAA
ATAATCACAAAAT 
2694-Rmi1 A128P F RMI1 A128P GGCGGATAACAACTGCcCCAA
GGAAAATAATAGCA 
2695-Rmi1 A128P R RMI1 A128P TGCTATTATTTTCCTTGGgGCA
GTTGTTATCCGCC 
2712-rmi1A139P F RMI1 A139P CAACAATAATAGCAGTcCCGC
CAAGAATAAAGCAG 
2713-rmi1A139P R RMI1 A139P CTGCTTTATTCTTGGCGGgACT
GCTATTATTGTTG 
2716-rmi1Y218P F RMI1 Y218P TCAGAAATTTTGTGATccTTTG
GAATCTAAATTAC 
2717-rmi1Y218P R RMI1 Y218P GTAATTTAGATTCCAAAggATC
ACAAAATTTCTGA 
3109-Rmi1F63K F RMI1 F63K AGACAGAGAACTGTTGaaaCA
GGTGTTGATGGTAG 
3110-Rmi1F63K R RMI1 F63K CTACCATCAACACCTGtttCAAC
AGTTCTCTGTCT 
3111-Rmi1Y218K F RMI1 Y218K TCAGAAATTTTGTGATaAaTTG
GAATCTAAATTAC 
3112-Rmi1Y218K R RMI1 Y218K GTAATTTAGATTCCAAtTtATCA
CAAAATTTCTGA 
3113-Rmi1L7P F RMI1 L7P ATGTCTTTTTCATCTATCccAaa
ACAGGATATCACAGATG 
3114-Rmi1L7P R RMI1 L7P CATCTGTGATATCCTGTttTggG
ATAGATGAAAAAGACAT 
3115-Rmi1 Y35P F RMI1 Y35P GATTGTTTTCAGAGCTccCCAA
AATGAACCTTGGT 
3116-Rmi1 Y35P R RMI1 Y35P ACCAAGGTTCATTTTGGggAGC
TCTGAAAACAATC 
 
All mutagenic PCRs were transformed into E. coli 5α cells via electroporation and plated 
on selective media (all mutations except Sgs1 N1-80 STOP were selected on LB-
Ampicillin plates; Sgs1N1-80 was selected on LB-Kanamycin). Colonies were selected 
from the overnight growth and plasmid was prepped according to the protocol below. 
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Mutants were sequenced via MWG operon and results were evaluated via Sequencher 
software for integration of the mutation of interest. 
 
Plasmid Isolation from Bacteria 
         All plasmid minipreps were prepared using the QIAprep miniprep kits from 
QIAGEN. Briefly, 5 ml of overnight bacterial culture was spun down at 3400 rpm for 10 
min; the pellet was resuspended in QIAGEN buffer P1, followed by lysis with buffer P2, 
and protein precipitation with buffer N3. The solution was then spun at 14 000 rpm for 
10 min, and the supernatant was harvested. The plasmid was purified on the kit-
provided column and eluted in 10 mM Tris, pH 8. 
 
Gross Chromosomal Rearrangement (GCR) Assay 
           All GCRs were done in strain KHSY1338 (ura3-52, leu2Δ1, trp1Δ63, his3Δ200, 
lys2ΔBgl, hom3-10, ade2Δ1, ade8, YEL069C::URA3, sgs1::HIS3). The assay surveys 
for the loss of both URA3 and CAN1 genes and is indicative of a high level of genomic 
instability. Five to ten colonies of KHSY1338 transformed with a mutant plasmid of 
choice were grown in synthetic media lacking leucine (SC-LEU) . From these cultures, a 
dilution was plated on SC-LEU and grown to obtain a viable cell count. The remaining 
culture was pelleted, resuspended in water, and plated on GCR plates containing 
canavanine and 5-FOA as previously described. [1].  
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Trichloroacetic Acid (TCA) Extraction 
           Protocol was adapted from the protocol first described in Wright et al, 1989 [2]. 
The yeast strain of interest was grown to saturation in liquid media overnight; from this 
culture, a culture is set up at OD600= 0.2 and grown to desired OD (varied from 0.5 to 
1.0, depending on protein being probed). Five ODs of the culture was then spun and the 
supernatant removed. The pellet was washed with water before being spun down again. 
The pellet was then resuspended in 20% TCA and  acid-washed glass beads and 
beaten in a bead beater. The lysate was drawn off, and the beads were washed with  
TCA; this wash was pooled with the lysate. The sample was then spun down and the 
pellet was resuspended in laemmli buffer and pH-adjusted with 2M Tris pH 8. The 
sample was boiled, and then used in SDS-PAGE. 
 
SDS-PAGE and Western Blot Analysis 
           Protocol was adapted from protocols in Schagger et al, 1987 and Towbin et al [3, 
4]. Samples were loaded into an SDS-PAGE gel with 10%-18% polyacrylamide and run 
in tris-glycine buffer (250 mM Tris, 1.9 M glycine, 1% SDS) at 170 V until good 
resolution of a protein band can be expected as determined by the protein marker. The 
proteins were then transferred to a PVDF membrane in 1x transfer buffer (250 mM Tris, 
1.9 M glycine, 20% methanol) for 1 hour and 15 minutes at 300 mV in a Hoefer semi-dry 
transfer machine. The membrane was then blocked overnight in 5% milk plus 1x TBST 
(150 mM NaCl, 10 mM Tris, 0.1% Triton-X100, pH 7.6). Primary antibody was added to 
5 ml of the same milk solution and the blot was incubated for 1 hour at room 
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temperature. Following incubation, the blot was washed three times with TBST for 30 
min. Secondary antibody (conjugated to horseradish peroxidase) was added to 5 ml 
milk solution and incubated for 1 hr at 4°C. The blot was then washed three times with 
TBST at 4°C for 30 min. The blot was then probed with 1:1 Amersham ECL prime kit 
reagents (GE Healthcare) for 2 min and visualized with film. 
 
Hydroxyurea Sensitivity Assay 
           Cultures were grown in SC-LEU overnight to saturation. A culture was prepared 
from each of these saturations at an OD600 = 0.2 and grown to OD600= 0.5. A volume 
equal to 0.5/OD times 50 µl of each culture was spun down at 14,000 rpm for 10 min 
and resuspended in 50 µl water. A series of 10-fold dilutions was prepared and 2 µl of 
each dilution was plated on YPD and YPD supplemented with 100 mM, 150 mM, or 200 
mM HU and grown at 30°C. Plates were monitored for 4-5 days. 
 
Yeast Mating for Diploids 
           Mating protocols were adapted from [5]. The two haploid strains of interest KHSY 
2494 (MATa, ura3Δ0, leu2Δ0, his3Δ1, lys2Δ0, RAD51.V5.6xHIS.KANMX6, Open 
Biosystems) and KHSY 2497 (MATα, ura3Δ0, leu2Δ0, his3Δ1, lys2Δ0, 
TOP3.V5.VSV.KANMX6), plus mating strains KHSY1435 (MATa, Δthr4) and 1436 
(MATα, Δthr4) were streaked on YPD and grown for 2 days at 30°C. A single colony 
from both strains of interest were mixed in 50 µl of water, spotted on YPD, and grown 
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overnight at 30°C. From this spot, a small scoop was taken and spread for singles on 
YPD and grown for 2 days at 30°C. A colony of tester strain 1435 was then suspended 
in 50 µl of water and spread on a warm YPD plate; this was repeated for a separate 
plate for tester strain 1436. Sixteen colonies from the mating plate were then suspended 
in 30 µl of water, and 2 µl was spotted on a YPD plate, and both tester lawn plates. 
Plates were incubated overnight at 30°C. The tester plates were replica plated onto 
minimal media (SC-Min) and incubated overnight at 30°C. Diploids were identified as 
those that did not grow on either tester plate as neither the tester nor strains of interest 
can survive on minimal media without mating with one another.  Diploids were frozen 
and stored.  
 
Lithium Acetate (LiAc) Transformation 
          The protocol used was previously described in Gietz and Woods, 2006 [6]. The 
strain used for transformation was grown overnight in YPD to saturation. This culture 
was then used to inoculate a 25 ml YPD culture to an OD600= 0.2 and grown to 
OD600=0.8± 0.04. The culture was then pelleted at 2000 rpm for 2 min, washed with 25 
ml water, and spun down again. The pellet was then resuspended in 1 ml 100 mM LiAc 
and spun down at 14,000 rpm for 30 seconds. This pellet was then resuspended in 240 
µl 100 mM LiAc and distributed into 4 equal aliquots before being spun down at 14,000 
rpm for 1 min. These pellets were then treated with 50% PEG, 36 µl of 1 M LiAc, 75 µl 
of plasmid or PCR product plus water, and 10 µl boiled and snap-cooled salmon sperm 
DNA and incubated for 30 min at 30 °C. Post-incubation, the cells were heat-shocked at 
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42°C for 15 min. The cells were then spun down at 7000 rpm for 1 min, and the pellet 
was resuspended in 100 µl water and plated on selective media for the target gene or 
mutation (SC-LEU for point mutants, SC-HIS for Rmi1.myc integrants) and grown for 2 
days at 30 °C. Single colonies were restreaked, incubated for 2 days at 30°C, and 
single colonies from this streak were frozen and stored post-verification. 
 
Media Types 
          Media recipes were derived from Sherman, 2002 [5].  YPD liquid media was 
made by autoclaving 10 g/l Yeast Extract (US Biological), 20 g/l Bacto-peptone (US 
Biological), and 20 g/l glucose (Fisher Scientific). YPD agar uses the same ratios, but 
with 20g/L Agar (US Biological). Selective media agar was made by autoclaving 20 g/l 
agar and combining it with 2% glucose and a filter-sterilized solution of 6.7 g/l Yeast 
Nitrogen base (US Biological) and 2 g/l of a dropout mix lacking the amino acid being 
selected for (-LEU, -HIS; US Biological). Liquid selective media was made the same, 
but without agar. SC-Minimal media contains only 20 g/l agar and 2% glucose. LB 
media consisted of 10 g/l Tryptone (Fisher Scientific), 5 g/l Yeast extract, and 5 g/l NaCl 
(Fisher Scientific). 
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CHAPTER 3: 
A TRANSIENT α-HELICAL MOLECULAR RECOGNITION ELEMENT IN THE 
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Abstract 
The RecQ-like DNA helicase family is essential for the maintenance of genome 
stability in all organisms. Sgs1, a member of this family in Saccharomyces cerevisiae, 
regulates early and late steps of double-strand break repair by homologous 
recombination. Using nuclear magnetic resonance spectroscopy, we show that the N-
terminal 125 residues of Sgs1 are disordered and contain a transient α-helix that 
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extends from residue 25 to 38. Based on the residue-specific knowledge of transient 
secondary structure, we designed proline mutations to disrupt this α-helix and observed 
hypersensitivity to DNA damaging agents and increased frequency of genome 
rearrangements. In vitro binding assays show that the defects of the proline mutants are 
the result of impaired binding of Top3 and Rmi1 to Sgs1. Extending mutagenesis N-
terminally revealed a second functionally critical region that spans residues 9–17. 
Depending on the position of the proline substitution in the helix functional impairment of 
Sgs1 function varied, gradually increasing from the C- to the N-terminus. The multiscale 
approach we used to interrogate structure/function relationships in the long disordered 
N-terminal segment of Sgs1 allowed us to precisely define a functionally critical region 
and should be generally applicable to other disordered proteins.  
 
Introduction 
The maintenance of genome stability is essential for organismal survival. A 
complex and diverse system of proteins has evolved to accomplish this function. Sgs1 
of Saccharomyces cerevisiae is a 3–5′ DNA helicase that belongs to the evolutionarily 
conserved RecQ helicase family whose members function in the maintenance of 
genome stability. Named after the RecQ helicase of Escherichia coli, members of this 
helicase family have been identified in all organisms, including five homologs in humans 
(RecQ1, BLM, WRN, RecQL4, RecQL5) [1]. Mutations in BLM, WRN and RecQL4 are 
associated with Bloom syndrome, Werner syndrome and Rothmund–Thompson 
syndrome, respectively, which are characterized by elevated levels of aberrant 
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recombination events, chromosome instability and extraordinary predisposition to 
cancer development early in life [1].  
Saccharomyces cerevisiae cells that lack Sgs1 exhibit several phenotypes that 
are similar to those of cells from persons with Bloom syndrome, most notably 
dysregulated homologous recombination, hypersensitivity to DNA-damaging agents, 
meiotic defects and cell cycle delay [2,3]. These defects are caused when the helicase 
activity of Sgs1 is inactivated by mutations in the ATPase domain or the RecQ C-
terminal domain, which together make up the helicase core. Also located in the C-
terminal half of Sgs1 is the Helicase and RNAase D C-terminal (HRDC) domain thought 
to be involved in DNA substrate binding and protein–protein interactions. These 
domains are conserved in most RecQ homologs; they are structurally ordered and 
crystal structures of this region have been reported for E. coli RecQ and human RecQ1 
[4,5]. In contrast, the N-terminal half of Sgs1 is devoid of conserved catalytic domains 
and provides binding sites for proteins with roles in DNA metabolism, including the 
topoisomerases Top2 and Top3, replication protein Rpa70, Rad16 and Srs2 [2,6–8]. 
Interaction with the Top3 homologs has also been shown for human BLM, RecQ1 and 
RecQ5, and the RecQ homolog of Schizosaccharomyces pombe, Rqh1 [9–12]. 
Superhelical relaxation activity and Holliday-junction dissolution activity of these 
topoisomerase/helicase complexes is greatly enhanced by interaction with the RecQ-
mediated genome instability 1 (Rmi1) protein [13–15].  
One of the most important functions of the Sgs1 N-terminus is the interaction with 
the Top3/Rmi1 complex (BLM/Topo IIIα/Rmi1/Rmi2 in humans, Rqh1/Top3/Rmi1 in S. 
pombe) [13–16]. The Top3 binding site is within the first 100–158 residues of Sgs1 [17–
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19]. The loss of this region produces more severe phenotypes that exhibit slower growth 
and higher sensitivity to DNA damage than those produced by loss of Sgs1 alone [3]. 
This may be due to toxic intermediates produced by Sgs1 that accumulate during 
homologous recombination and require Top3 decatenation for resolution. Despite the 
fact that Sgs1 and BLM bind Top3 and its human homolog Topo IIIα, respectively, there 
is little primary sequence similarity between the N-terminal regions where these 
interactions are predicted to occur. Both N-termini are predicted to be intrinsically 
disordered [20], which may help explain their level of sequence divergence [21,22]. 
Such intrinsically disordered proteins/regions (IDPs/IDRs) are widespread in eukaryotes 
and function arises from an ensemble of conformations that contain varying degrees of 
secondary structure and rarely form transient tertiary contacts [21, 23–28]. A high 
percentage of eukaryotic proteins are predicted to contain significant stretches (>30 
residues) of disorder; in S. cerevisiae, 50–60% of the total proteome are IDPs/IDRs, 
and a survey of cancer-associated human proteins found that ∼79% of the proteins in 
the database are IDPs/IDRs [29,30].  
Using multidimensional heteronuclear nuclear magnetic resonance (NMR) 
spectroscopy, we have identified a short segment within the first 125 residues of the 
intrinsically disordered N-terminus of unbound Sgs1 that has transient α-helical 
structure whose integrity is essential for Sgs1 function in vivo. We have rationally 
designed single amino acid substitutions that disrupt transient α-helices. Some of these 
mutations eliminate Top3 binding to Sgs1, cause DNA damage hypersensitivity and 
induce spontaneous chromosomal rearrangements.  
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Materials and Methods 
Expression and Purification of Peptides for NMR Spectroscopy 
Methods were based on a previously described procedure for the expression of 
an IDP [31]. Plasmid pKHS443, expressing Sgs11−125, was constructed by inserting the 
first 375 bp of SGS1 into pET28a (Novagen) using NdeI and BamHI sites. Plasmid 
pKHS463, expressing Sgs11−80, was constructed by introducing a stop codon after 240 
bp in pKHS443. pKHS443 or pKHS463 was transformed into E. coli BL21 (DE) cells 
and grown at 37°C in 2 l of M9 media (42 mM Na2HPO4, 22 mM KH2PO4, 8 mM NaCl, 2 
mM MgSO4, 11 mM d-glucose, 0.1 mM CaCl2, 10 µM FeCl3, 1 mg of Vitamin B1/L, pH 
7.3) plus 200 mg of ampicillin, supplemented with N15 ammonium chloride and C13 
glucose. Protein expression was induced at OD600 = 0.6 for 3 h with 1 mM Isopropyl-
beta-D-thiogalactopyranoside (IPTG) at 37°C. Cells were harvested via centrifugation at 
8000 rpm before being resuspended in buffer A1 (50 mM NaH2PO4, 300 mM NaCl, 10 
mM imidazole, pH 8.0) and lysed at 19 000 psi via French press. The lysate was 
cleared via centrifugation (18 000 rpm, 1 h, 4°C) and the supernatant was loaded onto a 
30 ml Ni-NTA column on an AKTA FPLC. The column was washed with 5 column 
volumes of buffer A2 (50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole, pH 8.0), and 
the peptide was eluted in buffer B (50 mM NaH2PO4, 300 mM NaCl, 300 mM imidazole, 
pH 8.0). Fractions containing the eluted protein were pooled and dialyzed into 50 mM 
Tris (pH 8.0) and 100 mM NaCl. The fractions were treated with 1 ml CleanCleave 
thrombin beads (Sigma) at room temperature for 8 h to remove the N-terminal (HIS)6 
tag. Cleaved proteins were dialyzed into gel filtration buffer (50 mM NaH2PO4, 300 mM 
NaCl, 1 mM EDTA, 0.02% NaN3, 4 mM DL-Dithiothreitol (DTT), pH 7), then 
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concentrated to a volume of 10 ml and loaded onto a 120-ml GE Hiload 16/60 Superdex 
70 column via fast protein liquid chromatography (FPLC) and harvested over four 2.5-ml 
runs. Fractions containing the peptide were pooled and dialyzed into NMR buffer (50 
mM NaH2PO4, 100 mM NaCl, 1 mM EDTA, 0.02% NaN3, 4 mM DTT, pH 6.8) before 
being concentrated to 600 µl (150 µM for Sgs11−125; 690 µM for Sgs11−80, 160 µM for 
Sgs11−80-F30P).  
 
NMR Analysis 
NMR data for Sgs11−80 and Sgs11−80-F30P were collected at 25°C on a Varian 
VNMRS 800 MHz spectrometer equipped with a triple resonance pulse field Z-axis 
gradient cold probe. To make the amide 1H and 15N as well as 13C, 13Cβ and 
13CO 
resonance assignments, sensitivity enhanced 1H-15N heteronuclear single quantum 
correlation (HSQC) and three-dimensional HNCACB and HNCO experiments were 
performed on a uniformly 15N- and 13C-labeled sample of Sgs11−80 at 470 µM (or 
Sgs11−80-F30P at 160 µM) in 90% H2O/10% D2O, phosphate buffered saline (PBS) 
buffer, at a pH of 6.8 (32–34). For the HNCACB experiment, data were acquired in 1H, 
13C and 15N dimensions using 9615.3846 (t3) × 16 086.4648 (t2) × 2000 (t1) Hz sweep 
widths, and 512 (t3) × 128 (t2) × 32 (t1) complex data points. For the HNCO, the sweep 
widths were 9615.3846 (t3) × 2000 (t2) × 2000 (t1) Hz, complex data points were 
identical to the HNCACB. The sweep widths and complex data points of the HSQC 
were 9615.3846 (t2) × 2100 (t1) Hz and 1024 (t2) × 128 (t1), respectively. Processing and 
analysis of the HNCACB data resulted in 66 nonproline amide 1H, 15N, 13Cα and 13Cb 
resonance assignments plus 8 proline 13Cα and 13Cβ resonance assignments. 1H-15N 
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steady-state nuclear Overhauser effect (NOE) experiments were recorded at 25°C on a 
Varian VNMRS 600 MHz spectrometer equipped with a triple resonance pulse field Z-
axis gradient cold probe in the presence and absence of a 120 off-resonance 1H 
saturation pulse every 5 ms for 3 s. A total of 512 (t2) × 128 (t1) complex points were 
recorded with 128 scans per increment with the sweep widths set to 7225.4335 (t2) × 
1700 (t1) Hz. The 
1H-15N heteronuclear Overhauser effect (NHNOE) values were 
determined by taking the quotient of the intensity for resolved resonances in the 
presence and absence of proton saturation. Three measurements were made on each 
protein and the values were averaged. Resonance assignments for Sgs11−125 were 
carried out at 25°C on a Varian VNMRS 600 MHz spectrometer equipped with a triple 
resonance pulse field Z-axis gradient cold probe. To make the amide 1H and 15N as well 
as 13Cα, 
13Cβ and 
13CO resonance assignments, sensitivity-enhanced 1H-15N HSQC and 
three-dimensional HNCACB and HNCO experiments were performed on a uniformly 
15N- and 13C-labeled sample at 150 µM in 90% H2O/10% D2O, PBS buffer, at pH 6.8. 
For the HNCACB experiment, data were acquired in 1H, 13C and 15N dimensions using 
7225.4335 (t3) × 12 064.1295 (t2) × 1499.9813 (t1) Hz sweep widths, and 512 (t3) × 108 
(t2) × 32 (t1) complex data points. For the HNCO, the sweep widths were 7225.4335 (t3) 
× 1500 (t2) × 1499.9813 (t1) Hz, and 512 (t3) × 74 (t2) × 32 (t1) complex data points. For 
the HNCACO, the sweep widths were 7225.4335 (t3) × 12 000 (t2) × 1499.9813 (t1) Hz, 
and 512 (t3) × 70 (t2) × 28 (t1) complex data points. Processing and analysis of the data 
resulted in 87 nonproline amide 1H, 15N, 13Cα and 
13Cb resonance assignments plus 12 
proline 13Cα and 13Cβ resonance assignments. All NMR spectra were processed with 
nmrPipe and analyzed using nmrView software (31,35,36). Apodization was achieved in 
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the 1H, 13C and 15N dimensions using a squared sine bell function shifted by 70°. 
Apodization was followed by zero filling to twice the number of real data points and 
linear prediction was used in the 15N dimension of the HNCACB.  
 
Hydroxyurea Hypersensitivity Assay 
Yeast strain KHSY1338 (ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-
10, ade2Δ1, ade8, YEL069C::URA3, sgs1::HIS3) was transformed with derivatives of 
plasmid pRS415-SGS1 (Supplementary Table S1) by standard lithium-acetate 
transformation [37] and selected on synthetic complete media lacking leucine (SC-Leu). 
Transformants were grown in liquid SC-Leu to OD600 = 0.5, then plated in 10-fold 
dilutions on YPD (yeast extract/peptone/dextrose) and on YPD supplemented with 100 
mM hydroxyurea (HU). Colony growth at 30°C was documented after 3–5 days.  
 
Top3 and Rmi1 Binding Assay 
Plasmid pKHS462, expressing GST-Sgs11−250, was constructed by inserting the 
first 750 bp of SGS1 into pGEX-6p-2 (GE Healthcare) using BamHI and XhoI sites. The 
Sgs1 fragment was expressed in E. coli BL21 (DE) cells in LB media (10 g/l tryptone, 5 
g/l NaCl, 5 g/l Yeast extract) supplemented with 1.5 mg ampicillin for 3 h in the 
presence of 1 mM IPTG. The cell pellet was resuspended in 100 µl GST buffer (125 mM 
Tris, 150 mM NaCl, pH 8.0) plus HALT protease inhibitors (Pierce) and sonicated for 10 
× 3 pulses. Lysate was cleared by centrifugation at 14 000 rpm for 10 min at 4°C. 
Glutathione magnetic beads (Pierce) were then incubated with 625 µg of cleared lysate 
for 1 h at 4°C, and washed three times with GST buffer. Native yeast whole-cell extract 
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containing endogenous levels of Top3 and/or Rmi1 was prepared from a culture of 
KHSY2497 (MATα, ura3Δ0, leu2Δ0, his3Δ1, lys2Δ0, TOP3.V5.VSV.KANMX6, Open 
Biosystems), KHSY4695 (MATα, ura3Δ0, leu2Δ0, his3Δ1, lys2Δ0, rmi1::HIS3, 
TOP3.V5.VSV.KANMX6) or KHSY4696 (MATα, ura3Δ0, leu2Δ0, his3Δ1, lys2Δ0, 
TOP3.V5.VSV.KANMX6, RMI1.myc.HIS3MX6) grown at 30°C in YPD overnight. To 
construct a top3Δ yeast strain that expresses myc-epitope tagged Rmi1, a diploid 
generated by mating RDKY3837 (MATa, ura3-52, trp1Δ63, his3Δ200, leu2Δ1, lys2Bgl, 
hom3-10, ade2Δ1, ade8, top3::TRP1) and KHSY4696 (MATα, ura3Δ0, leu2Δ0, his3Δ1, 
lys2Δ0, TOP3.V5.VSV.KANMX6, RMI1.myc.HIS3MX6) was sporulated (38) to isolate a 
top3::TRP1, RMI1.myc.HIS3MX6 haploid (KHSY4741) by genotyping on selective 
media. The presence of the top3::TRP1 and RMI1.myc.HIS3MX6 alleles was also 
confirmed by polymerase chain reaction. Yeast cells were collected by centrifugation at 
2000 rpm for 4 min, washed and resuspended in Top3/Rmi1 buffer (50 mM Tris, pH 7.5, 
0.01% NP-40, 5 mM β-glycerol phosphate, 2 mM magnesium acetate, 120 mM NaCl) 
plus HALT protease inhibitors (Pierce). The suspension was lysed via French press at 
19 000 psi or in a BeadBeater (Biospec Products, Inc.) by beating three times for 1 min. 
Lysates were cleared by centrifugation at 14 000 rpm for 15 min at 4°C. Cleared yeast 
lysate of 20 (KHSY2497, KHSY4695) or 10 mg (KHSY4696, KHSY4741) was incubated 
with Sgs1-bound magnetic beads for 90 min at room temperature on a nutator. Beads 
were washed four times with Top3/Rmi1 buffer plus HALT protease inhibitors (Pierce) 
and boiled for 10 min in Laemmli buffer (BioRad). Beads were collected by 
centrifugation and eluted protein complexes were separated by 10% sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). Presence of Sgs1 
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fragments, Top3 and Rmi1 and was determined by western blotting using monoclonal 
antibodies against GST (Covance), VSV (Sigma) and myc (Covance) epitopes, 
respectively.  
 
Gross-Chromosomal Rearrangement Assay 
Accumulation of cells that had undergone simultaneous inactivation of the URA3 
and CAN1 genes on chromosome V was determined as previously described [39] 
except that cells were grown in the absence of leucine to select for the presence of the 
pRS415-derived plasmids expressing the desired sgs1 mutants. Briefly, yeast strain 
KHSY1338 was transformed with derivatives of plasmid pRS415-SGS1 containing 
proline mutations (Supplementary Table S3.I) and grown to saturation at 30°C in 10 ml 
of SC-Leu. Cells were washed in water and plated on selective media containing 
canavanine (can) and 5-fluoro-orotic acid (5-FOA) to select for cells with inactive CAN1 
and URA3 genes. Cells were also plated on SC-Leu media to obtain a viable cell count. 
After incubation at 30°C, viable cell count was determined after 3 days, and colonies on 
5-FOA/can were counted after 5 days. Mutation rates and 95% confidence intervals 
were calculated from 6 to 16 cultures as previously described [39,40].  
 
Preparation of Yeast Whole-Cell Extracts by Trichloroacetic Acid Extraction 
To assess expression levels of Top3 and Rmi1 in rmi1::HIS3 and top3::TRP1 
strains, respectively, yeast cultures were grown in YPD with vigorous shaking and 10 
ODs were harvested by centrifugation at 2000 rpm for 2 min. To assess expression 
levels of sgs1-F30P and sgs1-H13P, the 3′-end of SGS1 in pKHS481 was fused to the 
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myc-epitope amplified from pFA6a-13Myc-HIS3MX6 [41] by gap repair of SacI-
linearized pKHS481 to generate pKHS596. F30P and H13P mutations were introduced 
into pKHS596 by QuikChange mutagenesis (Agilent Technologies) to generate 
pKHS598 and pKHS600, respectively. Cell pellets were washed in water and 
resuspended in ice-cold 20% trichloroacetic acid (TCA) and vortexed in a cell disruptor 
(USA Scientific) with acid-washed glass beads for 4 min at maximum speed. Cell lysate 
was cleared at 14 000 rpm for 3 min. The pellet was resuspended in Laemmli buffer, 
adjusted to neutral pH and boiled for 2 min before separation by 10% SDS-PAGE. 
Presence of Top3.VSV, Rmi1.myc, Sgs1.myc and GAPDH was determined by western 
blotting using monoclonal antibodies against VSV (Sigma) and myc (Covance) epitopes, 
and against GAPDH (Pierce), respectively.  
 
Results 
The First 125 Residues of the Structurally Disordered N-terminus of Sgs1 
Contain Two Transient α-helices 
Sgs1 is a modular protein containing both ordered and disordered domains. The 
ATPase domain, zinc-binding domain, winged-helix domain and the HRDC domain 
make up the structurally ordered C-terminal half of Sgs1. In contrast, most of the N-
terminal half of Sgs1 (residues 1–654) is predicted to be disordered [20,42]. This is also 
the case for other members of the RecQ helicase family, most notably S. pombe Rqh1 
and human BLM.  
A previous study has shown that the first 158 residues of Sgs1 are sufficient for 
binding to the topoisomerase Top3 [18]. It is well established that short segments within 
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longer disordered regions will undergo coupled folding and binding in the presence of 
protein binding partners [43–45]. Disorder predictors like IUPred [46] will frequently 
display short dips into the ordered region (disorder tendency < 0.5) that correspond to 
these protein binding sites, and it is expected that these regions will contain some 
degree of transient secondary structure. The lowest dips in the IUPred plot of the first 
158 residues of Sgs1 correspond to residues E24 and Y102 (Figure 3.1). To determine 
whether these small segments within the disordered N-terminus of Sgs1 could adopt 
functionally significant secondary structures, we characterized the solution structure of 
the first 125 residues of Sgs1 using NMR spectroscopy. Single (15N)- and double 
(15N/13C)-labeled samples of Sgs11−125 were overexpressed in E. coli and purified to 
apparent homogeneity. The double-labeled sample was used to measure the HSQC 
spectrum (Figure 3.2) as well as the triple resonance spectra that were used to make 
resonance assignments. The HSQC spectrum shows narrow chemical shift dispersion 
in the 1H dimension (7.85–8.5 ppm), consistent with a disordered peptide [47–49]. The 
15N-labeled sample was used to measure the NHNOE. NHNOE values are sensitive to 
the rotational correlation time for the residue of interest. In disordered regions, small 
positive NHNOE values indicate regions that are less dynamic and typically correlate 
with the presence of transient secondary structure, and negative NHNOE values 
indicate highly dynamic regions. The NHNOE values observed for Sgs11−125 are 
consistent with a mostly disordered protein that contains two transiently ordered regions 
centered on residues F30 and E92 (Figure 3.3A). Alpha carbon secondary chemical 
shifts (CAΔδ) were calculated for every residue by subtracting the amino acid–specific 
random coil chemical shift values for CA from the measured values [50]. This is a 
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reliable method for identifying the presence of transient secondary structure in IDPs 
[51–53]. The presence of transient α-helical secondary structure in Sgs11−125 was 
indicated by consecutive positive CAΔδ values for residues 23–34 and 88–97 (Figure 
3.3B).  
Several clusters of overlapping resonances in the HSQC and HNCACB spectra, 
and repeating amino acid motifs (e.g. Thr-Ala-Thr) limited resonance assignments to 
77% of the nonproline residues for the Sgs11−125 fragment. Several of the residues that 
could not be assigned were in or near the two transient α-helical segments preventing 
an identification of the helix boundaries. To develop a more complete picture of the first 
helical region, NMR analysis of a shorter Sgs1 fragment containing residues 1–80 
(Sgs11−80) was performed. Using this fragment, we were able to assign 93% of the 
nonproline resonances in the HSQC spectrum (Figure 3.2) and to fill in the gaps in the 
secondary 13Cα chemical shift analysis (Figure 3.3C and D). The overlap between the 
HSQC spectra of the Sgs11−80 and the Sgs11−125 peptides indicates that elimination of 
36% of the residues of the Sgs11−125 peptide (45 residues) did not affect the solution 
structure of the first 80 residues of Sgs1, consistent with this being a disordered region. 
Secondary 13Cα chemical shift analysis indicates the presence of α-helical secondary 
structure for residues 25–38 and residues 88–97 within this disordered region (Figure 
3B and D). However, as mentioned above, helical states for both regions are transient 
because secondary shift values of > 2.6 δppm would be expected for 13Cα in a 
persistent α-helix [51].  
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Functional Mapping of α-helices by Proline Mutagenesis 
To determine if the transient α-helical structures for residues 25–38 and 88–97 
are important for Sgs1 function, residues with the highest NHNOE and CAΔδ values in 
each helical region were replaced with prolines—a known helix breaker. V29 and F30 in 
the first helical region and W92 and L93 in the second helical region were changed to 
proline in the context of full-length Sgs1. Cells expressing the mutant helicases were 
plated on media containing 100 mM of the DNA-damaging agent HU (Figure 3.4). While 
the sgs1-V29P and sgs1-F30P mutants were as sensitive to HU as the sgs1Δ mutant, 
neither the W92P nor the L93P mutation caused increased sensitivity (Figure 3.4A and 
B), indicating that the α-helical structure centered on V29 and F30 contributes to Sgs1’s 
role in DNA damage repair, whereas that centered on W92 and L93 does not.  
According to the NHNOE and CAΔδ values, the strongest helical region in the 
first 125 residues of Sgs1 extends from residues 25 to 38. To determine the functional 
distance that this helical region extends on both sides of V29 and F30, residues were 
mutated according to the expected i, i + 4 intramolecular hydrogen-bonding pattern of a 
typical α-helix. The mutants using V29 as a starting point, therefore, were D25P, I33P 
and I37P and those based on F30 were K26P and Q34P. Because proline substitutions 
of disordered residues near the ordered region would not be predicted to affect Sgs1 
function, a T61P mutation (IUPred disorder score: 0.73) was included as a negative 
control. The sgs1-K26P, sgs1-Q34P, sgs1-I37P and sgs1-T61P mutants exhibited wild-
type levels of HU sensitivity, whereas the sgs1-D25P and sgs1-I33P mutants were 
hypersensitive, with a gradual decrease in functional impairment of Sgs1 being 
observed between proline substitutions near the N-terminus of the helix and those near 
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the C-terminus (Figure 3.4A). These observations are consistent with the functional α-
helix extending from residues 25 to 33.  
Whereas the lack of an effect of proline in position 26 argues against K26 being 
an internal residue of α-helix, our findings are consistent with K26 being in the first 
helical turn, more specifically in the N1 position, where proline is tolerated [54,55], 
whereas D25—as the N-cap residue [56]—defines the N-terminal helix boundary. 
Indeed, the AGADIR algorithm [57] identified a prominent peak of helical propensity 
centering on residue I33, and D25 received the highest N-cap score (Figure 3.5A). 
Consistent with the results of the DNA-damage-sensitivity assay, AGADIR predicted 
reduced helical content for the D25P mutant, but not for the K26P mutant (Figure 3.5B). 
Removing the N-cap by replacing the aspartic acid residue at position 25 with basic 
(D25K) or neutral (D25A) residues, which have excellent helical propensity, but are poor 
N-cap residues [58], leads to N-terminal extension of the helix in AGADIR (Figure 3.5C). 
This increase in helical content in the sgs1-D25K and sgs1-D25A mutants did not impair 
Sgs1 function in vivo (Figure 3.4C).  
Further extending the proline mutagenesis starting from V29 toward the N-
terminus revealed wild-type levels of HU sensitivity for sgs1-T21P, consistent with D25 
defining the N-terminal end of the α-helix. In contrast, the sgs1-K17P, sgs1-W15P, 
sgs1-H13P and sgs1-L9P mutants were more sensitive to HU than cells expressing 
wild-type Sgs1, indicating that this region is also critical for Sgs1 function (Figure 3.4B 
and D). The stretch of consecutive positive CAΔδ values for N8 to R11 is consistent 
with α-helical propensity and the HU hypersensitivity assay suggests that it extends C-
terminally to residue H17. At first sight, the negative CAΔδ value for W15 seems to 
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indicate that W15 is not in a transient helical structure (Figure 3.3D). If this is the case 
then it suggests that any helical structure in the bound state is not contiguous from 
residue 8 to 17. However, the inconsistent CAΔδ value for W15 could be owing to the 
inaccuracies associated with the random coil chemical shift library used for calculating 
the secondary chemical shifts [50] or related to an anomalous effect on the CA shift that 
results from the partial charge of the H13 and H17 side chains. Consistent with W15 
being an α-helix, substituting the tryptophan with other residues with good helical 
propensity, such as alanine or arginine, did not affect Sgs1 function in the DNA-damage 
hypersensitivity assay (W15A, Figure 3.4B) or its ability to induce slow growth in the 
sgs1Δ top3Δ strain [59]. However, α-helical content in this region could not be further 
assessed as assignments, and therefore NHNOE and CAΔδ values for residues S6, 
E12, H13 and K14 were not available owing to overlapping resonances in the HSQC 
spectra of both Sgs11−80 and Sgs11−125. That W15 and W92 could be changed to 
nonaromatic residues without increasing sensitivity of cells to DNA damaging agents 
(Figure 3.4B) also shows that these two residues are not involved in stacking 
interactions with each other, with other aromatic residues in the region, or with DNA 
[60,61], or at least that such stacking interactions are not important for the role of Sgs1 
in suppressing HU hypersensitivity.  
To verify that proline mutations that cause HU hypersensitivity indeed disrupt the 
α-helix between residues D25 and A38, we analyzed the solution structure of the 
sgs11−80-F30P mutant by NMR (Figure 3.6). We found that the resonances that shifted 
notably in the HSQC spectrum of the F30P mutant compared with the wild type were 
limited to residues F28–A38 (Figure 3.6A, Merged), suggesting that changes induced by 
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the F30P mutation are probably localized to the α-helix. Indeed, the consecutive positive 
secondary alpha carbon chemical shifts (CAΔδ) between residues D25 and A38 in wild-
type Sgs1, which indicate the presence of α-helical secondary structure, were markedly 
reduced in the F30P mutant (Figure 3.6B), demonstrating that a proline at position 30 is 
sufficient to prevent the formation of the α-helix between residues 25 and 38. We also 
confirmed that proline mutations that disrupt α-helical content in the N8–H17 region or 
the D25–A38 region and cause the highest HU sensitivity (H13P, F30P) do not affect 
Sgs1 expression levels and stability (Figure 3.9).  
 
Disruption of Transient α-helices Impairs Complex Formation Between 
Sgs1, Top3 and Rmi1 
The disordered region of Sgs1 where the transient α-helices were identified binds 
to the Type-1A topoisomerase Top3 [18]. To test if HU hypersensitivity caused by 
proline mutations in this region is owing to the disruption of transient helices that are 
required for the interaction between Sgs1 and Top3, the ability of various sgs1 mutants 
to form a complex with Top3 was assessed in vitro. Because overexpression of full-
length Sgs1 leads to insolubility [62,63], we chose the N-terminal 250 residues of Sgs1 
and expressed them as an N-terminal GST fusion in E. coli. This Sgs11−250 fragment 
pulled down endogenous Top3 from native yeast whole-cell extract in an Rmi1-
dependent manner (Figure 3.7A). Similarly, binding of Rmi1 to Sgs11−250 was reduced in 
the absence of Top3 (Figure 3.7B), suggesting that Top3 and Rmi1 depend on each 
other for binding to the N-terminal 250 residues. Despite the effect on Sgs1 binding, 
expression levels of Top3 and Rmi1 were not affected by the absence of Rmi1 and 
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Top3, respectively (Figure 3.7C and D). Sgs11−250 binds to Top3 more strongly than 
Sgs11−160 and, similar to what has been reported previously for an Sgs1 fragment 
comprising residues 107–283 [19], Sgs1125−250 did not bind to Top3 (Figure 3.7E and F). 
When we introduced L9P, H13P, K17P, D25P, V29P and F30P mutations into the 
Sgs11−250 fragment, its ability to pull down Top3 from cell extracts was diminished, 
whereas the T21P and K26P mutants were still able to bind Top3 (Figure 3.7G). 
Mutations of Sgs1 that disrupted binding to Top3 also disrupted binding to Rmi1 (Figure 
3.7H).  
 
Integrity of Transient α-helices is Critical for Maintaining Chromosomal 
Stability 
Lack of Sgs1 or disruption of its conserved C-terminal helicase core domain 
leads to mitotic hyperrecombination and a moderate increase in the accumulation of 
gross-chromosomal rearrangements (GCRs), including translocations between 
nonallelic sites [39,64,65]. To determine if the inability of Sgs1 to interact with Top3 and 
Rmi1 also leads to increased genome instability, we tested the ability of D25P, K26P, 
V29P, F30P and I33P mutants of full-length Sgs1 expressed from a CEN/ARS plasmid 
to suppress the elevated GCR rate of an sgs1Δ mutant. Mirroring the results of the HU 
hypersensitivity assay, D25P, V29P, F30P and I33P were unable to complement the 
defects of sgs1Δ cells, whereas cells expressing the K26P mutant accumulated GCRs 
at a similar rate as cells expressing wild-type Sgs1 (Table 3.1).  
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Discussion 
In the prokaryote-to-eukaryote transition, some members of the RecQ helicase 
family acquired long N-terminal regions that precede the ATPase domain of the helicase 
core. In Sgs1, the only RecQ homolog in S. cerevisiae, this N-terminal region is ∼650 
amino acids long, making up ∼45% of the 1447-residue long protein. This entire region 
is predicted to be intrinsically disordered and to contain several short segments of 
transient secondary structure (Figure 3.1). Using NMR spectroscopy, we have 
demonstrated that the first 125 residues of this N-terminal region of Sgs1 are 
intrinsically disordered in the unbound solution state with two short segments, between 
residues 25–38 and 88–97, that adopt transient α-helical structure. Transient α-helices 
in disordered regions of proteins are often stabilized by interactions with a binding 
partner [43–45,66,67]. This principle was used to rationally design single residue 
substitutions that disrupted the transient α-helical structures of residues 25–38 and 88–
97, and the effects of these mutations on Sgs1 function were tested in vitro and in vivo. 
Substitution of residues D25, V29, F30 and I33 with the α-helix breaker proline impaired 
Sgs1 function in vivo, as evidenced by increased sensitivity to DNA damage and 
increased chromosome instability, and reduced binding of Top3 and Rmi1 to Sgs1 in 
vitro. Additional proline mutagenesis following the i, i − 4 α-helix pattern revealed that 
L9, H13 and K17 were critical for the same Sgs1 functions as the D25–A38 α-helix.  
Our work demonstrates that the integrity of a transient α-helix is required for the in vivo 
function of Sgs1 and the binding of Sgs1 to Top3 and Rmi1. This helps explain why 
previous attempts to identify functionally critical single residues through alanine 
scanning of the region were unsuccessful (K4A, P5A, L9A) [68]. Alanine scanning is 
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often useful for identifying residues important for catalytic function, such as the ATPase 
activity of Sgs1 (K706A in the Walker A motif). However, the effectiveness of this 
approach to detect functionally important structural motifs in disordered segments, such 
as transient α-helices, is hampered by the high helical propensity of alanine and will 
depend on whether the substitution occurs at a residue that forms part of the binding 
interface [58]. Substitution with lysine and valine residues, which also have excellent 
helical propensity, also had no effect on Sgs1 function (D25K, Figure 3.4C; D25V [59], 
whereas a proline substitution at this same residue disrupted function (D25P, Figure 
3.4A). Even amino acid residues that have lower helical propensity and are therefore 
not commonly found in α-helices, such as glycine and serine, are not necessarily 
successful at disrupting transient α-helices when introduced as single-residue 
substitutions. For example, the E12G and H13S mutations by themselves were 
insufficient to disrupt the interaction between Sgs1 and Top3, but were effective when 
combined [68]. Rationally designing mutations based on residue-specific knowledge of 
transient secondary structure provided a direct test of structure/activity relationships for 
Sgs1 (and presumably other IDPs) that could only be realized by combining a high-
resolution structural approach, like NMR, with the in vivo and in vitro functional tests that 
can be performed in a model organism like S. cerevisiae. While this type of multiscale 
approach has commonly been used to interrogate structure/activity relationships for 
ordered proteins, the widespread application of this approach to IDPs/IDRs has been 
hampered by a lack of understanding of the general rules that connect their dynamic 
structures to their function. We believe our study helps clarify an approach that can be 
consistently applied to identify the functionally critical regions of IDPs/IDRs.  
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What functional advantages might the long, intrinsically disordered N-terminal tail 
provide to Sgs1? One possibility is that it contains multiple protein interaction sites, in 
addition to Top3/Rmi1. This hypothesis is supported by multiple dips below the 0.5 
threshold in the IUPred plot (Figure 3.1) and the fact that Sgs1 binds Top2, Rad16, 
Rpa70, Dna2 and Mre11 at sites that map to the disordered N-terminus, although the 
discrete binding sites have not been identified [6–8,13]. Sgs1 may need to bind several 
of these proteins, sequentially or concurrently, in the same process. For example, the 
Sgs1/Top3/Rmi1 complex is instrumental in DNA resection during double-strand break 
(DSB) repair in a reaction analogous to that performed by the RecBCD complex in 
bacteria. In this model, which was recently proposed by Cejka et al. [13], the 
Sgs1/Top3/Rmi1 complex is first recruited to the DSB by physically interacting with the 
Mre11 subunit of the Mre11/Rad50/Xrs2 complex. Subsequently, the Sgs1/Top3/Rmi1 
complex physically interacts with Dna2 to stimulate preferential degradation of the 5′-
end and with replication protein A (RPA) to protect the 3′-end. Still other physical 
interactions at the N-terminal tail, including those with Rad16 and Top2, are likely to be 
important for roles of the Sgs1/Top3/Rmi1 complex in DNA repair and chromosome 
segregation. Conformational flexibility may also be crucial to accommodating the 
various structures and sizes of DNA substrates that the Sgs1/Top3/Rmi1 complex acts 
on, which range from simple double-stranded or splayed ends to hairpins, 
quadruplexes, Holliday junctions and telomeres.  
In E. coli, RecQ and Top3 interact functionally, but not physically. One advantage 
of gaining physical contact between Sgs1 and Top3 would be the ability of one subunit 
in the complex to regulate another subunit’s enzymatic activity. Tight coordination 
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between a Type-IA topoisomerase activity, such as exhibited by Top3, and DNA-
dependent ATPase activity, such as exhibited by the helicase core of Sgs1, can be 
seen in the reverse gyrases of thermophile and hyperthermophile bacteria and archaea, 
where the two activities are either contained in a single polypeptide [69,70] or are 
encoded by two separate genes [71]. In these enzymes, the topoisomerase domain has 
been found to reduce the activity of the helicase-like ATPase domain [72] and, 
conversely, the ATPase domain has been shown to inhibit the supercoil relaxation 
activity of the topoisomerase subunit to induce positive supercoiling [71]. Inhibition of 
the helicase activity of the human Werner syndrome helicase WRN by its associated 
Type-1B topoisomerase Topo I hints at the possibility of coordination between the two 
activities also in RecQ-like helicases. Similarly, in Sgs1, deletion of the Top3 contact 
site (sgs1Δ1-158) causes a more severe phenotype than that caused by the absence of 
Sgs1 [3], which could be explained by Top3 binding having an inhibitory effect on the 
ATPase activity of Sgs1.  
The interaction with a Type-1 topoisomerase has been preserved in at least four 
of the five human RecQ-like helicases: BLM, WRN, RecQL1 and the long isoform of 
RecQL5. Like Sgs1, BLM and WRN interact with Topo IIIα (Type IA) and Topo I (Type 
IB), respectively, at the far end of a long N-terminal tail [12]. Human RecQL1 was also 
found to interact with Topo IIIα, whereas the long isoform of RecQL5 (RecQL5β) co-
immunoprecipitated with Topo IIIα and Topo IIIβ [10,11]. The predicted helical content 
of the N-terminus of BLM does not resemble that of the Top3/Rmi1 contact site between 
residues 25 and 38 in Sgs1, which appears to be the result of a proline substitution in 
BLM at position 30 (Figure 3.8A). Instead, the helAcal content in the segment starting 
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with residue L9, which is weak in Sgs1, is predicted to be dominant in BLM. Thus, 
although both BLM and Sgs1 interact with topoisomerase 3 at the N-terminus, the 
structural elements in the two proteins that mediate this interaction may not be 
conserved. This is also supported by the finding that the C-terminal 156 residues of 
BLM also bind to Topo IIIα [12], whereas only the N-terminus of Sgs1 interacts with 
Top3. Strikingly, the predicted helical content for residues N23 to R36 in WRN is nearly 
a perfect match to that of the confirmed α-helix in Sgs1 (Figure 3.8B). However, WRN 
has not been shown to interact with Topo IIIα [10], possibly owing to the insertion of the 
exonuclease domain just downstream of this site, and it will be interesting to test if 
residues N23–R36 of WRN can provide a contact site for the Top3/Rmi1 complex when 
placed in Sgs1. In the case of S. pombe Rqh1, the first 322 N-terminal residues are 
required for interaction with Top3 [9]. Although helical content is not predicted for the 
first 100 residues of this region, noticeable helical content is evident for the 27-residue 
region between residues H264 and R291 and the 15-residue region between residues 
D112 and Q127, which could be investigated as putative Top3 binding sites (Figure 
3.10 ). Although Topo IIIα also binds full-length RecQL1 and RecQL5 [10, 11], the 
binding regions in these two human RecQ homologs have not yet been narrowed down.  
Applying the same NMR-based structure–function analysis to the remaining 525 
residues of the disordered N-terminal tail of Sgs1 (and the tails of the other long RecQ-
like helicases) will help to identify additional structural elements, either transient or 
persistent, that serve as molecular recognition elements for protein partners or DNA, 
and allow for the rational design of new separation of function alleles that encode 
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mutants of RecQ-like helicases with single residue substitutions that are defective in 
discrete cellular functions.  
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Figure 3.1: Prediction of intrinsically unstructured regions in Sgs1. Disorder 
scores are from IUPred (46) with scores >0.5 predicting disordered residues and scores 
<0.5 predicting ordered residues. Residues 1–158 (upper panel) are predicted to be 
mostly disordered with two short segments around residues E24 and Y102 dipping into 
the ordered region.  
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Figure 3.2: HSQC spectra of the first 125 residues of Sgs1 (Sgs11–125) and the first 
80 residues of Sgs1 (Sgs11–80). Narrow chemical shift dispersion in the 1H dimension 
in both the HSQC spectra of the long (Sgs11–125) and short (Sgs11–80) peptide are 
consistent with a disordered peptide. The overlay of the long and short peptide 
(Merged) shows little discrepancy in the peak assignments between the two proteins, 
implying conservation of structural elements, even with the truncation.  
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Figure 3.3: Measurement of NHNOE and secondary alpha carbon shifts (CAΔδ) of 
the Sgs11–125 peptide and the Sgs11–80 peptide. Consecutive positive values in the 
NHNOE plot for the Sgs11–125 peptide (a) and the Sgs11–80 peptide (c) indicate regions 
with a slower rotational correlation time that may adopt secondary structure. 
Consecutive positive secondary alpha carbon chemical shifts (CAΔδ) between residues 
88 and 97 (b) and between residues 25 and 38 (d) indicate the presence of α-helical 
secondary structure in the unbound Sgs1 peptide as compared with standard chemical 
shifts in a random coil library (48,50).  
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Figure 3.4: HU hypersensitivity of cells expressing sgs1 alleles with mutations in 
(a) the α-helical region spanning residues 25–38 and (b) the α-helical region 
spanning residues 88–97. The wild-type phenotype exhibited by cells expressing 
W15A and W92A mutants of Sgs1 also demonstrates that these aromatic residues are 
not involved in stacking. T61P was included as a control for a disordered residue. (c) 
Replacing the N-cap residue D25 with basic (D25K) or neutral (D25A) residues that are 
poor N-caps, but have strong α-helical propensity, does not affect Sgs1 function. (d) 
Extending proline mutagenesis N-terminally of the first α-helical region reveals 
additional functional residues (L9, H13, H17).  
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Figure 3.5: AGADIR (57) prediction of the helical content of the N-terminus of 
Sgs1. (a) In wild-type Sgs1 (dotted line), a prominent peak of helical propensity is 
predicted at residue I33 and a smaller peak at residues R10–E12. Residue D25 
received the highest N-cap score (open columns). (b) The deleterious D25P mutation is 
predicted to reduce the helical content of the D25–A38 region, whereas the 
nondeleterious K26P mutation is not. (c) Replacing the N-cap residue D25 with residues 
that have excellent helical propensity, but are poor N-cap residues (lysine, alanine), is 
not predicted to reduce helical content of the D25–A38 region, but predicts an N-
terminal extension of the helical region with a new peak of helical content at residue 
Q23 in the D25A mutant and at residue L22 in the D25K mutant. 
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Figure 3.6: HSQC spectra and secondary chemical shift (CAΔδ) analysis of the 
first 80 residues of Sgs1 with a proline substitution at residue 30 (sgs11–80-F30P). 
(a) The overlay (Merged) of the HSQC spectra of wild-type Sgs1 (blue) and the sgs1-
F30P mutant (red) reveals shifts in the peak assignments for residues F28, V29, Q31, 
A32, I33, Q34, I37 and A38, which form a transient α-helix in wild-type Sgs1. (b) 
Consecutive positive secondary alpha carbon chemical shifts (CAΔδ) between residues 
D25–A38 in wild-type Sgs1 (open blue columns), which indicate the presence of α-
helical secondary structure in the unbound Sgs1 peptide, are markedly reduced in the 
Sgs1-F30P mutant (red filled columns). 
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Figure 3.7: Loss of function of Sgs1 proline mutants is due to loss of Top3 and 
Rmi1 binding. Sgs1 proline mutants were expressed as N-terminal GST fusions in E. 
coli and purified by binding to glutathione beads. Top3 and Rmi1 were obtained from 
native whole-cell extracts of yeast strains KHSY2497 (RMI1), KHSY4695 (rmi1Δ) or 
KHSY4696 (RMI1.MYC), KHSY4741 (top3Δ), which express epitope-tagged Top3 
and/or Rmi1 from their chromosomal loci under their native promoters. (a) Binding of 
Top3 to the Sgs11–250 peptide is Rmi1-dependent. (b) Binding of Rmi1 to the Sgs11–250 
peptide is Top3-dependent. (c) Deletion of RMI1 does not lead to loss of Top3 
expression. (d) Deletion of TOP3 does not lead to loss of Rmi1 expression. (e) The 
Sgs11–250 peptide binds Top3 more strongly than the shorter Sgs11–160 peptide. (f) The 
Sgs1125–250 peptide does not bind Top3, indicating that critical residues for Top3 binding 
are located in the first 125 residues of Sgs1. (g) Proline mutations at L9, H13, K17, D25, 
V29 and F30, but not at T21 and K26, reduce binding of Sgs11–250 to Top3. (h) Proline 
mutations at H13 and F30, which reduce binding of Sgs11–250 to Top3, also reduce 
binding to Rmi1.  
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Table 3.1. Effect of proline substitutions in the transient α-helix between residues 
D25 and A38 of Sgs1 on the rate of accumulating GCRs 
 
Relevant 
genotype 
Plasmid 
GCR rate (Canr 5–
FOAr × 10−8) 
95% CIa (Canr 5-
FOAr × 10−8) 
Increase over wild 
type (SGS1) 
SGS1 pKHS481 58 34–73 1 
sgs1-D25P pKHS494 334 260–789    6 
 
sgs1-K26P pKHS500 71 39–132    1 
 
sgs1-V29P pKHS492 320 189–352    6 
 
sgs1-F30P pKHS482 704 194–996  12 
 
sgs1-I33P pKHS496 211 165–255   4 
 
 ↵a95% confidence intervals were calculated according to Nair (40), with 
nonoverlapping confidence intervals indicating statistically significant differences 
(α < 0.05) between median GCR rates.  
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Figure 3.8. Helical content prediction for the N-termini of Sgs1, WRN and BLM  
(57). (a) In human BLM, which binds to the human Top3 homologue Topo IIIα, a 
prominent peak of helical content is predicted at residues Q12 and L13, which 
corresponds to the small R10–E12 peak in Sgs1. A peak corresponding to that at 
residue I33 in Sgs1 is not predicted in BLM, in part because of a proline residue at 
position 30. (b) The distribution of predicted helical content for the N-terminus of human 
WRN, which binds to Topo I, but has not been shown to bind to Topo IIIα, is similar to 
Sgs1, with two prominent peaks at residues E10 and A30, corresponding to similar 
peaks at R10–E12 and I33 in Sgs1.  
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Table 3.2: Plasmids used in this study 
 
Plasmid Description                                                                                                                
pRS415 CEN/ARS, LEU2 
pKHS443 pET28a-Sgs1N1-125 
pKHS463 pET28a-Sgs1N1-80 
pKHS481i pRS415-SGS1                                                                             
pKHS482 pRS415-SGS1-F30P 
pKHS484 pRS415-SGS1-W92PL93P  
pKHS485 pRS415-SGS1-L93P  
pKHS489 pRS415 -SGS1-K26P  
pKHS492 pRS415-SGS1-V29P  
pKHS494 pRS415-SGS1-D25P  
pKHS496 pRS415-SGS1-I33P  
pKHS497 pRS415-SGS1-Q34P  
pKHS546 pGEX-6p-2-SGS1N1-250-K26P  
pKHS547 pGEX-6p-2-SGS1N1-250-V29P   
pKHS548 pGEX-6p-SGS1N1-250-F30P  
pKHS582 pRS415-SGS1-L9P  
pKHS583 pRS415-SGS1-H13P  
pKHS584 pGEX-6p-2-SGS1N1-250-L9P  
pKHS585 pGEX-6p-2-SGS1-250-H13P  
pKHS586 pGEX-6p-2-SGS1N1-250-T21P  
pKHS587 pGEX-6p-2-SGS1N1-250-K17P  
117 
 
Table 3.2: Plasmids used in this study 
(Continued) 
Plasmid Description                                                                                                                
pKHS588 pRS415-SGS1-L181P  
pKHS589 pRS415-SGS1-L215P  
pKHS590 pRS415-SGS1-T61P  
pKHS591 pRS415-SGS1-L176P  
pKHS592 pRS415-SGS1-W15P  
pKHS594 pRS415-SGS1-I37P  
pKHS595 
pKHS596 
pKHS598 
pGEX-6p-2-SGS1N1-250-D25P 
pRS415-SGS1.MYC 
pRS415-SGS1.MYC-F30P 
pKHS600 pRS415-SGS1.MYC-H13P 
pRS415 is a gift from Dr. Steven Brill (Rutgers University) 
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Figure 3.9: Proline substitutions in Sgs1 that cause hypersensitivity to the DNA 
damaging agent hydroxyurea do not affect expression levels of the sgs1 mutant 
proteins. The sgs1Δ mutant KHSY1338 was transformed with plasmids pKHS596 
(Sgs1.myc), pKHS598 (sgs1-F30P.myc) or pKHS600 (sgs1-H13P.myc). Whole cell 
extracts were prepared by TCA extraction from mid-log phase cultures and separated 
by 10% SDSPAGE. Wildtype Sgs1 and the sgs1-F30P, sgs1-H13P mutants were 
detected by Western blotting with monoclonal antibody against the C-terminal myc-
epitope. GAPDH was detected by a monoclonal antibody against GAPDH.  
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Figure 3.10: Helical content prediction for the N-terminus of S. pombe 
Rqh1 by AGADIR (57). The distribution of helical content for the first 
322 residues, which are required for interaction with Top3 (9), are 
shown. The first prominent peak is predicted at residue M117 within a 
15-residue segment spanning from D112 to Q127, and a second peak at 
I286 within a 27-residue segment spanning from H264 to R291.  
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CHAPTER FOUR: 
 
THE ROLE OF PROTEIN DISORDER IN CHROMATIN PROCESSES OF S. 
CEREVISIAE 
 
 
Introduction 
Classically, proteins have been defined by three dimensional structure—function 
is dictated by the shape a protein takes.  Recent developments, however, suggest that 
Intrinsically Disordered Proteins/Regions (IDP/Rs) play a large role in the sometimes 
complex functions of many proteins.  Disordered proteins are found in the regulation of 
transcription/translation, cell signaling, phosphorylation, and small molecule storage [1-
6]; given this wide range of duties, it should be unsurprising that this class of proteins is 
well-represented in many organisms. Studies using disorder prediction software have 
suggested that bacterial proteomes can be expected to be between 7-33% disordered, 
and Archaea 9-37% [7]. This percentage increases with organism complexity. In 
Saccharomyces cerevisiae, up to 60% of the total proteome is predicted to have some 
degree of disorder spanning at least 30 consecutive residues, the minimum definition for 
an IDR [8]. Approximately 6% of the proteome estimated to be wholly disordered [9]. 
Biologically, these proteins appear to be enriched in functions including the stress 
response, cell cycle, and electron transport [9].  Up to 25% of the total human proteome 
is predicted to be disordered, and include proteins with a wide range of functions, 
including Securin, Calpastatin, Caldesmon, and Tau [8-10]. As a class, IDRs are 
characterized by a large degree of polar and charged residues, a deficiency in large, 
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bulky, hydrophobic residues, a lack of persistent secondary and tertiary structure, little 
sequence complexity, a low degree of compactness, and a high degree of open, 
random-coil “shape,” existing as an ensemble of dynamic conformations [1, 11-13].  A 
lack of hydrophobic residues may prevent the protein from adopting structure as it 
prevents the formation of a hydrophobic core, but there are known instances of 
“induced-folding” models, whereupon disordered proteins assume structure once they 
are bound by a specific ligand [14-19].  Such disordered regions may have small 
pockets of persistent or transient secondary structure that may facilitate initial binding 
[20].  Because the proteins do not commit to one particular structure, a common theory 
of “binding promiscuity” in disordered proteins means that open conformation becomes 
a boon to proteins needed in several biological pathways, as the same area could serve 
as a binding site to several different proteins. A well-studied example is the 
Transactivation Domain of p53, which mediates interactions between several proteins, 
including p300/CBP and MDM2/MDM4 [21].  In addition to this benefit, IDP/Rs are also 
good sites for post-translational modifications, since the protein’s flexible nature allows 
for easy access to modification sites by a wide range of effectors [22].   Flexibility in the 
protein can also favor faster interaction rates between protein and ligand, as the open 
conformation’s larger target size may eliminate the restrictions of orientation present in 
the rigid “lock-and-key” models of structured proteins.  IDRs provide easy access for 
kinases and phosphatases, thus making them ideal with regards to biological processes 
that have time constraints and the need for transient modification events [7]  
IDP/Rs can exist as either entropic chains—which provide elasticity or act as 
“linker” regions between structured domains—or a second major functional class that is 
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comprised of “display sites” (sites for post-translational modification by modifying 
enzymes), “chaperones,” “effectors” (modifiers of binding partners), “assemblers” 
(responsible for binding several proteins, possibly in large complexes) and “scavengers” 
that store small molecules [23].   As proteins can have multiple disordered regions, it is 
not impossible that one protein can serve several of these functions.  A look at the 356 
wholly disordered proteins of S. cerevisiae reveals this complexity—142 are unidentified 
reading frames with no known function; truly, these proteins may serve in many 
capacities, and this level of complexity may make elucidation of some functions difficult 
[8]. Difficulty assigning a function to the protein products of these genes may also arise 
from the lack of structure that the proteins are hypothesized to assume; with no known 
folds and domains, it becomes difficult to make comparisons to proteins with similar 
structure and known function.  Disordered regions can also adopt different structures 
upon binding to different ligands which further complicates the identification of relevant 
biochemical pathways and protein/protein interaction in that the same disordered area 
can serve as a functionally different hub for several different partners.  For instance, the 
tumor suppressor p53 C-terminus has been found to adopt different types of secondary 
structure when bound to different partners, and the HIF-1α activation domain adopts 
either alpha helical or extended structures depending on whether it is binding co-
activator p300 or transcriptional mediator FIH [1].  This caveat is important when 
considering conservation of certain structural motifs between homologs; since 
disordered proteins can undergo induced folding upon partner binding, the use of X-ray 
crystallography as a means to study these regions coupled with a partner may be 
misleading.  In addition to perhaps underestimating the degree of disorder in a 
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proteome based on tandem purification and crystallization [8], the conformation of the 
protein that is disordered in apo formation may vary substantially depending on which 
partner it is coupled with in the 3d analysis.  Hence, there are many other tools in use to 
study disordered proteins in both complexed and unbound form, including nuclear 
magnetic resonance, small-angle x-ray scattering, atomic force microscopy, and 
paramagnetic spin labelling  [24].  
 When DNA damage in S. cerevisiae occurs, DNA repair proteins in several 
different pathways receive signals from DNA damage sensor proteins via mediator 
proteins and kinases in an effort to modify the chromatin in such a way that facilitates 
repair such as homologous recombination, non-homologous end joining, and excision 
repair. Depending on the type of damage, proteins involved in detecting and properly 
repairing damage can include several checkpoint proteins and kinases [25-27] (e.g. 
Mec1, Rad53), which require modification from and interaction with upstream and 
downstream protein elements, and enzymes for functions ranging from break resection 
[28-30] (e.g. Exo1, Sgs1, MRX proteins), base excision [31] (e.g. Rad27) nucleotide 
excision [32] (e.g.. Rad16), and ligation of DNA breaks [33] (e.g. Lig4), which require 
the ability to themselves be modified, as well as interact with other proteins that may be 
found at DNA breaks, unusual DNA structures, or stalled replication forks. Given this 
complex network of interaction and modification, we hypothesized that S. cerevisiae 
DNA repair proteins may contain an enrichment of functional disorder, since this type of 
non-structure facilitates these protein functions well.  Study into some yeast proteins 
have indeed found that these proteins have predicted or confirmed regions of disorder 
important for proper protein function [34, 35].    Given that the proteins of DNA repair 
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and related chromatin processes are, overall, highly prone to interaction and 
modification, and since one of the major roles of disordered regions is to facilitate these, 
we asked whether or not disorder is overrepresented in the S. cerevisiae proteins, and, 
if so, which of these points seems to be a driving force in the occurrence of functional 
disorder. To this end, we have conducted a survey of 160 proteins classified in  the 
protein database, Uniprot,  as DNA repair proteins and analyzed them using PONDR-
VLXT[36] and PONDRFIT [37], software that can predict both the presence of disorder 
and putative protein binding sites.  Analysis established the degree to which disorder 
plays a role in budding yeast DNA repair, and how this disorder may be a function of 
protein/protein interaction and phosphorylation.  Our analysis gives some insight into 
the role of functional disorder in this protein subset, and can be used as a source for 
experimental design beyond classical approaches like sequence alignments. 
 
Methods 
Formulation of protein data set 
Our protein data set was manually constructed by searching the S. cerevisiae 
Uniprot (European Bioinformatics Institute) database for the term “DNA repair.”  The top 
160 non-repetitive hits were selected and their FASTA sequence files were obtained 
from the Saccharomyces Genome Database (SGD) at http://www.yeastgenome.org/.  
 
 
 
 
125 
 
Disorder prediction and interaction site prediction 
Disorder prediction was provided by PONDR-VLXT [36], and interaction site 
prediction was analyzed using PONDRFIT [37] software, provided at 
http://www.disprot.org/pondr-fit.php and http://www.pondr.com/index.  
 
Repair classification and phosphorylation 
Repair classifications for all protein in the data set were manually determined by 
using the GO terms provided in the Saccharomyces Genome Database (SGD).  
Phosphorylation sites were manually evaluated by using the SGD Phosphogrid 
database on the “protein” section of each entry. Phosphogrid can be found at 
www.phosphogrid.org.  
 
Results 
 PONDR-VLXT predicts disorder based on a protein’s likelihood to form a folded 
core. Analysis using PONDR-VLXT in human cancer-associated proteins found that 
these proteins, as well as regulatory and cytoskeletal proteins were two-fold as likely to 
contain disordered regions >30 residues than proteins involved in metabolism, 
biosynthesis and degradation [3]. Hub proteins, those with >10 binding partners, were 
found to be significantly more disordered than non-hubs in protein sets from C. elegans, 
S. cerevisiae, D. melanogaster, and H. sapiens [35]. A study of the yeast transcriptional 
network showed that within yeast transcriptional proteins, transcriptional hubs contained 
the greatest amount of disorder [38]. In addition to binding, functional disorder can be 
used to modulate post-translational modifications, as flexible linker regions, as a 
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stimulus for protein degradation, and as scaffolding regions for protein complexes [7, 
39, 40]. Given the prevalence of IDRs, and given that proteins in the chromatin 
processes are often subject to roles that disorder facilitates, we asked whether or not S. 
cerevisiae chromatin processes proteins were more prone to disorder than the whole S. 
cerevisiae proteome. We evaluated proteins in the chromatin processes data set for the 
presence of at least one IDR as predicted by PONDR-VLXT; in the data set, 72.5% of 
the proteins contained disorder (Figure 4.1A), versus the predicted 60% in the total 
proteome [9]. In order to further investigate the function of this overrepresentation, we 
first considered the possibility of increased number of protein/protein interaction sites in 
chromatin processes proteins, since IDRs are prone to modulate several interactions. 
PONDRFIT has the capability to predict interaction sites on a protein by evaluating 
whether a stretch of amino acids will be chemically fit for burial into a partner protein. Of 
the 160 proteins in our set, PONDRFIT predicted at least one interaction site in 110 of 
the proteins, with an expected decrease in the number of proteins found with an 
increasing number of predicted sites (Figure 4.1B). To further investigate the role of 
disorder in protein/protein interaction of chromatin processes proteins, we asked what 
fraction of these interaction sites occurred in proteins with an IDR (Figure 4.1C). 
Interestingly, the proteins with no predicted interactions sites were overwhelmingly 
proteins without IDRs (20% ordered vs. 11% disordered), while proteins with one or 
more interactions were overwhelmingly proteins with at least one predicted IDR.  
Perhaps even more striking, proteins with 3 or more predicted interaction sites are 
exclusively proteins with IDRs, suggesting a primary role for protein/protein interaction 
with regards to disorder in the chromatin processes data set.  When evaluating the data 
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for predicted interaction sites, we further focused on the proteins in the top 5% with 
regards to number of predicted interactions. These proteins contained a large number of 
interaction sites (8-13 sites). In order to establish a connection between number of 
interaction sites and biological function, we researched the putative physical binding 
partners for the proteins in this top 5%, including Mrc1, Rad9, Slx4, Sgs1, Zip1, Rad2, 
and Xrs2 (Figure 4.1D), using the SGD database, and found that all seven have been 
found to interact with a large number of protein partners (Table 4.1).  
 With these proteins in mind, we hypothesized that the high occurrence of 
disorder in the chromatin processes proteins was a result of disorder facilitating the 
predicted interaction sites. We then mapped the PONDRFIT data to the disorder 
prediction from PONDR-VLXT in an effort to ascertain to what degree disorder and 
interaction sites are connected. For the top 5%, there is a clear bias toward interaction 
sites located in disordered regions; for all proteins in this set, anywhere between 50 and 
75% of the predicted interaction sites occurred in areas of disorder. There was also a 
large overall number of disordered regions in these proteins, with anywhere from 4 to 10 
total regions ≥30 residues identified (Figure 4.2A). These regions vary in length 
between 30 residues in Rad2 and 304 residues in Sgs1; for the most part, however, 
there is little variation in average region length, with a mean range of 65-119 residues 
for the 7 proteins (Figure S4.2). Also of note was the location of the majority of those 
residues predicted by PONDR-VLXT to be disordered; for the top 5% of interactors, 
there was little difference between the percent of disordered residues found within IDRs 
and the overall percentage of disordered residues in the total protein, implying that the 
majority of disordered residues are in longer stretches of disorder, and suggesting that 
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the disorder is functional (Table 4.3).   In an effort to understand the biological role that 
these interaction sites in disorder may play, we looked at the DNA damage signaling 
cascade, which contains 3 of the 7 proteins in the top 5%. The adaptors of the pathway, 
Rad9 and Mrc1, contain the greatest number of predicted interaction sites, and a large 
percentage (64% and 69%, respectively), are predicted in disordered regions. Because 
these proteins mediate several up and downstream partners, it is possible that the 
increased number of binding sites in disorder serves to accommodate all partners over 
the smallest amount of primary structure possible, as has been seen in other IDRs (e.g. 
p53) [41]. Another protein from the top 5%, Xrs2, is not a mediator of the signaling 
response, but is a member of an upstream complex whose partners contain small 
numbers of predicted interaction sites. Thus, Xrs2 presents another function for 
increased disorder and protein interaction in the chromatin processes set; Xrs2 can 
contain a large number of interaction sites, freeing the remaining complex members, 
Mre11 and Rad50, for other functions, particularly catalytic nuclease and ATPase 
activities; we discuss this function further below (Figure 4.2B).  
 Given that the top 5% had a large number of interactions predicted in IDRs, and 
given that a large number of predicted interactions seemed to connect well with a 
biological function requiring disorder modulating protein/protein interaction in the 
signaling cascade, we asked whether or not there were other traits of disorder in these 
proteins that correlated with an increased number of protein interaction sites. We first 
evaluated the data set for overall percentage of disordered residues per protein as 
predicted by PONDR-VLXT. No proteins in the set contained all residues with a disorder 
probability < 0.5, and one protein, Sml1, was 100% disordered. Sml1 is an inhibitor of 
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ribonucleotide reductase, and is degraded in response to DNA damage to increase 
dNTP pools needed for repair [42]. This degradation is regulated by post-translational 
modifications, which are easily accessed in IDRs. In addition, it has been suggested 
that there is a weak correlation between disorder and increased degradation rate; given 
Sml1’s need to be overturned in the presence of DNA damage, the prevalence of 
disorder in this protein could have a functional role [43]. Overall, the proteins in the data 
set were skewed toward being 40% or less disordered, with 20% of the proteins 
exhibiting 1-10% total disorder, 26% exhibiting 11-20% total disorder, 24% exhibiting 
21-30% disorder, and 14% exhibiting 31-40% disorder (Figure 4.3A).  We predicted a 
relationship between the overall percentage of disordered residues and number of 
interactions predicted by PONDRFIT, but found little correlation between the two values 
(R2= 0.3149) (Figure 4.3B). Extreme examples like Sml1 and Slx8 reveal why this 
correlation is so poor; the two proteins are 100% and 76% disordered, but contain two 
and zero predicted interaction sites, respectively. This could imply that the prevalence of 
disorder in these proteins is the result of an increased need for modification rather than 
protein/protein interaction. It is possible, too, that the PONDRFIT analysis is insufficient 
to detect binding if a protein is in a “fuzzy complex.” These binding events are often 
more dynamic than those seen in induced-fit models [44], and may be overlooked in the 
algorithm, since they do not normally form a structural state that requires specific (likely 
hydrophobic) chemistry that the program accounts for when predicting binding sites.  
When we evaluate the checkpoint cascade, we saw little overall difference in percent 
disorder amongst most of the proteins in the cascade, despite differences in predicted 
interaction sites seen in Figure 2B (Figure 4.4). Thus, we suggest that while the high 
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degree of chromatin processes protein with IDRs is likely a result of need for 
protein/protein interaction, overall disorder is a poor indicator of increased protein 
interaction. We then reevaluated the distribution of disorder within the protein set by 
taking into account only the percentage of the protein residues that have both PONDR-
VLXT scores ≥ 0.5 and are located in IDRs. This changed the protein profile from that 
seen in Figure 4.3A; almost 28% of the proteins contained no residues with PONDR-
VLXT scores > 0.5 in IDRs (Figure 4.5A). This shift suggests that a considerable 
amount of the overall disorder in some proteins in the set are distributed in smaller 
regions, which may be less likely to be functionally protein-binding than a larger region 
exceeding 30 residues. We considered that not overall disorder, but rather the number 
of disordered regions a data set protein contains is a good predictor of protein/protein 
interaction propensity.   When we compared this value to predicted interaction sites, a 
stronger correlation resulted (R2= 0.6026) (Figure 4.5B). Looking back at the checkpoint 
cascade, we see that the proteins in the cascade with the highest number of disordered 
domains, Xrs2, Rad9, and Mrc1, are also the proteins identified as having a the largest 
number of putative interactions (Figure 4.6). Rad50 bucks this trend with 4 disordered 
domains (like Rad9 and Xrs2), but only 3 predicted interaction sites. One suggestion is 
that because Rad50 may play a role in binding DNA at double strand break ends, and 
because disorder has been found to be prevalent in proteins that bind DNA [45] . We 
propose that overall number of disordered domains, then, is a better indicator of 
increased protein/protein interaction, and that biological function, particularly as a 
binding hub or central binding protein in a complex, is highly connected to a greater 
number of disordered domains. 
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 While evaluating the connectivity between biological function in the checkpoint 
cascade with protein interaction, we noticed Xrs2 as the sole member in its complex 
with Mre11 and Rad50 with a high number of predicted interaction sites versus the 
partners (10, versus 3 for both Mre11 and Rad50). We asked whether this pattern was 
also repeated in other complexes that had two or more members in our data set. When 
we compared the number of predicted interaction sites between complex protein 
members, we noticed that, in general, most complexes, including Mre11/Rad50/Xrs2, 
Slx4/Slx1, Rad55/Rad57, Slx5/Slx8, Lif1/Lig4 Sgs1/Rmi1, and 
Rad2/Tfb1/Tfb2/Rad3/Ssl1 contained a complex member that had 3 or more predicted 
interaction sites and a complex member with little or no predicted interaction (Figure 
4.7A). This observation correlates well with the complex member with the highest 
number of predicted interactions also being the complex member with the greatest 
number of disordered domains, with Mre11/Rad50/Xrs2 and Rad55/Rad57 being the 
two notable exceptions (Figure 4.7B).  Conservation of those proteins in complex with 
the most protein interaction and disorder is often the most poor of all complex members. 
Slx4 is so poorly conserved that BLAST analysis only returns hits for Saccharomyces 
species [46]. Xrs2 is poorly conserved when compared to Mre11 and Rad50, and is only 
found in eukaryotes [47]. The human homolog, Nbs1, only has 29% homology to Xrs2 in 
the structured N-terminal region, and no significant homology in the C-terminus, which 
is predicted to be disordered in both proteins [48]. As disordered regions tend to tolerate 
evolution better than ordered regions [49], it suggests an evolutionary advantage to 
these complex members with regards to chromatin processes. Evolution can occur in 
one protein more neutrally to account for increasing organismal complexity, while the 
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others, often with catalytic domains or specialized folds, can evolve more 
conservatively.  
 Another major role of functional disorder in proteins is post-translational 
modification. The “open” conformation of disordered regions provides a more accessible 
area for modifiers like kinases to apply modifications to residues than those seen in 
folded proteins, which bury a large percentage of its primary structure [50]. Post-
translational modification like phosphorylation is also used as a means of enthalpy 
compensation for the entropy loss incurred when disordered regions undergo folding in 
response to protein/protein interaction; thus, modification and interaction at disordered 
sites are sometimes tied [51, 52].  Protein/protein interaction is clearly a driving force for 
increased need in disorder in the chromatin processes proteins over the yeast proteome 
at large, but since several of these proteins undergo post-translational modification in 
response to cellular signal for chromatin modification, we also considered that 
modification played a role in the disorder overrepresentation in our data set. 
Phosphorylation is one of the most closely studied modifications in S. cerevisiae, and 
high-throughput studies of the phosphoproteome have been conducted [53, 54]. Thus, 
we decided to use phosphorylation as an indicator of the role of disorder in modification 
of chromatin processes proteins. We used phosphogrid to acquire phosphorylation sites 
for all proteins and began by accessing whether phosphorylation tended to occur more 
often in proteins with or without disorder. In our set, 14% of the proteins have no IDRs 
or any phosphorylation sites; 11% were completely ordered, but contained at least one 
phosphorylation event. The most represented group in the set, however, were proteins 
both containing disorder and at least one phosphorylation site, which comprised 64% of 
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the total chromatin processes data set (Figure 4.8A). We decided to look at this 
particular group more closely to ascertain if this increase in phosphorylation was 
actually occurring in IDRs in these proteins. When we looked at proteins with at least a 
single phosphorylation event and mapped the site to disordered regions as predicted by 
PONDR-VLXT, we established that a small percentage (19%) had no known 
phosphorylation occurring in disorder. The overwhelming majority of proteins had at 
least one of the known phosphorylation events occurring in disorder, and 32% of the 
proteins had all known phosphorylation events occurring in disordered regions (Figure 
4.8B). Given these results, it can be surmised that disorder in the chromatin processes 
proteins exists to accommodate both increased protein/protein interaction and 
phosphorylation events. 
 
Discussion 
In this study, we evaluated the role of disorder in the Chromatin Process 
proteome, and established that disorder is overrepresented in these proteins, likely as a 
result of the need for extensive protein/protein interactions and sites for modification via 
phosphorylation.  We identified a subset of Chromatin Process proteins that are highly 
connected in the number of predicted interaction sites and the location of these sites in 
disorder.  Based on other studies in disorder, the overrepresentation of disorder in DNA 
repair is consistent with other findings; it has been reported that biological function with 
a high need for regulation, signaling, and complex formation [55], all roles that are 
highly prevalent in DNA repair.  While our analysis in the checkpoint cascade clearly 
shows that there is not a need for disorder at all steps, those proteins with the highest 
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orders of disordered domains are the mediators/adaptors of the cascade response, and 
have a larger number of substrates.  A large number of disordered interaction areas 
allow the protein to accommodate the various proteins in downstream interaction 
without the need for the protein being too large or adding large, bulky domains over the 
course of evolutionary history as species and DNA damage response becomes more 
complex.  Proteins in the cascade like the kinases, however, do not have a need to be 
extensively disordered if their downstream substrates are; indeed, the kinases in the 
cascade (Mec1, Tel1, Dun1, Chk1, Rad53), all display low orders of disorder.  In the 
case of Mec1 and Tel1, the immediate substrates are rich in disordered domains, and in 
the complete data set, there is a high variability in disorder in the effector proteins; it is 
not beyond reason that a good deal of these will be disordered or in complex with a 
disordered protein, as approximately half of kinase substrates are highly unstructured, 
while only 19% are not, and 85% of kinases with 50% or more of substrates with a high 
level of disorder (>30% of the protein) are implicated in response to a particular stimulus 
or stress, such as DNA damage [56]. 
It is interesting that greater number of protein/protein interactions is not a function 
of total protein disorder, as a great deal of flexibility may imply a greater deal of binding 
promiscuity possible, allowing for several interactions over one large area via an 
induced-fit folding model.  However, the role of linear motifs, short, sometimes well-
conserved stretches often found in disordered regions can explain why we see a greater 
number of interaction in proteins with several smaller disordered domains; linear motifs 
are interaction areas that are a subset of induced-fit interactors, and are implicated in 
transient and low-affinity binding events, such as modification by kinases [57].  Using 
135 
 
the profiles of the high-number interactors as an example, one can see that there are 
several “dips” in the disorder prediction plots that cover short spans of residues (Figure 
4.9).  It is possible that these are linear motifs that break up what would otherwise be a 
long disordered domain, thereby increasing the number of domains, but decreasing the 
overall percentage of disorder, especially in shorter proteins.  These motifs can work 
alone or in tandem with other motifs, and can acquire post-translational modifications 
that can change the target of the motif.  In total, the presence of these motifs may serve 
as anchoring points for several protein/protein interactions and the disorder flanking 
them may serve to further facilitate binding.  A large number of disordered domains with 
a large number of surrounding linear motifs are a likely explanation for the higher order 
interactions; in fact, we have already studied the presence of one motif in Sgs1 
extensively using NMR [34].  The transient alpha-helix in the N-terminus of the protein 
facilitates the binding of the Top3/Rmi1 complex, and the downstream disorder has 
been shown to accommodate the binding as well, as the optimal binding domain 
extends well beyond the indispensable docking structure.  There may, in fact, even be a 
second motif that facilitates binding as well, as we found that a longer 250 residue 
peptide bound Top3 and Rmi1 better than a shorter 160 residue peptide [34].  There is 
a notable dip in the disorder profile in Sgs1 in the region the shorter peptide lacks; while 
it is larger than one would expect from a linear motif, it is possible that there are several 
small structures that make up the region, skewing interpretation of the profile, but 
implying further binding events over the same length.  
The finding that phosphorylation in DNA repair proteins has a strong bias in 
disorder is something that has been described in whole proteomes previously; a study 
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of the human proteome revealed that proteins described in GO terms as 
“phosphorylation” targets was one of the categories investigated most enriched in 
disordered proteins [58].  An intensive study of the residue composition flanking 
phosphorylated residues showed an enrichment of “surface exposed” residues around 
all 3 types of phosphorylated residues and the sequence complexity of these flanking 
regions were relatively low [59]; both qualities are used to define disordered proteins. 
p53 is a well-studied example of how phosphorylation provides versatility in disordered 
regions often not afforded in folded regions; the phosphorylation status of p53 changes 
the affinity of different protein interactions and some regions have been shown to adopt 
a different three-dimensional form depending on the partner bound to it, thus this 
important protein can regulate the protein/protein interactions in time and cover several 
interactions over a smaller distance needed than seen in a folded protein by utilizing 
disorder [16, 60, 61].  Because several of the proteins in chromatin processes 
participate in several different interactions and/or types of repair, the degree of disorder 
and phosphorylation overrepresented in the chromatin processes protein set is to be 
expected; in an effort to keep the proteins involved from becoming so large that they are 
metabolically draining on the cell, the addition of disorder in the transition from bacteria 
to yeast allows one protein to accommodate several binding events over one region and 
be modified by signaling proteins as a means to regulate when and where these 
interactions take place.  The DNA damage checkpoint response and facets of DNA 
repair require interactions that are transient in nature, and disorder that is easily 
modified accommodates this need, as it tends to be high in specificity, low in affinity, 
and easily accessed by regulating enzymes.  Biochemically, phosphorylation is likely 
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also biased to these areas in order to accommodate extended protein/protein interaction 
as the modification can sometimes be sufficient to drive the enthalpic penalty that is 
incurred when the disordered region undergoes a transition from disorder to order [61].  
Since we hypothesize that many of these disordered regions in Chromatin Process 
proteins, especially in higher order interactors, contain recognition elements to facilitate 
binding and eventually undergo extensive folding, it is likely that, in some cases, 
modification of these proteins may be a function of providing the necessary energy for 
the folding of the element and its flanking disorder to occur. 
Because we have shown that disorder is predicted to occur in a large percentage 
of chromatin processes proteins, and because there is a role for interaction and 
modification in these regions, we offer a warning to those studying these proteins using 
classical methods like primary sequence alignment. While it is possible that sequence 
conservation can exist in areas of conserved disorder, it is more likely that the sequence 
can vary substantially so long as disorder and the overall chemistry of the region does 
not change [62, 63]. It is possible, then, to miss areas of functional binding and 
modification if one relies solely on sequence identity as a means of studying homologs. 
We suggest that the presence of disordered regions in chromatin processes protein be 
considered in the future when trying to solve pertinent functional domains and when 
comparing regions of binding and modification between orthologs. 
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Figure 4.1: Prevalence of disorder and predicted interaction sites in Chromatin 
Processes proteins. A) Proteins in the Chromatin Processes data set were evaluated 
using PONDR-VLXT for at least one stretch of disordered residues (VLXT value ≥ 0.5) 
greater than or equal to 30 residues (proteins with disorder). B) PONDRFIT was used to 
predict the protein/protein interaction sites of the proteins in the data set. C) Proteins 
were divided into proteins with and without at least one disordered region with regards 
to number of predicted interactions. Interaction prediction is most prevalent in proteins 
with at least one disordered region. D) Identity of the top 5% of proteins in the set with 
the highest number of predicted interaction sites. 
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Figure 4.2: Predicted interaction in disorder for top 5% of highest-number 
interactors and role in checkpoint cascade. A) The top 5% of interacting proteins 
were evaluated by location of PONDRFIT-predicted interaction in disordered regions 
predicted by PONDR-VLXT ≥30 consecutive residues. B) The role of 3 of 7 of the 
top5% in a simplified model of the DNA damage checkpoint cascade. Mediators of the 
response have the highest number of predicted interaction sites, while the kinases up- 
and downstream have few or no interactions predicted. 
 
A) 
B) 
145 
 
 
 
Figure 4.3: Percentage of disordered residues is not an indicator of a large number of predicted interactions. A) 
Overall protein disorder (residues with value ≥ 0.5) as predicted by PONDR-VLXT versus percent of the protein. B) 
Correlation between percentage of overall disordered residues and number of PONDFIT-predicted interaction sites.  
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Figure 4.4: Evaluation of percent disordered residues in damage checkpoint response pathway. There is no 
correlation between role of a protein and/or the number of predicted interactions and percentage of overall disorder. 
Percent disorder is noted next to the protein. 
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Figure 4.5: Number of disordered domains is the best indicator of a large number of predicted interactions. A) 
Percent of disordered residues in IDRs as predicted by PONDR-VLXT (residues with value ≥ 0.5). B) A moderate 
correlation exists between number of total IDRs in a Chromatin Processes protein and the number of predicted interaction 
sites. 
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Figure 4.6: Evaluation of number of disordered domains in damage checkpoint response pathway. There is a 
correlation between role of a protein and/or the number of predicted interactions and number of IDRs as predicted by 
PONDR-VLXT. Mediators of the checkpoint appear to have the greatest number of IDRs; large numbers are also present 
in complexed proteins, usually in conjunction with one or more proteins with few IDRs. The number of domains is noted 
next to the protein. 
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Figure 4.7: Protein complexes in Chromatin Processes proteins have one member with a large number of 
predicted interactions and disordered domains. PONDR-VLXT predicted disordered domains and PONDRFIT 
predicted interactions were compared between protein complex members who had at least two members in the data set. 
The number of predicted sites or domains is indicated next to the protein. 
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Figure 4.8: Phosphorylation in chromatin processes proteins occurs most 
frequently in disordered domains. A) Phosphorylation sites for the protein set were 
taken from PHOSPHOGRID; proteins without a disordered domain dominated the group 
of proteins in the set with no phosphorylation events, while almost 70% of the data set 
was both phosphorylated and had at least one disordered domain. B) Phosphorylation 
occurs completely in disorder in nearly 35% of all proteins with at least one disordered 
domain. 
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Table 4.1: Known interacting partners of top 5% highest-number interactors in the 
Chromatin Processes data set 
Protein 
Name 
Total # of 
Predicted 
Interaction 
Sites Known Interacting Proteins 
Mrc1 13 
Cdc45, Cmk2, Cse4, Csm3, Ctf4, Dia2, Dpb2, Gwt1, Hht1, 
Hht2, Hog1, Mcm2, Mcm3, Mcm4, Mcm6, Mec1, Pol2, Prp9, 
Psf2, Rad53, Rpn3, Sld5, Smt3, Spt7, Stb2, Taf9, Tof1, Tye7, 
Ubi4 
Rad9 11 
Cdc14, Cdc28, Cdc5, Chk1, Clb2, Dpb11, Dun1, Hta1, Hta2, 
Mec1, Nab2, Rad17, Rad52, Rad53, Rad9, Smt3, Ubi4 
Sgs1 10 
Bud27, Cdc28, Cmr1, Dna2, Frk1, Gis1, Ksp1, Mec1, Mlh1, 
Mlh3, Mre11, Msh6, Prp45, Rad16, Rad51, Rad53, Rfa1, 
Rmi1, Rtt107, Smt3, Srs2, Stu2, Swd3, Top3, Ubc9, Yck2 
Xrs2 10 
Ahp1, Cdc16, Cmr1, End3, Erg20, Hmt1, Htb1, Htb2, Ino4, 
Lif1, Mre11, Nab2, Pch2, Pst2, Rad50, Rec107, Rif2, Smt3, 
Tek1, Xrs2, YBR063C 
Zip1 9 
Apl1, Atg1, Bli1, Cdc28, Cmr1, Cnl1, Cst9, Did2, Eto1, Far10, 
Gyp5, Hhf1, Hhf2, Htb1, Htb2, Kar3, Kin3, Lhs1, Mad1, Met4, 
Mps3, Myo2, Nam7, Nnf1, Nnf2, Not3, Nuf2, Pan1, Red1, 
Sec9, Smt3, Smy1, Spra2, Spc24, Spc72, Spr3, Tae2, Tpk3, 
Tpm2, Ubi4, Yaf9, YHR080C, Yta6 
Slx4 8 
Ahp1, Bmh2, Cdc27, Cpr1, Dpb11, Gus1, Hxk1, Rad1, 
Rad10, Rtt107, Slx1, Smc5, Smt3, Ssz1, Tdh1, Yef3 
Rad2 8 
Cmk2, Dhh1, Frk1, Gal4, Msh2, Nab2, Pat1, Pex15, Puf3, 
Rad3, Rpo21, Sat4, Sen1, Slf1, Smt3, Srb4, Srs2, Ssl1, Ssl2, 
Tfb1 
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Table 4.2: Characterization of disordered domains in top 5% highest-number 
interactors in the Chromatin Processes data set 
Protein 
Name 
Length of Disordered 
Regions (# of residues) 
Average 
Region 
Length 
Mrc1 
38, 41, 43, 51, 56, 63, 67, 81,  
120, 155 72 
Zip1 41, 42, 44, 49, 59, 69, 182 69 
Slx4 36, 62, 88, 102 72 
Rad9 61, 73, 134, 201 117 
Sgs1 48, 56, 59, 129, 304 119 
Rad2 30, 44, 76, 85, 105 68 
Xrs2 44, 66, 70, 79 65 
 
Table 4.3: Characterization of disordered residues in top 5% highest-number 
Interactors in the Chromatin Processes data set 
Protein 
Name 
Total 
Protein 
Length 
% disordered 
residues in 
domains ≥30 
residues 
% 
disordered 
residues in 
protein 
Mrc1 1096 65 75 
Zip1 875 55.5 67 
Sgs1 1447 41 47 
Slx4 748 38.5 39 
Rad9 1309 35.8 56 
Rad2 1031 33 44 
Xrs2 854 30 39 
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Figure 4.1: IUPRED plots of high-level interactors with putative binding sites. Binding sites predicted by PONDRFIT 
are highlighted in yellow. A disorder probability > 0.5 suggests a disordered section of the protein. Mrc1 phosphorylation 
are mapped in red as described . 
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Table 4.4: Proteins in the Chromatin Processes data set 
Protein 
% 
Residues 
≥.5 
% in 
Disordered 
Domains 
≥30 
Residues Interactions 
# 
Disordered 
Domains 
# 
Phosphorylation 
sites 
Pathways 
(GO terms) 
Apn1 24 19 1 1 3 BER 
Apn2 24 9 0 1 0 BER 
Bre1 40 31 4 3 2 
HR, 
Checkpoint 
Cdc25 38 34 7 7 29 Checkpoint 
Cdc28 7 0 0 0 6 Checkpoint 
Cdc45 23 16 1 2 2 
HR, 
Checkpoint 
Cdc7 16 6 3 1 5 
HR, 
Checkpoint, 
Replication 
Cdc9 24 19 1 2 5 
HR, NER, 
BER 
Chk1 6 0 0 0 8 Checkpoint 
Chl1 16 8 0 1 3 SCC 
Csm1 23 0 1 0 0 HR 
Csm3 35 10 2 1 1 Replication 
Ctf18 20 0 1 0 4 HR, SCC 
Ctf4 17 11 2 3 7 HR, SCC 
Ddc1 30 22 5 3 7 
HR, 
Checkpoint 
Din7 12 0 1 0 0 Replication 
Dmc1 8 0 1 0 0 HR 
Dna2 23 18 5 2 9 HR 
Dot1 33 25 4 2 3 
HR, NER, 
Checkpoint 
Dpb11 33 19 2 2 5 
MMR, 
Replication 
Dun1 20 16 1 2 25 Checkpoint 
Eco1 25 13 1 1 1 SCC 
Esc2 61 53 3 2 9 
HR, 
Checkpoint 
Est1 12 7 0 1 2 Misc 
Exo1 39 31 2 2 5 HR, MMR 
Hmi1 5 0 0 0 2 Misc 
Hnt3 14 0 0 0 0 Misc 
Hsm3 9 0 0 0 1 MMR 
Htb1 53 43 0 1 1 Misc 
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Table 4.4: Proteins in the Chromatin Processes data set (Continued) 
Protein 
% 
Residues 
≥.5 
% in 
Disordered 
Domains 
≥30 
Residues Interactions 
# 
Disordered 
Domains 
# 
Phosphorylation 
sites 
Pathways 
(GO terms) 
Irc20 17 12 3 4 1 HR, NHEJ 
Ku70 13 0 0 0 3 HR, NHEJ 
Ku80 17 5 2 1 0 HR, NHEJ 
Lif1 57 49 3 3 1 NHEJ 
Lig4 7 0 0 0 3 NHEJ 
Mag1 10 0 1 0 2 BER 
Mcd1 43 29 4 2 8 SCC 
Mcm10 42 37 4 2 9 Replication 
Mcm2 32 28 3 2 8 
HR, 
Replication 
Mcm3 26 20 3 2 20 
HR, 
Replication 
Mcm4 28 25 3 2 24 
HR, 
Replication 
Mcm5 19 4 0 1 4 Replication 
Mcm6 30 22 2 3 16 Replication 
Mcm7 16 9 1 2 9 
HR, 
Replication 
Mec1 2 0 0 0 4 
Checkpoint, 
Replication 
Mec3 36 12 1 1 2 Checkpoint 
Mgm101 29 20 0 1 1 Misc 
Mgs1 18 11 2 1 0 Replication 
Mgt1 13 0 0 0 0 Misc 
Mhr1 17 0 0 0 0 HR 
Mlh1 20 15 2 2 3 MMR 
Mlh2 20 13 5 2 0 MMR 
Mlh3 5 0 0 0 0 HR, MMR 
Mms1 5 0 0 0 2 Replication 
Mms2 27 0 1 0 1 Replication 
Mms21 14 0 1 0 1 Replication 
Mms22 22 14 6 3 0 Replication 
Mms4 29 15 2 2 8 HR 
Mph1 20 16 3 3 2 
HR,  
Replication 
Mrc1 75 65 13 10 31 
Checkpoint, 
Replication 
Mre11 35 30 3 2 2 
HR, 
Checkpoint 
Msh1 11 5 0 1 2 HR, MMR 
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Table 4.4: Proteins in the Chromatin Processes data set (Continued) 
Protein 
% 
Residues 
≥.5 
% in 
Disordered 
Domains 
≥30 
Residues Interactions 
# 
Disordered 
Domains 
# 
Phosphorylation 
sites 
Pathways 
(GO terms) 
Msh2 3 0 0 0 1 HR, MMR 
Msh3 14 11 3 1 0 HR, MMR 
Msh4 14 11 3 1 0 HR 
Msh5 7 0 1 0 0 HR 
Msh6 25 24 6 1 16 MMR 
Mus81 26 13 2 2 2 HR 
Nej1 27 23 2 1 3 NHEJ 
Nhp10 56 42 3 2 4 Misc 
Nse1 7 0 0 0 0 Replication 
Nse4 45 37 1 3 2 Replication 
Ntg1 13 9 0 1 0 BER 
Ntg2 8 0 1 0 0 BER 
Ogg1 11 0 0 0 0 BER 
Pan2 6 0 0 0 1 Replication 
Pan3 32 23 3 1 8 Replication 
Pap2 35 34 4 3 3 Misc 
Pds1 79 60 7 3 19 Misc 
Phr1 6 0 0 0 4 Misc 
Pif1 31 26 4 3 5 HR 
Pms1 26 23 3 4 6 MMR 
Pol1 24 18 6 4 21 Replication 
Pol2 6 3 0 2 3 Replication 
Pol30 9 0 0 0 0 Replication 
Pol31 13 0 0 0 2 Replication 
Pol32 67 64 2 1 9 Replication 
Pol4 14 9 0 1 0 NHEJ 
Pph3 7 0 0 0 0 
HR, 
Checkpoint 
Pri1 9 0 0 0 2 Replication 
Psf1 9 0 0 0 0 Replication 
Pso2 28 19 1 2 2 Misc 
Rad1  22 19 2 4 5 
HR, NER, 
MMR 
Rad10 44 42 2 1 0 
HR, NER, 
MMR 
Rad14 56 42 3 2 2 NER 
Rad16 22 20 2 1 6 NER 
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Table 4.4: Proteins in the Chromatin Processes data set (Continued) 
Protein 
% 
Residues 
≥.5 
% in 
Disordered 
Domains 
≥30 
Residues Interactions 
# 
Disordered 
Domains 
# 
Phosphorylation 
sites 
Pathways 
(GO terms) 
Rad17 24 17 1 1 4 
HR, 
Checkpoint 
Rad18 64 53 3 4 9 Replication 
Rad2 44 33 8 5 7 NER 
Rad23 63 55 1 3 15 NER 
Rad24 28 24 4 2 4 
HR, NER, 
Checkpoint 
Rad27 24 8 1 1 2 
BER, NHEJ, 
Replication 
Rad3 8 0 1 0 0 NER 
Rad30 11 6 0 1 0 Replication 
Rad34 17 13 2 1 0 NER 
Rad4 27 25 3 2 0 NER 
Rad5 25 18 4 4 7 Replication 
Rad50 37 26 3 4 3 
HR, 
Checkpoint 
Rad51 23 19 2 1 0 HR 
Rad52 55 49 6 2 6 HR 
Rad53 26 16 5 3 36 Checkpoint 
Rad54 18 8 2 1 2 HR 
Rad55 20 0 3 0 5 HR 
Rad57 17 7 0 1 1 HR 
Rad59 12 0 0 0 0 HR 
Rad6 37 37 1 2 1 
Checkpoint, 
Replication 
Rad7 31 25 3 1 7 NER 
Rad9 52 36 11 4 45 
NER, 
Checkpoint 
Rdh54 25 14 2 2 3 HR 
Rev1 11 4 3 1 1 Replication 
Rfa1 12 9 1 1 2 Replication 
Rfa2 28 15 1 1 7 Replication 
Rfa3 23 0 0 0 1 Replication 
Rfc1 31 23 3 2 7 Replication 
Rfc2 6 0 1 0 0 Replication 
Rfc3 7 0 0 0 0 Replication 
Rfc4 7 0 0 0 0 Replication 
Rmi1 30 14 0 1 1 
HR, 
Checkpoint 
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Table 4.4: Proteins in the Chromatin Processes data set (Continued) 
Protein 
% 
Residues 
≥.5 
% in 
Disordered 
Domains 
≥30 
Residues Interactions 
# 
Disordered 
Domains 
# 
Phosphorylation 
sites 
Pathways 
(GO terms) 
Rrm3 33 32 5 1 1 Replication 
Rsc2 41 28 4 3 15 Misc 
Sae2 35 21 4 2 7 HR 
Sae3 53 45 0 1 1 HR 
Sgs1 47 41 10 5 2 
HR, 
Checkpoint 
Shu2 8 0 0 0 0 
HR, 
Replication 
Sir2 20 13 2 1 4 Replication 
Sld2 80 62 6 5 8 
HR, 
Replication 
Sld3 47 41 5 4 60 
HR, 
Replication 
Sld5 28 14 0 1 0 Replication 
Slx1 9 0 0 0 0 HR 
Slx4 56 39 8 4 13 HR 
Slx5 52 47 6 4 2 Misc 
Slx8 76 72 0 1 4 Misc 
Smc1 27 7 6 2 2 Misc 
Smc5 18 9 2 1 0 Misc 
Sml1 100 100 2 1 2 Misc 
Snf5 57 52 7 3 3 Misc 
Srs2 33 24 4 5 9 HR, NHEJ 
Ssl1 21 18 1 1 2 
NER, 
Replication 
Ssl2 24 16 4 2 1 
NER, 
Replication 
Tah11 18 12 1 1 4 Replication 
Tdp1 14 9 1 1 0 Misc 
Tel1 1 0 0 0 2 Checkpoint 
Tfb1 31 20 2 2 2 NER 
Tfb2 14 8 0 1 2 NER 
Tfb5 38 0 0 0 1 NER 
Tof1 15 13 2 2 12 
SCC, 
Checkpoint, 
Replication 
Ubc13 16 0 0 0 0 Replication 
Ung1 16 0 0 0 0 Misc 
Xrs2 39 30 10 4 9 
HR, 
Checkpoint 
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Table 4.4: Proteins in the Chromatin Processes data set (Continued) 
Protein 
% 
Residues 
≥.5 
% in 
Disordered 
Domains 
≥30 
Residues Interactions 
# 
Disordered 
Domains 
# 
Phosphorylation 
sites 
Pathways 
(GO terms) 
Yen1 39 32 3 5 4 HR 
Zip1 67 56 9 7 6 HR 
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CHAPTER 5: 
BIOINFORMATICALLY GUIDED MUTAGENESIS IN RMI1, THE NONCATALYTIC 
SUBUNIT OF THE S. CEREVISIAE SGS1/TOP3/RMI1 COMPLEX, REVEALS TWO 
FUNCTIONAL MOTIFS  
 
 
Introduction 
 The RecQ-like DNA helicase family is evolutionarily conserved and necessary for 
genomic stability from bacteria to humans. In yeast the RecQ-like DNA helicase Sgs1 
forms a complex with Top3/Rmi1 (STR) and facilitates both early and late stage DNA 
break repair [1]. Early in double strand break (DSB) repair, STR resects the ends of the 
DSB to facilitate the formation of a single-strand 3’ overhang to which Rad51 binds [2-
5]. This Rad51 filament is then able to initiate a genome-wide search for sequence 
homology (strand invasion), eventually leading to the formation of Holliday Junctions 
(HJs) that need to be resolved prior to cell division. Resolution can be achieved by the 
HJ-specific endonuclease Yen1, randomly leading to crossover and noncrossover 
products, or HJs can be dissolved by STR in a process involving HJ migration and 
decatenation of the single strands that yields noncrossover products [6]. STR has also 
been implicated in the reversal of strand invasion after extension of the invading 3’end 
by DNA synthesis to promote DSB repair by synthesis-dependent strand annealing, as 
well as reversal of strand invasion prior to 3’end extension (D-loop reversal) [7]. 
Through these functions, STR promotes noncrossover outcomes of HR and regulates 
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HR levels. Hence, yeast cells that lack the helicase activity of the STR complex (sgs1) 
are prone to hyperrecombination, increased chromosomal instability, gross 
chromosomal rearrangement (GCR) formation, hypersensitivity to DNA-damaging 
agents and, in the case of top3 and rmi1 single mutants, very poor growth [8-11]. 
  Despite the severe growth phenotype of the rmi1 mutant, the functional 
contribution of Rmi1 to the STR complex is still poorly understood. Rmi1, was first 
discovered in S. cerevisiae in a screen for components of the Sgs1/Top3 pathway [9]. 
Yeast cells lacking Rmi1 were found to be hypersensitive to hydroxyurea (HU) and 
methylmethanesulfonate (MMS), have an increased rate of spontaneous DNA damage 
as indicated by an increase in Rad52 foci, an increase in GCRs, and deficiency in 
Rad53 phosphorylation [9, 11]. Diploids lacking Rmi1 are defective in meiosis, and 
deletion of genes with roles in the checkpoint response to replication stress, such as  
Mrc1, Tof1, Csm3, lead to synthetic lethality, implying a diverse role for Rmi1 in several 
chromatin processes [9, 11]. Despite the severity of rmi1 phenotypes, Rmi1 has no 
known catalytic function. It has been shown to stimulate the catalytic functions of 
Sgs1/Top3, particularly the decatenation of HJs [12-14]. This function is conserved in 
the BLM/TopoIIIα/Rmi1/Rmi2 (BTR) complex,  the human variant of STR, and studies in 
human cell lines imply a role for Rmi1 in TopoIIIα stability and expression [14-16]. 
 The N-terminus of human Rmi1 has been crystallized, providing some clues to its 
role in catalytic enhancement and BTR complex stability [17, 18]. The N-terminus of 
human Rmi1 is most closely related to the S. cerevisiae Rmi1, is capable of binding 
BLM and TopoIIIα,  and contains a central oligonucleotide-binding (OB) fold that is 
similar in structure to that of the replication protein A subunit RPA70, though it is 
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suggested that it is incapable of binding DNA like RPA [18, 19]. Human Rmi1 contains a 
disordered loop needed for dHJ dissolution enhancement of TopoIIIα [17]. Co-
crystallization of the Rmi1 N-terminal lobe peptide with TopoIIIα reveals that the OB-fold 
of Rmi1 lies opposite of the ssDNA-binding domain of TopoIIIα, and the loop of Rmi1 
physically interacts with the topoisomerase by inserting itself into the topoisomerase 
gate. It has been hypothesized that this loop may be what facilitates the catalytic 
enhancement of TopoIIIα by regulating opening and closing of the topoisomerase gate 
[17, 18].  
 In an effort to better understand the molecular basis of Rmi1 function, we have 
combined bioinformatics tools with an in vivo mutational analysis of RMI1 function in 
yeast.  This approach has identified short, N- and C-terminal structural motifs that are 
essential for Rmi1 function and are conserved in human Rmi1. We propose hypotheses 
for how these motifs contribute to Rmi1’s role in maintaining the functional integrity of 
the STR complex. 
 
Experimental Procedures 
Bioinformatics analysis 
The 241 residues of S. cerevisiae Rmi1 and the N-terminal 240 residues of the 
625-residue human Rmi1 were analyzed for helical propensity, structural disorder, and 
amino acid sequence similarity [20-24].  
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Plasmids 
The open reading frame of RMI1 plus 500 bp up- and downstream was amplified 
by PCR from the endogenous RMI1 locus of KHSY1338 (ura3-52, leu21, trp163, 
his320,0 lys2-Bgl, hom3-10, ade21ade8, YEL069C::URA3, sgs1::HIS3). The 
fragment was  inserted into XbaI-digested pRS415 by gap-repair cloning using the non-
homologous-endjoining deficient yeast strain KHSY2331 (ura3-52, leu2Δ1, trp1Δ63, 
his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1, ade8, YEL069C::URA3, lig4::loxP-G418-loxP) 
and standard lithium-acetate transformation [25]. The integrity of RMI1 and the promoter 
region in the resulting pRS415-RMI1 plasmid (pKHS 621) was verified by sequencing. 
Point mutations were introduced into pKHS 621 by QuikChange site-directed 
mutagenesis (Agilent Technologies). The list of plasmids used in this study is provided 
in Table 5.1. 
 
Yeast strains 
To construct yeast strains with chromosomally integrated rmi1 mutants that are 
expressed as C-terminally myc-epitope-tagged proteins, pKHS 621 was linearized with 
BoxI and the HIS3-linked myc-coding sequence from pFA6a-13MYC-HIS3MX6 [26] was 
inserted by gap-repair cloning.  Point mutations were introduced into the resulting 
plasmid (pKHS630) using the QuikChange protocol (Agilent Technologies). Fragments 
spanning MYC-tagged RMI1 and rmi1 mutant alleles were amplified from pKHS 630 
and its derivatives by PCR and used to replace the endogenous RMI1 locus in the 
BY4711-derived yeast strain MATa, ura30, leu20, his31, lys20, 
TOP3.V5.VSV.KANMX6. Integrity of RMI1 and the mutant alleles was confirmed by 
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sequencing and expression verified by Western blot analysis with c-myc monoclonal 
antibody (Covance).  
 
Hydroxyurea hypersensitivity assay 
Derivatives of pKHS621 were transformed into KHSY4695 (MATα, ura30, 
leu20, his31, lys20, rmi1::HIS3, TOP3.V5.VSV.KANMX6), grown to OD600 = 0.5 in 
synthetic complete media lacking leucine (SC-Leu), and spotted in 10-fold dilutions on 
yeast extract/peptone/dextrose (YPD) and on YPD supplemented with 150 mM HU. 
Growth was documented after 3 to 5 days of incubation at 30°C. 
 
Cycloheximide chase 
Yeast cultures were grown overnight to OD600 = 1.0. Cells were synchronized by 
addition of 2 µg/µl alpha factor for 1 hour, followed by addition of 1 µg/µl alpha factor for 
an additional 1 hour. Cells were washed twice with warm YPD and resuspended in YPD 
to reach OD600 = 1.0. Cycloheximide was added to the culture at a final concentration of 
50 µg/ml and the culture was incubated with vigorous shaking at 30 °C. Aliquots 
equivalent to 2 ODs were removed at the indicated intervals over a 24-hour time course. 
Whole cell extracts were prepared as previously described [27]. Briefly, washed cell 
pellets were resuspended in 20% trichloroacetic acid and vortexed in a cell disruptor 
with glass beads for 10 minutes at maximum speed. Lysate was cleared by 
centrifugation at 14000 rpm for 2 min. The pellet was resuspended in Laemmli buffer, 
the pH adjusted with 2 M Tris, pH 8.3, and boiled. Extracted proteins were separated by 
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SDS-PAGE and transferred to PVDF membrane before being probed for Rmi1 and rmi1 
mutants using a c-myc monoclonal antibody (Covance). 
 
Results 
Determining functionally important residues in S. cerevisiae Rmi1 has been 
challenging as there, are no known catalytic domains, no crystal structure, and only 
minimal conservation of primary sequence (~35% between yeast genera, 18% between 
S.cerevisiae and human Rmi1) and length, ranging from 241 residues in S. cerevisiae to 
625 in humans. We reasoned that combining structural prediction tools [23, 24, 28] in 
such a way that they detect ‘order within disorder’ could reveal functionally important 
motifs in Rmi1. We focused our analysis on the N- and C-terminal tails flanking the 
predicted OB-fold, and an apparent disordered loop emerging from the OB-fold (Figure 
5.1A). We identified two regions of increased helical propensity, spanning residues 58-
69 and residues 212-228, as well as two regions of lesser helical propensity between 
residues 126-131 and 138-145 (Figure 5.1B). We had previously determined that 
disruption of an α-helix was most effective when a residue with high helical propensity 
near the peak or in the N-terminal half of the helix was replaced with the helix breaker 
proline. Therefore, we constructed F63P, A128P, A139P and E220P mutations (Fig. 
5.1A) to determine the importance of these regions for Rmi1 function in vivo. These 
proline substitutions led to marked decreases in helical propensity in these regions 
(Figure 5.1C-F). We also noted that the proline at position 88 seemed to disrupt what 
might otherwise be a region with high helical propensity, and hypothesized that this 
native break was helping to maintain a degree of flexibility in what would otherwise be a 
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persistent, structured region. We considered that replacing P88 with a residue with high 
helical propensity that was otherwise benign, such as alanine, would restore helicity to 
this region. Indeed, the P88A mutation is predicted to lead to an extraordinary increase 
in helical propensity not seen in any region of the wildtype forms of yeast or human 
Rmi1 (Figure 5.1G). We exploited the HU hypersensitivity of yeast cells lacking 
Rmi1[11] to assess the functional impact of these proline substitutions in vivo. We found 
that rmi1 cells expressing rmi1-A128P and rmi1-A139P exhibited the same HU 
sensitivity as the rmi1 mutant complemented with wildtype RMI1, whereas rmi1-P88A 
was able to partially suppress the HU hypersensitivity of  rmi1 (Figure 5.1H). The rmi1-
F63P mutant caused the same degree of HU hypersensitivity as a deletion of RMI1, 
indicating that it was a null allele (Figure 5.1H). We considered the possibility that the 
phenotype of the F63P mutation could also be due to the loss of a strong hydrophobic 
interaction via the aromatic residue, and decided to evaluate the importance of the 
chemical composition of this predicted helical region. We chose to replace F63 with a 
hydrophilic residue with high helical propensity, such as lysine, that would be predicted 
to maintain the structural integrity of the motif, but change its chemical characteristics. 
We found that the F63K mutation caused the same hypersensitivity to HU as the F63P 
mutations (Figure 5.1G), implicating that this residue maps to an α-helical structure that 
must conserve both its shape and hydrophobic character in order to maintain wildtype 
function of Rmi1. Similarly to F63, substitution of E220 with proline abolished Rmi1 
function (Figure 5.1H). 
 Next we analyzed primary sequence alignments of S.c. Rmi1 to identify 
conserved residues and regions of conserved chemical character that could also be 
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indicative of a functional role. We found that the 241-residue long S.c. Rmi1 is ~85% 
identical to Rmi1 of other Saccharomyces species, but identity markedly decreased to 
~30% when compared to yeast species outside of the genus (e.g., K. lactis, C. 
glabrata), and to ~18% when compared to the N-terminal 241 residues of human Rmi1. 
Because of this low level of sequence conservation we decided to analyze an alignment 
of twelve closely related Rmi1 sequences from fully sequenced Saccharomyces and 
non-Saccharomyces yeast species in PhylomeDB v4 [22] (Figure 5.2C, Supplemental 
Figure 5.1). This alignment revealed that the chemical characteristics of the α-helical 
region centered on residue E220 were conserved, with a short stretch of hydrophobic 
residues surrounded by charged residues. Whereas neither E220 nor the acidic or 
hydrophilic character of the residue was conserved outside of the Saccharomyces 
genus, the hydrophobic residues were, including a tyrosine at position 218 (Figure 
5.2C). We hypothesized that this residue was not only part of the functional α-helical 
structure we had inferred from the E220P mutant, but was also a key residue for binding 
in an otherwise fairly charged α-helix. Indeed we found that either breaking the helix 
(rmi1-Y218P) or increasing its hydrophilicity (rmi1-Y218K) abolished Rmi1 function 
(Figure 5.2D).  Although S.c. Rmi1 and human Rmi1 are only 18% identical, we found 
that they share regions of similar helical propensity, including the region that surrounds 
Y218 in yeast and Y201 in human Rmi1 (Figure 5.2A,B).  
When we extended the computational analysis to the N-terminus of human Rmi1, 
we identified three regions of increased helical propensity (Figure 3B), which have been 
shown to form three α-helices in the crystal structure [17, 18]. Comparisons of helical 
propensity and primary sequences of S.c. Rmi1 and the N-terminus of human Rmi1 
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suggest a structural equivalence between the predicted sole α-helix in yeast and 3 in 
human Rmi1, with a potential equivalent of F63 at residue F50 in human Rmi1 (Figure 
5.3A,B; Figure 5.5). The lack of helical propensity in the first 57 residues of S.c. Rmi1 
suggests that this region does not form α-helices in the apo form as human Rmi1 does. 
However, we noticed two discrete regions in the yeast sequence alignment (residues 
S2-T16 and E28-E38)  that contain hydrophobic residues in the i+4 pattern typical of an 
α-helix and are separated from each other by residues with the lowest helical 
propensity, proline and glycine (Figure 5.3C). To test the possibility that these two mildly 
hydrophobic regions could become helical upon binding to another protein, possibly 
Sgs1, or could be analogous to α1 and α2 in human Rmi1 we replaced L7 and Y35 with 
proline (Figure 5.3C). Expression of either mutant, however, was sufficient to fully 
restore wildtype growth to the rmi1 mutant on HU (Figure 5.3D), suggesting either that, 
unlike in human Rmi1, this region in S.c. Rmi1 does not adopt α-helical structures or 
that any helical structure or binding-induced folding in this region is not required for 
Rmi1’s role in tolerating HU-induced DNA-damage. 
 
Discussion 
In this study, we have used three bioninformatic tools – disorder prediction, 
helical propensity prediction and phylome alignments – to elucidate structure/function 
relationships in the N- and C-terminal regions of S.c. Rmi1 that surround it’s postulated, 
central OB-fold.  
Short structured motifs are common in areas of disorder, and are often Molecular 
Recognition Features (MoRFs), which are short sequences of marginal order used for 
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protein binding that induces further disorder-to-order transition [29-31]. PONDR-VLXT 
[32] and IUPRED [33] predict order for residues 134-227,  the majority of which likely 
form the OB-fold observed in the crystal structure of human Rmi1. This ordered region 
contains a disordered loop (residues 120-136) that seems to be equivalent to the 
disordered insertion loop in the OB-fold of human Rmi1 [17]. Deletion of this loop in 
human Rmi1 eliminates complex formation with BLM and TopoIIIα [18] whereas  
replacement of the equivalent loop in S.c. Rmi1, as estimated by sequence alignment 
with a scrambled version of equal chemistry, showed that Rmi1 was able to bind Sgs1 
and Top3, but was unable to stimulate Top3 catalytic activity and dHJ dissolution [17]. 
Our proline mutagenesis (A128P, A139P) suggests that the adoption of helical structure 
in this disordered loop is not required for Rmi1’s function in tolerating HU-induced DNA 
damage.  
The N- and C-terminal regions flanking the OB-fold contain many disordered 
residues and short ordered segments. In these regions, we have identified three 
mutations (F63P/K, Y218P/K, E220P) that display rmi1-like defects during chronic 
exposure to HU, and one mutation, P88A, that exhibits an intermediate growth defect on 
HU. To date, only one other point mutant in S.c. Rmi1 has been reported, E69K [34]. At 
the permissive temperature of 25°C the sensitivity of this mutant to DNA-damaging 
agents resembles that of wildtype, but at 35°C it exhibits the defect of an rmi1. That 
E69K appears to be better tolerated than F63P/K can be explained by the location of 
E69 at the C-terminus of the predicted helical region (residues 58-69), where mutations 
appear to have less functional impact [27], whereas F63 maps closer to the center and, 
in contrast to E69, is conserved in other yeast species (Figure 5.3C).  
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At the C-terminus, E220P and Y218P/K mutations caused the same HU 
hypersensitivity as F63P/K mutations at the N-terminus, leading us to propose that 
residues 58-69 and 212-228 of S.c. Rmi1 form functionally critical α-helices that must 
retain a certain degree of hydrophobic character for full functionality. Based on the 
hydrophobicity of the α-helices we hypothesize that they function as interaction sites, 
with the F63 and Y218 residues part of the binding interfaces. This type of small binding 
motif paired with disorder has been seen in other proteins, including the yeast protein 
Adr1, which contains two small zinc finger domains in a disordered domain [35]; 
interestingly, the disordered components of this domain undergo extensive folding when 
contact is made between the zinc fingers and DNA. We tested if binding-induced helix 
formation was also a function of the extended unstructured N-terminus of yeast Rmi1, 
but found that introducing proline residues at positions (L7, Y35), where prospective 
helices might form, did not impair Rmi1 function as assessed by growth on HU.  
Regarding the binding events that the F63 helix and Y218 helix may be engaged 
in, we present two possibilities: First, one or both of the helices may be stabilizing the 
OB-fold of Rmi1 as seen in other proteins containing this fold type [36]. Crystallography 
of human Rmi1 suggests that the three alpha helices in the N-terminus (α1-3) mediate 
protein stabilization via L57 and T59 in the third helix and K166 in the OB fold via 
hydrogen bonding [18]. If the predicted α1 (58-69) in S.c. Rmi1 is analogous to α3 in 
human Rmi1, it is possible that F63P eliminates the structural element needed for 
stabilizing stacking interactions, and F63K induces an electrostatic repulsion strong 
enough to prevent the packing between the strands of the central fold and the N-
terminal α-helix.  
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The functional impairment of S.c Rmi1 by the P88A mutation is consistent with 
the role of the putative N-terminal α-helix in stabilizing the OB-fold. We propose that the 
helix-breaking property of the proline at position 88 (Figure 5.1G) contributes to the 
flexibility of a linker between the α-helix and the first -sheet of the OB-fold. 
Replacement of this proline with alanine, which has excellent helical propensity, is 
predicted to make this linker helical. The resulting rigidity may weaken the interactions 
between the N-terminal α-helix and the first -sheet of the OB-fold, leading to a 
destabilization of the OB-fold, but not as severe as that resulting from disrupting the 
integrity of the α-helix itself by F63P/K. Crystallography of human Rmi1 supports this 
role for the N-terminal α-helix and, by extension, the flexible linker, with the 
corresponding residues being in close proximity to the central OB-fold. F50 in α3 of 
human Rmi1, which we propose to be equivalent to F63 in the predicted α1 of S.c. 
Rmi1, is in close proximity to β1 and β4 of the OB-fold (Figure 5.4). Similarly, at the C-
terminus, Y201, the equivalent of Y218 of S.c. Rmi1, appears close to the rear of the 
OB-fold, also in proximity to β1 (Figure 5.4) [17].  
Second, one or both of the α-helices in Rmi1 may mediate physical interactions 
between the Rmi1/Top3 complex and Sgs1. Crystallography of the human 
Rmi1/TopoIIIα complex shows that the central OB-fold of Rmi1 is the primary interactor 
with TopoIIIα [17]. This suggests that aside from stabilizing the OB-fold, it is unlikely that 
the putative helices at F63 and Y218 play a role in Top3 binding. Where the RecQ 
helicase interacts with the Rmi1/topoisomerase complex is still unknown, but the 
location of the α helices at the N- and C-terminal ends of S.c Rmi1, their hydrophobic 
172 
 
faces, and their conservation in human Rmi1 may make the α-helices at F63 and Y218 
candidates for Sgs1 binding.  
 
Future Directions 
 In an effort to test the hypothesis that the structures destroyed by proline 
mutation are providing stability to the protein at large, a cycloheximide chase will be 
employed to compare the stability of the wildtype Rmi1 protein to the mutant proteins. 
Upon introduction of cycloheximide, all protein synthesis ceases, and the degradation 
time of a protein can be probed. To date, the wildtype protein has been evaluated via 
chase as described in the method section; preliminary results suggest that protein levels 
reach near zero around 7-8 hours following cycloheximide exposure. It is hypothesized 
that both F63P and Y218P are contributing to protein instability that yields the sick 
phenotypes seen on HU; thus, it is expected that the chase results will show that the 
proteins degrade much more quickly than the wildtype protein. A128P is being used as 
a positive control, and is expected to have a similar stability profile to wildtype Rmi1. 
Future directions also include P88A protein stability with the cycloheximide chase. 
Considering that the phenotype on HU is intermediate to the wildtype and F63P/Y218P 
phenotypes, it is possible that the protein will be intermediate in stability and time to 
complete degradation. It is also possible that P88A plays no role in stability of Rmi1 
itself, but rather prevents some other sort of binding event or function that requires the 
flexible linker that P88 maintains. To test this possibility, we may test the ability for the 
mutant protein to bind its only known partners, Sgs1 and Top3. This could be 
accomplished via in vitro pulldown, as previously described [27]. In this case, it is 
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hypothesized that Sgs1 binding is more likely to be mediated by this flexible loop, as 
previous crystallography of the human orthologs puts the binding of Top3 out of reach of 
the region [17]. 
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FIGURE 5.1: Sites of directed mutagenesis predicted by Agadir software. A) 
Residues F63, A128, A139, and E220 are residues near the peak of the helical 
prediction. P88 is predicted to be responsible for the sudden loss in helical prediction in 
the area just N-terminal of it. B-F) Wildtype and Mutation Agadir profiles show 
dissolution of predicted structure when proline mutants are introduced to these areas or 
induction of structure when proline is removed. G) Plasmids containing the ORF of 
RMI1 and rmi1 mutants were transformed into a Δrmi1 strain and challenged with HU. 
F63P and F63K are phenotypically like the empty vector negative control; E220P and 
P88A have intermediate phenotypes. 
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FIGURE 5.2: Yeast Rmi1 and human Rmi1-N have comparable predicted structure 
in the far C-terminus.  A) The Agadir profile of yeast Rmi1 predicts an alpha helix at 
the end of the protein. B) An equivalent helix is predicted at the end of human Rmi1-N, 
which is the only region of the human protein with sequence similarity to the yeast 
ortholog. C) Phylome DB alignment of yeast species reveals a highly conserved 
tyrosine at position 218. This residue is in the same predicted helix as E220 and has a 
potential equivalent in Y201 in humans. D) Y218P and Y218K rmi1 plasmids cannot 
complement Δrmi1 strains on HU. 
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FIGURE 5.3: Yeast and human Rmi1 have potentially comparable predicted 
structure and “proto-structure” in the far N-terminus. A) Agadir profile of S. 
cerevisiae Rmi1 N1-80. B) Agadir profile of H. sapiens Rmi1 N1-80. The profile predicts 
three helices, as labeled. The estimated human equivalent to yeast F63, F50, is 
highlighted. C) Phylome DB alignment of yeast species illustrates clusters of conserved 
residue chemistry about L7 and Y35, which are themselves highly conserved. The 
predicted threshold of the yeast Rmi1 helix is plotted in the red box; the thresholds of 
two hypothesized proto-helices, which may assume structure upon a binding event, are 
plotted in the red hashed boxes. The human Agadir prediction (light blue boxes) and 
actual crystal structure helical thresholds [79] (dark blue boxes) are included for 
comparison. D) Mutagenesis in L7 and Y35 meant to prevent the induction of alpha-
helical structure does not affect growth on HU. 
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FIGURE 5.4: Structural hypotheses for proline mutant phenotypes based on 
disorder prediction and crystal structure. Mapping the equivalent human residues to 
F63 (light blue helix) and Y218 (dark blue helix) in the human Rmi1-N crystal structure 
(PDB database: 4CGY) [65] shows a close proximity of these residues and their 
accompanying structures to the central barrel of the OB fold , suggesting a role for 
these structures in protein stabilization. Both residues are removed in space from Top3α 
(green), suggesting that they are not important for direct Top3α/Rmi1 interaction. 
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FIGURE 5.5: Alignment between S.c. Rmi1 and H.s. Rmi1N. Human equivalents to 
yeast F63 and Y218 are highlighted in red boxes. 
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Table 5.1: Plasmids used in this study 
 
Plasmid Description 
  
pKHS 621 pRS415-Rmi1 
pKHS 622 pRS415-Rmi1-F63P 
pKHS 623 pRS415-Rmi1-E220P 
pKHS 624 pRS415-Rmi1-A128P 
pKHS 625 pRS415-Rmi1-A139P 
pKHS 626 pRS415-Rmi1-P88A 
pKHS 627 pRS415-Rmi1-Y218P 
pKHS 628 pRS415-Rmi1-L7P 
pKHS 629 pRS415-Rmi1-Y35P 
pKHS 630 pRS415-Rmi1.myc 
pKHS 631 pRS415-Rmi1.myc- F63P 
pKHS 632 pRS415-Rmi1.myc-A128P 
pKHS 633 pRS415-Rmi1.myc-Y218P 
pRS415 is a gift from Dr. Steven Brill (Rutgers University) 
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APPENDIX A: 
SGS1 TRUNCATIONS INDUCE GENOME REARRANGEMENTS BUT SUPPRESS 
DETRIMENTAL EFFECTS OF BLM OVEREXPRESSION IN SACCHAROMYCES 
CEREVISIAE 
 
 
Note to the reader: This chapter has been previously published with permission from the 
publisher as Mirzaei, H, Syed, S, Kennedy, JA, and Schmidt KH (2011). “Sgs1 
Truncations Induce Genome Rearrangements but Suppress Detrimental Effects of BL 
Overexpression in Saccharomyces cerevisiae.” J Mol Biol., 405(4); 877-891. 
Research was designed by K. Schmidt. Sgs1 Truncations and experiments were 
performed by S. Syed. BLM diploid experiments and chimera protein construction was 
done by H. Mirzaei. Point mutations and experiments on the zinc-binding domain were 
done by H. Mirzaei and J. Kennedy. Corresponding author: Kristina Schmidt, 
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Florida, 4202 E. Fowler Avenue, ISA2015, Tampa, FL 33620. Phone: (813) 974-1592. 
Fax: (813) 974-1614.; E-mail: kschmidt@usf.edu 
 
Abstract 
RecQ-like DNA helicases are conserved from bacteria to humans. They perform 
functions in the maintenance of genome stability, and their mutation is associated with 
cancer predisposition and premature aging syndromes in humans. Here, a series of C-
terminal deletions and point mutations of Sgs1, the only RecQ-like helicase in yeast, 
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show that the HRDC and Rad51 interaction domain are dispensable for Sgs1’s role in 
suppressing genome instability, whereas the zinc-binding domain and the helicase 
domain are required. BLM expression from the native SGS1 promoter had no adverse 
effects on cell growth, but also was unable to complement any sgs1Δ defects. BLM 
overexpression, however, significantly increased the rate of accumulating GCRs in a 
dosage dependent manner and greatly exacerbated sensitivity to DNA-damaging 
agents. Co-expressing sgs1 truncations of up to 900 residues, lacking all known 
functional domains of Sgs1, suppressed HU sensitivity of BLM overexpressing cells, 
suggesting a functional relationship between Sgs1 and BLM. Indeed, protein disorder 
prediction analysis of Sgs1 and BLM was used to produce a functional Sgs1-BLM 
chimera by replacing the N-terminus of BLM with the disordered N-terminus of Sgs1. 
The functionality of this chimera suggests that it is the disordered N-terminus, a site of 
protein binding and post-translational modification, that confers species-specificity to 
these two RecQ-like proteins. 
 
Introduction 
RecQ-like DNA helicases, named after the DNA repair protein RecQ of E. coli [1-
3] are evolutionarily highly conserved. These 3’- to 5’-helicases function at the interface 
between DNA replication and recombination to maintain genome integrity. Sgs1 is the 
only known member of this helicase family in Saccharomyces cerevisiae [4]. Sgs1-
deficient cells show increased sensitivity to the DNA-damaging agents hydroxyurea 
(HU) and methylmethane sulfonate (MMS), missegregate chromosomes, accumulate 
gross-chromosomal rearrangements (GCRs) and have a shortened lifespan [5-8]. In 
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contrast, five RecQ-like helicases (RecQL1, BLM, WRN, RecQL4 and RecQL5) are 
known in humans, and mutations in the BLM, WRN and RECQL4 genes are associated 
with the rare, cancer-prone Blooms syndrome, Werner syndrome and Rothmund 
Thompson syndrome, respectively [9-13]. All RecQ-like helicases share a seven-motif 
helicase domain with Walker A and DEAH motifs. The RQC (RecQ-helicase-conserved) 
domain, located C-terminal to the helicase domain, is thought to be involved in DNA 
binding and conferring specificity of binding to DNA structures, such as G4-tetrads 14; 
[15-17]. The HRDC (Helicase and RNaseD C-terminal) domain is the most C-terminal of 
the conserved domains and resembles domains in other proteins that are involved in 
nucleic acid metabolism, such as RNase D and UvrD; but, like the RQC domain, it is not 
found in all RecQ-like helicases [18; 19]. The HRDC domain has been implicated in 
binding and resolving DNA structures, such as Holliday junctions, and in mediating 
protein-protein interactions [18; 20-23]. Two acidic regions have also been identified N-
terminal of the helicase domain and may be involved in mediating protein-protein 
interactions [10; 24; 25]. Sgs1 is found in a complex with Top3 and Rmi1, and there is 
also evidence of physical interactions of the N-terminal half of Sgs1 with 
Top2, Srs2 and Rad16, and interactions of the C-terminus with Mlh1 and Rad51 [26; 27] 
[28-31].  
Defects in BLM, the human RecQ-helicase considered to be most closely related 
to Sgs1 cause Bloom’s syndrome (BS), an autosomal recessive disorder characterized 
by chromosome gaps and breaks, elevated sister chromatid exchange, mitotic 
hyperrecombination, and aberrant DNA replication events [32-34]. Affected individuals 
suffer from a high incidence and wide variety of cancers, infertility and dwarfism 
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(reviewed in reference 33). BLM catalyses ATP-dependent 3' to 5' DNA unwinding with 
a preference for DNA structures that may arise spontaneously during DNA replication or 
as a result of homologous recombination (HR) [35]. For example, by unwinding unusual 
secondary DNA structures, BLM may aid replication fork progression, prevent 
illegitimate recombination during replication and assist in restarting stalled forks [36-39]. 
Evidence supporting a role of BLM in maintaining genome integrity has been 
accumulating. For example, BLM-defective cells exhibit a retarded rate of strand 
elongation during DNA replication 40, accumulate abnormal replication intermediates 
[41] and are hypersensitive to agents that impair DNA replication [42]. BLM physically 
interacts with several proteins that play important roles during DNA replication and 
repair, such as replication protein A (RPA), the flap-endonuclease FEN-1, chromatin 
assembly factor CAF-1, the mismatch repair protein Mlh1, HR factor Rad51 and 
topoisomerase III α [43-49]. BLM peaks in S phase and it localizes to replication foci, 
most likely through its physical interaction with a subunit of DNA polymerase δ [50-54].  
Here we have determined the role of C-terminal domains and protein interaction 
sites of Sgs1 in suppressing GCR accumulation by expressing point mutants and 
truncations of Sgs1 lacking as few as 20 and as many as 1428 residues. To investigate 
BLM’s ability to complement sgs1Δ defects, such as increased genome instability and 
sensitivity to HU and MMS, human BLM cDNA was expressed under control of the 
native SGS1 promoter and overexpressed from a galactose-inducible promoter, 
revealing that BLM could suppress sgs1Δ defects neither in haploid nor in diploid cells. 
However, using computational protein disorder prediction tools, we have designed a 
yeast/human chimera that consists of two nonfunctional segments of BLM and Sgs1. 
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The ability of this chimera to suppress all sgs1Δ defects that we tested suggests a 
functional relationship between BLM and Sgs1, which is also supported by our finding 
that short N-terminal fragments of Sgs1, which are devoid of all known functional 
domains for helicase activity and DNA binding, suppress severely detrimental effects of 
BLM overexpression in yeast. 
 
Materials and Methods 
Yeast Strains and Media 
All strains are derived from KHSY802, a derivative of S288C. Yeast strains 
expressing truncations of Sgs1 helicase were constructed by homologous-
recombination-mediated integration of PCR products, replacing the desired 3’-segment 
of SGS1 on chromosome VIII with a myc-epitope coding sequence (from pFA6a-
13Myc.His3MX655, gift from Mark Longtine, University of Washington) in frame with the 
SGS1 coding sequence. Expression of all truncation alleles and the myc-epitope-tagged 
wildtype allele of SGS1 was confirmed by western blot analysis. All gene replacements, 
insertions and truncations were performed by the standard LiAc protocol [56], using 
PCR products with at least 50-nucleotides on each end that matched the chromosomal 
target locus. To express BLM from the native SGS1 promoter (PSGS1), a PCR 
fragment containing BLM cDNA (Open Biosystems) and a HIS3 cassette was amplified 
by PCR from plasmid pKHS293 using primers that include 50-nt homology to the 
chromosomal SGS1 locus. This PCR product was fused to the native chromosomal 
SGS1 promoter by homologous-recombination-mediated integration [56]. A PCR 
fragment coding for a 13Myc epitope tag was amplified from pFA6a-13Myc-kanMX6 55 
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and integrated in-frame at the 3’end of cDNAs or sgs1 alleles for detection of protein 
expression by western blot analysis. In strain KHSY3350 and KHSY3218, galactose-
inducible promoters amplified from plasmids pFA6a-kanMX6-PGAL1 or pFA6a-TRP1-
PGAL155, respectively, were used to replace the native SGS1 promoter. To construct 
KHSY3355, the 3’-terminal 2313 bp of BLM cDNA linked to a HIS3 cassette were 
amplified by PCR from plasmid pKHS293 and used to replace the 3’-terminal 2400 bp of 
SGS1 in KHSY802. The accuracy of PCR-derived SGS1 or BLM integrations was 
confirmed by sequencing. Amino acid changes C1047F and F1056A in Sgs1 were 
made by sitedirected mutagenesis (QuikChange, Stratagene) of pKHS360 and 
integrated at the sgs1::HIS3 locus in KHSY1338. All yeast strains used in this study are 
listed in Table S1 (Supplementary Information). Cells were grown in YPD consisting of 
10g/l yeast extract (Fisher Scientific), 20 g/l Bacto-peptone (BD Diagnostic Systems), 
2% glucose (Fisher Scientific), unless indicated otherwise. For plates, agar (BD 
Diagnostic Systems) was added at a concentration of 20 g/l. 
Western blot analysis 
To confirm expression of myc-epitope tagged BLM and SGS1 alleles, cells were 
grown to OD600 = 0.5 in YPD and whole cell extracts were prepared from 5 ml of 
culture (~ 3.5 × 107 cells) by standard trichloroacetic acid (TCA, Fisher Scientific) 
extraction [57]. Five microliters of TCA extract were separated on 10% polyacrylamide 
gels, transferred to a PVDF membrane (BioRad), probed with anti-c-myc monoclonal 
antibody (9E10, Covance Research Products) and visualized by chemiluminescence 
(ECL Plus, GE Healthcare). To confirm expression of SGS1 and BLM from the GAL1 
promoter the same western blot procedure was used, but cells were grown overnight in 
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YP ((10g/l yeast extract (Fisher Scientific), 20 g/l Bacto-peptone (BD Diagnostic 
Systems)) supplemented with 2% sucrose (Fisher Scientific), then diluted to OD600 = 0.2 
either in YP supplemented with 2% sucrose (uninduced sample) or 2% galactose 
(induced sample) and harvested for TCA extraction when cultures reached OD600 = 0.5. 
Molecular weight marker (Broad Range) was from BioRad. 
 
Sensitivity to DNA damaging agents HU and MMS 
Cell cultures were grown in YPD to OD600 = 0.5 and 10-fold serial dilutions were 
spotted on YPD supplemented with 0.05% methyl-methanesulfonate (MMS, Sigma 
Aldrich) or hydroxyurea (HU, US Biologicals) at 50 mM or 100 mM, as indicated. For 
experiments that included strains expressing BLM or Sgs1 from the GAL1 promoter 
(Figure 5), cultures were grown in YP-2% sucrose instead of YPD, and spotted on YP-1 
% sucrose + 1% galactose (to induce gene expression) supplemented with 100 mM HU, 
or without HU as the growth control. 
 
GCR rate measurements 
Rates of accumulating gross-chromosomal rearrangements (GCRs) in YPD were 
determined as previously described [58]. For GCR rate measurements of yeast strains 
expressing BLM or Sgs1 from the GAL1 promoter the same procedure was followed, 
except that media was supplemented with 2% galactose to induce gene expression. 
Briefly, 10 ml of YP-2% galactose were inoculated with a single colony, which had been 
grown on YPD agar for 3 days. After 3 days of growth in liquid media at 30° C with 
vigorous shaking, cells were plated on GCR plates 58 supplemented with 2% galactose 
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instead of 2% glucose, and 10−6 dilutions were plated on YPD to obtain the viable cell 
count. Colonies on GCR plates were counted after 5 days of incubation at 30° C. For 
GCR rate measurements in the presence of varying BLM expression levels (Table 2), 
0.1% or 0.5% galactose was added to liquid YP media and to GCR plates instead of 2% 
galactose, and sucrose was supplemented to reach a total of 2% sugar in the media. 
95% confidence intervals were calculated according to Nair [59]. 
 
Random Spore Analysis 
Diploids heterozygous for the desired mutant alleles were grown overnight at 
30°C in YPD, washed, transferred to 0.1% potassium acetate (Fisher Scientific) and 
incubated for 5 days at 30°C with vigorous shaking. Asci were incubated in the 
presence of zymolase (MP Biomedicals, 500 μg/ml) in 1 M sorbitol (Fisher Scientific) for 
20 min at 30°C and enriched for haploid spores as previously described [60]. Spores 
were plated on YPD, incubated at 30°C and genotyped by spotting on synthetic drop-
out media (US Biologicals) to detect the presence of TRP1 and HIS3 marker cassettes 
linked to the mutant alleles. Presence of mutant alleles linked to the kanMX6 cassette 
was detected by the ability of haploids to grow on YPD supplemented with 200 μg/ml 
G418 (Axxora LLC, San Diego, CA). 
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Results 
Requirement of the RQC domain of Sgs1, but not the HRDC domain, for 
GCR suppression 
Sgs1 contains a conserved DEAH helicase domain, a conserved helicase and 
RNaseD Cterminal (HRDC) domain, two acid regions (AR1, AR2) and a RecQ-
conserved (RQC) domain composed of zinc-binding and winged-helix domains. Several 
protein interaction sites have also been located in the 1447-amino-acid long protein 
(Figure A.1A). To determine the role of these domains in the maintenance of genome 
stability, systematic deletions to the 3’ end of the chromosomal SGS1 gene were 
generated, such that truncations of the C-terminus of Sgs1, ranging from 20 to 1428 
amino acids, were expressed as fusions to a myc epitope. Truncations of up to 80 
amino acids were constructed to not affect any known functional domain of Sgs1 while 
ΔC100 and ΔC200 deletions partially or completely, respectively, removed the HRDC 
domain and ΔC300 and ΔC400 deletions partially or completely removed the RQC 
domain. The largest deletions (ΔC700, ΔC800, ΔC900, ΔC1000 and ΔC1100) eliminate 
the entire helicase domain, including the Walker A motif (803–812 aa), with the ΔC800-
ΔC1100 deletions also affecting the part of the N-terminal half of Sgs1 that contains 
protein interaction sites (e.g., Rad16, residues 421–792; Top2, residues 432–724; Srs2, 
residues 422–722) and two acid regions (AR1, residues 321–447; AR2, residues 502–
648), whereas ΔC500 and ΔC600 deletions partially remove the helicase domain while 
leaving the Walker A motif intact (Figure 1A). All truncation alleles were stably 
expressed from the chromosomal SGS1 locus under control of the native SGS1 
promoter (Figure A.1B). C-terminal fusion to the myc-epitope did not adversely affect 
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Sgs1 function, as indicated by equal sensitivity to HU and MMS of strains expressing 
tagged and untagged Sgs1 (wildtype) (Figure 2A). The largest deletion, leaving intact 
only the 19 N-terminal amino acids of Sgs1 (sgs1ΔC1428), was as sensitive to HU and 
MMS as a complete SGS1 deletion (sgs1Δ), thus behaving like a null allele (Figure 
A.2A). Loss of up to 200 C-terminal amino acids did not increase sensitivity to HU or 
MMS, whereas loss of 300 or more amino acids led to sensitivity similar to that of the 
sgs1ΔC1428 and sgs1Δ mutants (Figure A.2A). The construction of additional 20-
amino-acid truncations extended the C-terminal region that is dispensable for HU/MMS 
resistance to 240 amino acids (Figure A.2B). 
It was previously shown that cells lacking the DNA helicase Srs2 (srs2Δ) depend 
on functional Sgs1 for their viability [61]. To assess the ability of sgs1 truncation alleles 
to support growth of the srs2Δ mutant, we constructed diploid strains heterozygous for 
the srs2Δ deletion and heterozygous for the sgs1ΔC200, sgs1ΔC260 or sgs1ΔC300 
alleles. The meiotic products of the sporulated diploids were spread on nonselective, 
rich media (YPD), allowing all spores to grow (Figure A.2C). Diploids heterozygous for 
the srs2Δ deletion and the sgs1ΔC200 truncation yielded spores that grew into colonies 
of the same size, suggesting that the C-terminal 200 amino acid residues of Sgs1, 
which harbor the HRDC domain and an interaction site with the homologous 
recombination factor Rad51, are not required for the viability of the srs2Δ mutant. In 
contrast, sporulation of diploids heterozygous for the srs2Δ deletion and sgs1ΔC260 or 
sgs1ΔC300 alleles yielded mixtures of normal-sized and small colonies. Genotyping 
revealed that the small colonies were srs2Δ sgs1ΔC260 or srs2Δsgs1ΔC300 mutants 
whereas the normal-sized colonies corresponded to wildtype spores or single mutants. 
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Thus, Sgs1 that lacks 260 or more C-terminal residues and therefore does not contain a 
complete RQC domain cannot support normal growth of cells lacking Srs2. When we 
tested the effect of the C-terminal deletions on the accumulation of GCRs, we found that 
the C-terminal 240 amino acids were dispensable for maintaining genome integrity, 
whereas deleting as little as an additional 20 amino acids (sgs1ΔC260) caused the 
GCR rate to increase to that exhibited by the null mutant without a discernable 
intermediate phenotype (Table A.1). Combining the sgs1ΔC300 truncation allele with a 
deletion of the DNA-damage checkpoint sensor MEC3 led to a synergistic GCR rate 
increase, while, as expected, combining the sgs1ΔC200 allele with a mec3Δ mutation 
did not. Thus, these findings show that the HRDC domain and the previously reported 
C-terminal interaction with Rad51 are not required for Sgs1’s role in preventing the 
accumulation of GCRs and supporting normal growth of the srs2Δ mutant, whereas the 
integrity of the RQC domain, which has been suggested to span amino acids 1075 to 
1207 based on the alignment of three-dimensional structures 62, is essential. 
 
Bloom’s Syndrome Associated RQC Domain Mutations Cause Loss of Sgs1 
Function in vivo 
Of the 32 exonic base substitutions that are causative of Bloom’s syndrome, 
thirteen are missense mutations [9; 13; 63; 64], with six of these mutations affecting 
conserved residues that have been shown in vitro to participate in zinc binding and G-
tetrad DNA binding activity (Figure A.3A). Studies, however, have been limited to 
biochemical and biophysical analyses of mutant proteins and were hampered by the 
inability to purify some mutant BLM proteins [16; 17; 65]. Since the cysteine residues 
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are highly conserved between RecQ-like helicases, including Sgs1, we replaced the 
corresponding cysteine residue in Sgs1 with the BS-associated mutation (sgs1-
C1047F). Unlike BLM with mutations in any of the three conserved cysteine residues 
C1036, C1063 or C1066, which degraded upon purification and could therefore not be 
characterized [65], the sgs1-C1047F mutant allele was stably expressed in vivo from 
the native SGS1 locus (Figure A.3B). The sgs1-C1047F mutant showed increased HU 
and MMS sensitivity, which, however, did not reach the level of the sgs1Δ allele, and 
exhibited levels of GCR accumulation comparable to the sgs1Δ mutant, demonstrating 
that the C1047F mutation severely impairs Sgs1 function (Figure A.3C, Table A.1). In 
addition to conserved cysteine residues and immediately adjoining arginine (R1037) 
and aspartic acid (D1064) residues, ClustalW2 alignments showed F1056 to be the only 
other fully conserved amino acid residue in the zinc-binding domain of Sgs1 (Figure 
3A). Although the corresponding residue in BLM (F1045) is not associated with a BS 
mutation, the BLMF1045A mutation has been shown to cause a severe helicase defect 
and ssDNA binding deficiency in vitro [65]. When we introduced the corresponding 
mutation into Sgs1 (F1056A), however, the mutant was no more sensitive to HU and 
MMS than wildtype cells (Figure A.3C), but instead appeared fully functional with a 
wildtype GCR rate (Table A.1). 
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Expression of human BLM cDNA from the endogenous SGS1 promoter 
does not complement Δsgs1 defects 
RecQ-like DNA helicases are evolutionarily conserved from bacteria to humans. 
Since cells from BS patients share defects seen in sgs1Δ cells, including increased 
sensitivity to DNA-damaging agents, increased levels of aberrant genetic exchange and 
reduced life-span, it has been suggested that RecQ-like DNA helicases from different 
phyla or even kingdoms might complement each other, thus allowing the development 
of simple model organisms for the functional and mutational characterization of disease-
associated human RecQ-like helicases, such as BLM and WRN [66]. Thus, to assess 
the ability of BLM to suppress genome instability in the sgs1Δ mutant, BLM cDNA was 
inserted in-frame with the start codon of SGS1 at its chromosomal locus (PSGS1BLM). 
We reasoned that insertion at the wildtype SGS1 locus would promote cell-cycle-
dependent regulation of BLM expression and expression levels similar to those 
previously shown for Sgs1 [67]. Stable expression of BLM was confirmed by western 
blot analysis, using a yeast strain expressing myc-tagged BLM (Figure A.4A); however, 
all subsequent experiments were carried out with untagged BLM. Expression of a single 
copy of BLM (PSGS1 BLM ) did not lead to a statistically significant difference in the 
GCR rate compared to the sgs1Δ mutant (Table A.1, Table A.2), or alleviate HU 
sensitivity (Figure A.4B), demonstrating that BLM can be successfully expressed in 
yeast under control of the native SGS1 promoter without detrimental effects on cell 
growth, but is unable to complement the tested sgs1Δ defects to any extent. 
 
195 
 
Overexpression of BLM leads to increased sensitivity to DNA damaging 
agents and rapid accumulation of GCRs 
Since a single copy of BLM (PSGS1BLM) did not complement Δsgs1 defects, we 
examined the effect of increasing BLM expression levels on sgs1Δ mutant phenotypes. 
For this purpose, the native SGS1 promoter was replaced with a GAL1 promoter and 
galactose-dependent expression of BLM was verified by fusing BLM to a myc-epitope 
tag (Figure A.4A). Overexpression of BLM did not compensate for the lack of Sgs1 
when cells were exposed to HU, but instead led to a further increase in sensitivity to HU 
compared to the sgs1ΔC1428 cells or cells expressing BLM under the SGS1 promoter 
(Figure A.4B). We found that maximum induction of BLM expression led to a 1665-fold 
increase in the GCR rate compared to wildtype and a 34-fold increase compared to the 
sgs1Δ mutant assayed under the same conditions (Table A.2). In contrast, 
overexpression of Sgs1 from the GAL1 promoter did not lead to GCR accumulation 
(Table A.2). The GCR rate increase upon BLM overexpression was dependent on 
induction levels, with the GCR rate gradually decreasing to that of the sgs1Δ mutant as 
the galactose concentration in the media decreased (Table A.2). Thus, sgs1Δ defects 
cannot be complemented by any level of BLM expression; in fact, increasing BLM 
expression levels induce higher sensitivity to DNA damaging agents and significantly 
higher genome instability compared to the sgs1Δ mutant. 
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N-terminus of Sgs1 suppresses detrimental effects of BLM overexpression 
Since Sgs1 is important for the suppression of illegitimate recombination 
between identical sequences, such as those found in related genes, on homologous 
chromosomes and sister chromatids, we tested HU sensitivity of diploid strains 
expressing truncated sgs1 alleles in the presence or absence of the SGS1 wildtype 
allele (Figure A.5). HU sensitivity was fully suppressed for all alleles if a single copy of 
wildtype SGS1 was expressed from the other allele (Figure A.5A), demonstrating that 
the sgs1 truncation alleles did not have a dominant effect. As in haploid cells, only the 
sgs1ΔC200 allele complemented HU sensitivity of the sgs1Δ diploid completely (Figure 
A.5B); however, cells expressing the sgs1ΔC300 to sgs1ΔC900 alleles were less 
sensitive than diploids that expressed larger truncations or the sgs1ΔC1428 null allele 
(Figure A.5B). This ability of sgs1Δ300 to sgs1ΔC900 truncation alleles to at least 
partially suppress HU sensitivity indicates that there may be N-terminal segments in 
Sgs1 that contribute to HU resistance. 
 Diploids expressing BLM from native SGS1 promoters on both alleles 
were as sensitive to HU as diploids not expressing Sgs1, whereas diploids 
overexpressing BLM from one allele or from both alleles were severely HU-sensitive, 
with the highest expression level lacking any growth on 100 mM HU (Figure A.5C), 
reflecting the severe HU sensitivity of haploid cells expressing the PGALBLM allele 
(Figure A.4B). Diploids overexpressing BLM also appeared to grow more slowly than 
any other diploid tested here (Figure A.5C). Remarkably, expression of a single copy of 
SGS1 from its endogenous promoter (SGS1/PGALBLM) completely eliminated the 
severe HU sensitivity conferred by overexpression of BLM. To determine if full-length 
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Sgs1 was required for this suppression, we crossed the haploid strain overexpressing 
BLM with haploids expressing various Sgs1 truncations. We found that a single copy of 
the sgs1ΔC200 allele was as sufficient as wildtype Sgs1 in suppressing HU sensitivity 
and slow growth of the BLM overexpressing strain, and as few as the N-terminal 547 
amino acids remaining in the sgs1ΔC900 allele were sufficient for significant 
suppression of HU sensitivity and slow growth caused by BLM overexpression (Figure 
A.5C). These findings suggest that none of the known enzymatic activities or functional 
and conserved domains are required for suppressing the HU sensitivity of the BLM 
overexpressing diploids, but that the N-terminal 547 amino acids are sufficient for 
suppressing the detrimental effects of BLM overexpression in a diploid. That the 
sgs1ΔC1000 and sgs1ΔC1100 alleles were clearly less effective at suppressing HU 
sensitivity shows that the N-terminal 447 amino acids, which contain the Top3 
interaction site, are necessary but not sufficient for complementation. 
 
Design of a functional Sgs1-BLM chimera 
Sgs1 and BLM share about 21% of their amino acid residues in a pair-wise 
alignment of the full-length proteins (ClustalW2), with most of the identical residues in 
the helicase domain. In fact, the N-terminal segment of Sgs1 expressed by the 
sgs1ΔC800 allele, which is able to suppress the HU sensitivity of BLM-overexpressing 
diploids, shares only 11% with the corresponding N-terminal segment of BLM. Devoid of 
conserved domains and known enzymatic activities, the N-terminus of Sgs1 has been 
shown to be required for physical interactions with Top3, Top2, Srs2 and Rad16 [6; 26-
30]. Using IUPred, an algorithm for the prediction of intrinsically disordered proteins, we 
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found that the N-terminal 650 residues contain a similar distribution of ordered and 
intrinsically disordered segments (Figure A.6A, B). In disorder prediction algorithms, 
such as IUPred [68; 69], a score of > 0.5 predicts a disordered amino acid residue and a 
score of < 0.5 predicts an ordered residue, with 30 consecutive disordered amino acids 
commonly being used as a lower limit for detecting disorder in whole proteome 
searches [68-71]. The helicase domains of Sgs1 and BLM coincide with the predicted 
ordered regions in both proteins, starting at around residue 648, and are surrounded by 
a long N-terminal and a short C-terminal segment, which contain mostly disordered 
residues. In fact, using the IUPred output scores, 83% of the 648 N-terminal residues of 
Sgs1 (538/648) are disordered, with 70% of all 648 residues being located in segments 
of more than 30 consecutive disordered residues, whereas only 16% of the C-terminal 
800 residues of Sgs1 are predicted to be disordered, with only a single disordered 
segment that is longer than 30 residues (residues 1396–1447). 
Based on the IUPred prediction, BLM can also be divided into a disordered N-
terminus and an ordered C-terminus (Figure A.6A, B). For BLM, 52% of the N-terminal 
648 residues are predicted to be disordered but only 15% of these residues are found in 
stretches of more than 30 disordered residues. The difference in the pattern of disorder 
predicted for the N-terminal segments of Sgs1 and BLM led us to hypothesize that this 
region may be involved in conferring species-specificity to BLM and Sgs1 function and, 
thus, prevent BLM from functioning in yeast. This hypothesis is supported by the fact 
that the N-terminus of Sgs1 is sufficient for complementation of the HU sensitivity 
induced by overexpression of BLM. To test this hypothesis, we constructed a yeast-
human chimera in which the N-terminal 647 residues of BLM were replaced by the N-
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terminal 647 residues of Sgs1 (sgs1ΔC800- blmΔN647) (Figure A.6C). To express this 
chimera from the native SGS1 promoter we replaced nucleotides 1941 to 4344 of the 
endogenous SGS1 gene with nucleotides 1941 to 4254 of BLM cDNA (Figure A.6E). 
Remarkably, the chimera was nearly as effective as wildtype SGS1 in conferring 
resistance to HU, whereas the N-terminal segment of Sgs1 by itself was ineffective 
(Figure A.6D). Moreover, when we combined the chimeric allele with a mec3Δ mutation, 
GCRs accumulated at a significantly lower rate than in the mec3Δ mutant carrying the 
GCR-deficient sgs1ΔC300 or sgs1ΔC800 alleles, albeit not at the low rate of the mec3Δ 
mutant carrying the GCR-proficient sgs1ΔC200 allele, signifying partial functionality of 
the chimerical protein in the suppression of chromosomal rearrangements (Table A.1). 
Finally, besides Srs2, the sgs1Δ mutant also requires the DNA helicase Rrm3 for 
viability. Synthetic lethality between sgs1Δ and rrm3Δ mutations is suppressed by 
disrupting HR factors such as Rad51 and Rad55, suggesting that the lethality is due 
accumulation of aberrant HR intermediates [72-74]. To assess if the Sgs1-BLM chimera 
was capable of preventing the accumulation of lethal levels of aberrant recombination 
intermediates we constructed a diploid heterozygous for the rrm3Δ mutation and 
heterozygous for the sgs1ΔC800-blmΔN647 allele, expressing the Sgs1-BLM chimera. 
Spreading of spores from this diploid on YPD, which allows all spores to grow, showed 
that the rrm3Δ mutant expressing the chimera grows normally with the diameter of 
double mutant colonies measuring approximately 90% of that of the single mutants 
(Figure A.6F). These findings indicate that the Sgs1-BLM chimera is functional and, 
while not capable of fully suppressing chromosomal rearrangements, prevents the 
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accumulation of lethal levels of aberrant recombination intermediates when Rrm3 
helicase is absent. 
 
Discussion 
Yeast cells that lack Sgs1 exhibit upregulated and aberrant recombination in 
mitosis, increased sensitivity to DNA damaging agents, accumulation of GCRs, 
synthetic lethality with mutations in other DNA metabolic genes, such as the SRS2 and 
RRM3 helicase genes, and meiotic defects that lead to poor spore viability [8; 30; 61; 
67; 73; 75-79]. Sgs1 contains several conserved domains (DEAD-helicase, RQC, 
HRDC, AR1 and AR2) and protein interaction sites (Top2, Top3, Srs2, Rad16, Rad51, 
Mlh1) have been identified by two-hybrid screens [27; 29; 30; 46; 80]. How the integrity 
of these conserved motifs and protein-protein interaction sites affects the role of Sgs1 in 
suppression of aberrant genome rearrangements has not been determined. The 
requirement of some domains and/or protein interaction sites, but not others, may shed 
light on the poorly understood mechanism(s) by which Sgs1 contributes to the 
maintenance of genome integrity in yeast. Here, we find that the C-terminal 240 amino-
acid segment, which contains Rad51 and Mlh1 interaction sites as well as the 
conserved HRDC domain thought to be involved in DNA binding and in recognition and 
processing of double Holliday junctions [20; 23], is dispensable for Sgs1’s role in 
suppressing GCRs. The integrity of the RQC domain, however, is essential for GCR 
suppression. That zinc-binding is crucial for Sgs1 activity, and loss of function of the 
Cterminal truncation allele was not due to disruption of protein structure/function 
because of such a large deletion, was further confirmed by the finding that the point 
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mutation of a conserved zinc-coordinating cysteine, which has also been observed in 
BS patients 64, led to loss of Sgs1’s ability to suppress HU sensitivity and GCR 
accumulation. This loss of function was not due to degradation of the mutant protein as 
had been previously observed for some cysteine mutants of BLM during attempts at 
overexpression and purification from E. coli. However, we cannot exclude the possibility 
that the loss of function resulted from intracellular mislocalization of the mutant protein. 
Previously, modeling of the zinc-binding domain of BLM and instability of purified mutant 
proteins had indicated that hydrogen bonds between three conserved residues, Y1029 
(Y1040 in Sgs1), R1037 (R1048 in Sgs1) and D1064 (D1070 in Sgs1), are required for 
folding of the zinc-binding domain and overall protein stability 17. Although F1056 of 
Sgs1 does not appear to be involved in this zinc-domain stabilization and the Sgs1-
F1056A mutant protein appears stable in this study, F1056 is the only other fully 
conserved residue in the zinc-binding domain of RecQ-like helicases, suggesting 
functional significance. However, introduction of the F1056A mutation had no effect on 
Sgs1 function in vivo when we assessed HU sensitivity, consistent with a previous study 
81, or GCR accumulation. That in a previous in vitro study 65 the corresponding BLM 
mutation (F1045A) had severely impaired helicase and ssDNA binding activities could 
either be due to differences in the importance of this residue for enzymatic activity of 
BLM and Sgs1 or, more likely, be due to the fact that only the helicase-core segment of 
BLM, lacking 769 residues of N- and C-termini, was purified. The in vitro function of this 
isolated domain could be more strongly affected by a mutation than the in vivo function 
of the full-length Sgs1 mutant protein assessed here. Although nearly half of all BLM 
alleles that are associated with single-amino-acid changes (7 of 17 alleles) in BS 
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patients are located in the RQC domain [9; 13; 63; 64] none affect F1045, consistent 
with our finding that mutation of this conserved residue may not be associated with 
significant loss of function in vivo. 
We find that Sgs1 retains partial functionality even when it lacks the HRDC, RQC 
and DEAH helicase domains, as demonstrated by the greater HU resistance of diploids 
that only express the N-terminal 547 amino acid residues compared to those alleles 
expressing fewer than 447 residues of Sgs1. One explanation for this finding could be 
that protein-protein interactions conferred by the N-terminus could contribute to the 
structural stability of multi-protein complexes, such as the Sgs1/Top3/Rmi1 31 complex 
or, even more relevant to HU resistance, DNA-damage-specific complexes with Srs2 
and Mre11 [29]. In these multi-protein complexes, enzymatic activity of Sgs1 may be 
dispensable. Indeed, sgs1 alleles with point mutations in the helicase domain have 
been shown to be capable of performing some functions of the wildtype allele, including 
those carried out during meiosis and checkpoint activation [79; 82]. 
In contrast to two previous reports [66; 83], which both used the same yeast 
strain that constitutively expressed BLM from a GAPDH promoter and showed partial 
suppression of some sgs1Δ defects, including HU sensitivity, we found that neither BLM 
expression under control of the natural SGS1 promoter nor varying levels of BLM 
expression under control of a galactose-inducible promoter had any positive effect on 
the sgs1Δ mutant. That a single copy of BLM, when expressed under control of the 
native SGS1 promoter, cannot alleviate sgs1Δ defects initially suggested to us that BLM 
had no functionality in yeast. In fact, the strong increase in genome instability, 
accompanied by severe HU sensitivity and some growth retardation upon 
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overexpression of BLM, indicated that BLM expression is detrimental to yeast cells. The 
absence of any GCR accumulation upon Sgs1 overexpression suggests that increased 
accumulation of GCRs in BLM overexpressing cells is not simply due to increased 
unwinding. Rather, we propose that BLM may possess helicase activity in yeast, leading 
to increased unwinding upon overexpression, but fails to elicit proper downstream 
responses, for example due to lack of proper N-terminal protein-protein interactions, 
which ultimately leads to an overabundance of aberrantly repaired lesions. That 
endogenous levels of N-terminal segments of Sgs1 as short as 547 residues 
suppressed the slow growth phenotype and the severe HU sensitivity of BLM-
overexpressing cells argues in favor of a functional relationship between Sgs1 and 
BLM. For example, co-expression of Sgs1 and BLM could alleviate HU sensitivity in 
BLM overexpressing cells by acting as a bridge between BLM and Top3 (and/or other 
protein complexes interacting with the Sgs1 N-terminus), thereby linking enzymatic 
activity to appropriate upstream and downstream events. Remarkably, even relatively 
short N-terminal fragments of Sgs1 are sufficient for the suppression of the increased 
HU sensitivity of BLM-overexpressing cells, further supporting the importance of the 
Sgs1 N-terminus with its role in mediating interaction with other DNA metabolic factors. 
HU resistance comparable to wildtype cells and significantly reduced GCR 
accumulation of cells expressing a chimeric fusion of the Sgs1 N-terminus, which is 
devoid of enzymatic function and dispensable for helicase activity and ssDNA binding in 
vitro, and the BLM C-terminus, which contains helicase/RQC and HRDC domains, is 
consistent with helicase activity of BLM in yeast and a biologically significant, functional 
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interaction between BLM and Sgs1. That not only fusion of the Sgs1 and BLM 
segments provides HU resistance, but also co-expression of BLM and Sgs1 
polypeptides from separate alleles in the same cell may indicate that the N-terminus of 
Sgs1 can physically interact with BLM. Our findings also suggest that it is the inability of 
the N-terminus of BLM to interact with or be modified by yeast proteins that leads to the 
inability of BLM to function in yeast. A previous report that BLM expression in yeast 
alleviates several sgs1Δ phenotypes, including partial suppression of HU sensitivity 
[66;83], could be explained by the fact that in the earlier study BLM was expressed from 
a GAPDH promoter, whereas here it was expressed either from the native SGS1 
promoter or from a galactose-inducible promoter. However, in light of the findings 
presented here, there could also be an alternative explanation. Since the GAPDH-
promoter-BLM construct appears to have been inserted into the middle of the wildtype 
SGS1 gene, an N-terminal segment of Sgs1 could have been expressed from the native 
SGS1 promoter in addition to BLM being expressed from the GAPDH promoter. As 
shown here for haploids expressing the chimera and for diploids coexpressing the N-
terminus of Sgs1 and full length BLM, such co-expression of an Sgs1-N-terminal 
segment from the native SGS1 promoter and BLM from the GAPDH promoter could be 
the an explanation for the reported increase in HU resistance of BLM-expressing cells 
compared to sgs1Δ cells. 
Of the five human RecQ-like DNA helicases, BLM is considered to be most 
closely related to Sgs1. Even though we show here that BLM cannot suppress any 
defects of the sgs1Δ mutant, the functional chimera does provide evidence for a 
functional relationship between the two RecQ-like helicases and provides a model 
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system for the further characterization of BLM functional domains in yeast. In fact, all 
BS-associated missense mutations and numerous polymorphisms are located within the 
770-residue C-terminal fragment of BLM that is part of the chimera, so that they are now 
accessible to further functional and mutational characterization in yeast. The in vivo 
functionality of the Sgs1-BLM chimera also demonstrates the remarkable utility of 
protein disorder prediction as a tool for the construction of functional mutants. It will be 
interesting to see whether domains of any of the other human RecQ-like helicases will, 
like BLM, be able to form functional chimeras with the Sgs1 N-terminus. 
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Figure A.1. C-terminal truncations of Sgs1 used in this study. (A) Full-length Sgs1 
contains a DEAH helicase domain, an RQC domain and an HRDC domain in its C-
terminal half and acidic regions AR1 and AR2 in its N-terminal half; interaction sites with 
Top3, Top2, Srs2, Rad51 and Rad16 are indicated. C-terminal truncations ranging in 
size from 200 residues to 1428 residues were constructed by fusion to a myc-epitope 
tag. All truncations were introduced at the endogenous SGS1 locus on chromosome 
VIII. (B) Expression of wildtype Sgs1 and truncation alleles from the endogenous SGS1 
promoter (PSGS1) was confirmed by western blotting, using a myc-antibody. Molecular 
weights (MW) are indicated on the left. 
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Figure A.2. Sensitivity of cells expressing Sgs1 truncation alleles to the DNA 
damaging agents HU and MMS. Ten-fold dilutions of exponentially growing cultures 
(OD600 = 0.5) were spotted on YPD for viable cell count and on YPD containing 
100mM HU or 0.05% MMS, followed by incubation at 30° C. (A) Haploid cells 
expressing sgs1 alleles lacking 300 or more residues from the C-terminus are as 
sensitive to HU and MMS as the null allele. (B). Additional incremental 20-amino-acid 
deletions reveal that cells expressing sgs1 alleles lacking up to 240 residues are as 
resistant to HU and MMS as wildtype cells whereas those lacking 260 or more residues 
are as sensitive as the sgs1Δ mutant. (C) Spores from diploids heterozygous for an 
srs2Δ deletion and heterozygous either for the sgs1-ΔC200, sgs1Δ-C260 or sgs1- 
ΔC300 were spread on YPD to allow for growth of spores of all possible genotypes. 
Similar sized colonies obtained from the spores of the diploid heterozygous for 
sgs1ΔC200 and srs2Δ mutations (left) indicate that the sgs1ΔC200 srs2Δ mutant grows 
as well as the single mutants, suggesting that deletion of the C-terminal 200 amino acid 
residues does not negatively affect growth of the srs2Δ mutant. In contrast, spores from 
diploids heterozygous for the srs2Δ mutation and the sgs1ΔC260 allele (middle) or the 
sgs1ΔC300 allele (right), grew into a mixture of normal-sized colonies (corresponding to 
single mutants and wildtype) and small-sized colonies (corresponding to srs2Δ 
sgs1ΔC260 or srs2Δ sgs1ΔC300 mutants as determined by genotyping), demonstrating 
that an intact RQC domain in Sgs1 is required for the viability of the srs2Δ mutant. 
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Figure A.3. Effect of zinc-binding domain mutations on Sgs1 function in vivo. (A) 
Zinc-binding domain is conserved from bacterial to human RecQ-like DNA helicases. 
Protein sequences were aligned with ClustalW2 84. The alignment of RecQL1 was 
manually adjusted. Amino acid residues identical in all sequences are highlighted in 
gray and indicated by '*' below the alignment, conserved substitutions are indicated by 
':' below the alignment, and cysteine residues thought to be involved in zinc-binding are 
shown in red. At least six different missense mutations in the zinc-binding domain are 
associated with Bloom’s syndrome. (B) C1047F and F1056A mutations were introduced 
into Sgs1 and expression was confirmed by western blot using antibody against the C-
terminal myc-epitope. Molecular weights (MW) are indicated in kDa to the left. (C) 
Mutation of the highly conserved F1056 does not impair Sgs1 function whereas the 
C1047F mutation leads to an increase in sensitivity to HU and MMS, but not to the level 
seen in the sgs1Δ mutant. 
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Figure A.4. BLM expression does not suppress sgs1Δ defects and BLM 
overexpression is detrimental to yeast cells. (A) Expression of myc-epitope tagged 
Sgs1 (lane 1) and BLM (lane 2) from the native chromosomal SGS1 locus or galactose-
inducible overexpression of myc-epitope tagged Sgs1 (lane 4) and BLM (lane 6) in 
yeast cells grown in YP supplemented with 1% sucrose and 1% galactose (to induce 
expression, lanes 4 and 6) or without galactose (lanes 3 and 5). Both BLM and Sgs1 
show signs of degradation upon overexpression (lanes 4 and 6) whereas expression 
from the native SGS1 promoter is stable (lanes 1 and 2). Molecular weights (MW) are 
indicated in kDa on the left. (B) Cells expressing BLM from the SGS1 promoter on 
chromosome VIII are as sensitive to HU as cells lacking Sgs1 (Δsgs1). Replacement of 
the natural SGS1 promoter with a galactose-inducible GAL1 promoter induces BLM 
overexpression and leads to increased HU sensitivity. Ten-fold dilutions of cells were 
spotted on media containing 1% sucrose and 1% galactose (to induce BLM 
overexpression) with and without 100 mM HU. 
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Figure A.5. HU sensitivity of diploid cells expressing BLM and mutant alleles of 
SGS1. (A) Ten-fold dilutions of exponentially growing diploids expressing truncation 
alleles of SGS1 in the presence of a wildtype allele were spotted on YPD media with 
and without 100 mM HU. (B) Ten-fold dilutions of exponentially growing diploids 
expressing truncation alleles of SGS1 in the absence of a wildtype allele were spotted 
on YPD media with and without 100 mM HU. (C) Ten-fold dilutions of exponentially 
growing diploids overexpressing BLM from a GAL1 promoter inserted at the native 
SGS1 locus and expressing truncation alleles of SGS1 under control of the native SGS1 
promoter on the other allele were spotted on media containing 1% galactose (to induce 
gene expression) and 1% sucrose with or without 100 mM HU. 
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Figure A.6. Construction of a functional chimerical protein composed of the N-
terminus of Sgs1 and the C-terminus of BLM. (A – B) Protein disorder prediction of 
Sgs1 (red) and BLM (black) using the IUPred algorithm. Values above 0.5 indicate a 
disordered residue whereas values below 0.5 indicate ordered residues; amino acid 
residue numbers (1–1447) are indicated on the abscissa. Black lines above the graph 
show a simplified order and disorder distribution along the length of the protein with 
values above 0.5 being assigned a “1” and values below 0.5 being assigned a “0”. The 
vertical red line indicates the site in Sgs1, BLM and the chimera where the disordered 
N-terminal segment transitions into the ordered helicase domain at residue 647/648. 
This site was chosen as the fusion site for the chimera. The approximate location of 
Sgs1 domains is indicated above panel A. (C) Disorder prediction for the Sgs1-BLM 
chimera in which the N-terminal 647 residues of BLM (black) were replaced with the N-
terminal 647 residues of Sgs1 (red). (D) Ten-fold dilutions of exponentially growing 
haploids were spotted on YPD with or without 100 mM HU. (E) The C-terminus of the 
Sgs1-BLM chimera was fused to a myc-epitope tag and expression was confirmed by 
western blotting. Molecular weight marker bands (kD) are indicated on the left (F) A 
diploid heterozygous for the rrm3Δ mutation and the sgs1ΔC800-blmΔN647 allele 
expressing the chimera was sporulated and random spores were plated on YPD to 
allow all spores to grow. An open circle indicates the haploid double mutant, and the 
open square and pentagon indicate haploid sgs1ΔC800-blmΔN647 and rrm3Δ single 
mutants, respectively. 
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Table A.1. 
          Accumulation of GCRs in cells expressing mutant alleles of SGS1 
Relevant Genotype 
GCR rate (Canr 5-FOAr × 10− 
10) 
95% CIb (Canr 5-FOAr × 
10− 10) 
Wild type 1.1 < 1–6.2 
sgs1Δ 251 80–310 
sgs1ΔC200 7 < 6–23 
sgs1ΔC220 31 5–41 
sgs1ΔC240 10 < 6–27 
sgs1ΔC260 159 85–362 
sgs1ΔC280 244 166–387 
sgs1ΔC300 145 76–204 
sgs1ΔC400 106 60–180 
sgs1ΔC500 102 53–252 
sgs1ΔC600 152 26–283 
sgs1ΔC700 189 49–271 
sgs1ΔC800 133 71–225 
sgs1ΔC1428 206 97–273 
sgs1-C1047F 64 35–131 
sgs1-F1056A   < 16 < 10–26 
mec3Δsgs1ΔC200 11 < 7–22 
mec3Δsgs1ΔC300 1003 691–1500 
mec3Δsgs1ΔC800 758 645–895 
mec3Δsgs1ΔC800-
blmΔN647 c 361 330–419 
i 
All sgs1 truncations (sgs1ΔC) are C-terminally fused to a myc-epitope tag. 
ii 
95% confidence intervals (CI) were calculated according to Nair [59]. 
c 
The sgs1ΔC800-blmΔN647 allele expresses a chimeric protein that consists of the N-
terminal 647 residues of Sgs1 and the C-terminal 770 residues of human BLM. 
 
 
 
 
218 
 
 
 
 
 
 
 
Table A.2. 
           Effect of BLM expression on GCR accumulation in the sgs1Δ 
mutant 
 
Relevant genotype 
Galactose 
concentration in 
media (%) 
GCR rate (Canr 
5-FOAr × 10− 
10) 
95% CIb (Canr 
5-FOAr × 10− 
10) 
Wild type 0 1.1 < 1–6.2 
PSGS1BLM 0 70 56–151 
PGALBLM 0 61 30–153 
PGALBLM 0.1 335 233–576 
PGALBLM 0.5 382 170–777 
PGALBLM 2 1832 1090–2910 
PGALSGS1 2 < 11 < 9–12 
sgs1Δ 2 54 23–104 
 
1 
Human BLM cDNA was inserted at the endogenous SGS1 locus, fused to the native 
SGS1 promoter (PSGS1) or fused to a galactose-inducible promoter (PGAL). In 
PGALSGS1, the native SGS1 promoter region was disrupted by fusing the SGS1 ORF 
to a galactose-inducible promoter. If strains expressing BLM or SGS1 genes from the 
galactose-inducible GAL1 promoter were grown in less than 2% galactose (to lower 
protein expression levels) media was supplemented with sucrose to reach a total sugar 
concentration of 2%. 
2 
95% confidence intervals (CI) were calculated according to Nair [59]. 
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TABLE A.3: Yeast strains used in this study 
Strain Genotype 
KHSY802 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1, 
ade8, YEL069C::URA3 
KHSY1338 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1, 
ade8, YEL069C::URA3, sgs1::HIS3 
KHSY1705 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1, 
ade8, YEL069C::ura3::TRP1, sgs1::BLM.HIS3 
KHSY2341 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1, 
ade8, YEL069C::URA3, mec3::kanMX6, sgs1ΔC200.MYC.HIS3 
KHSY2347 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1, 
ade8, YEL069C::URA3, mec3::kanMX6, sgs1ΔC300.MYC.HIS3 
KHSY2599 ura3-52/ura3-52, leu2Δ1/ leu2Δ1, trp1Δ63/trp1Δ63, his3Δ200/his3Δ200, 
lys2ΔBgl/ lys2ΔBgl, hom3-10/ hom3-10, ade2Δ1/ade2Δ1, ade8/ade8, 
YEL069C::URA3/YEL069C::URA3 
KHSY2602 ura3-52/ura3-52, leu2Δ1/ leu2Δ1, trp1Δ63/trp1Δ63, his3Δ200/his3Δ200, 
lys2ΔBgl/ lys2ΔBgl, hom3-10/ hom3-10, ade2Δ1/ade2Δ1, ade8/ade8, 
YEL069C::ura3::TRP1/YEL069C::ura3::TRP1, 
sgs1::kanMX6/sgs1::kanMX6 
KHSY2726 ura3-52/ura3-52, leu2Δ1/ leu2Δ1, trp1Δ63/trp1Δ63, his3Δ200/his3Δ200, 
lys2ΔBgl/ lys2ΔBgl, hom3-10/ hom3-10, ade2Δ1/ade2Δ1, ade8/ade8, 
YEL069C::URA3/YEL069C::URA3, SGS1/sgs1C200.MYC.HIS3 
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Table A.3: Yeast strains used in this study (Continued) 
KHSY2828 ura3-52/ura3-52, leu2Δ1/ leu2Δ1, trp1Δ63/trp1Δ63, his3Δ200/his3Δ200, 
lys2ΔBgl/ lys2ΔBgl, hom3-10/ hom3-10, ade2Δ1/ade2Δ1, ade8/ade8, 
YEL069C::URA3/YEL069C::ura3::TRP1, 
sgs1::kanMX6/sgs1C200.MYC.HIS3 
KHSY2837 ura3-52/ura3-52, leu2Δ1/ leu2Δ1, trp1Δ63/trp1Δ63, his3Δ200/his3Δ200, 
lys2ΔBgl/ lys2ΔBgl, hom3-10/ hom3-10, ade2Δ1/ade2Δ1, ade8/ade8, 
YEL069C::URA3/YEL069C::ura3::TRP1, 
sgs1::kanMX6/sgs1C300.MYC.HIS3 
KHSY2880 ura3-52/ura3-52, leu2Δ1/ leu2Δ1, trp1Δ63/trp1Δ63, his3Δ200/his3Δ200, 
lys2ΔBgl/ lys2ΔBgl, hom3-10/ hom3-10, ade2Δ1/ade2Δ1, ade8/ade8, 
YEL069C::URA3/YEL069C::URA3, SGS1/sgs1ΔC300.MYC.HIS3 
KHSY2883 ura3-52/ura3-52, leu2Δ1/ leu2Δ1, trp1Δ63/trp1Δ63, his3Δ200/his3Δ200, 
lys2ΔBgl/ lys2ΔBgl, hom3-10/ hom3-10, ade2Δ1/ade2Δ1, ade8/ade8, 
YEL069C::URA3/YEL069C::URA3, SGS1/sgs1ΔC400.MYC.HIS3 
KHSY2886 ura3-52/ura3-52, leu2Δ1/ leu2Δ1, trp1Δ63/trp1Δ63, his3Δ200/his3Δ200, 
lys2ΔBgl/ lys2ΔBgl, hom3-10/ hom3-10, ade2Δ1/ade2Δ1, ade8/ade8, 
YEL069C::URA3/YEL069C::URA3, SGS1/sgs1ΔC500.MYC.HIS3 
KHSY2889 ura3-52/ura3-52, leu2Δ1/ leu2Δ1, trp1Δ63/trp1Δ63, his3Δ200/his3Δ200, 
lys2ΔBgl/ lys2ΔBgl, hom3-10/ hom3-10, ade2Δ1/ade2Δ1, ade8/ade8, 
YEL069C::URA3/YEL069C::URA3, SGS1/sgs1ΔC600.MYC.HIS3 
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Table A.3: Yeast strains used in this study (Continued) 
KHSY2892 ura3-52/ura3-52, leu2Δ1/ leu2Δ1, trp1Δ63/trp1Δ63, his3Δ200/his3Δ200, 
lys2ΔBgl/ lys2ΔBgl, hom3-10/ hom3-10, ade2Δ1/ade2Δ1, ade8/ade8, 
YEL069C::URA3/YEL069C::URA3, SGS1/sgs1ΔC700.MYC.HIS3 
KHSY2895 ura3-52/ura3-52, leu2Δ1/ leu2Δ1, trp1Δ63/trp1Δ63, his3Δ200/his3Δ200, 
lys2ΔBgl/ lys2ΔBgl, hom3-10/ hom3-10, ade2Δ1/ade2Δ1, ade8/ade8, 
YEL069C::URA3/YEL069C::URA3, SGS1/sgs1ΔC800.MYC.HIS3 
KHSY2898 ura3-52/ura3-52, leu2Δ1/ leu2Δ1, trp1Δ63/trp1Δ63, his3Δ200/his3Δ200, 
lys2ΔBgl/ lys2ΔBgl, hom3-10/ hom3-10, ade2Δ1/ade2Δ1, ade8/ade8, 
YEL069C::URA3/YEL069C::URA3, SGS1/sgs1ΔC1428.MYC.HIS3 
KHSY2928 ura3-52/ura3-52, leu2Δ1/ leu2Δ1, trp1Δ63/trp1Δ63, his3Δ200/his3Δ200, 
lys2ΔBgl/ lys2ΔBgl, hom3-10/ hom3-10, ade2Δ1/ade2Δ1, ade8/ade8, 
YEL069C::URA3/YEL069C::ura3::TRP1, 
sgs1::kanMX6/sgs1ΔC400.MYC.HIS3 
KHSY2931 ura3-52/ura3-52, leu2Δ1/ leu2Δ1, trp1Δ63/trp1Δ63, his3Δ200/his3Δ200, 
lys2ΔBgl/ lys2ΔBgl, hom3-10/ hom3-10, ade2Δ1/ade2Δ1, ade8/ade8, 
YEL069C::URA3/YEL069C::ura3::TRP1, 
sgs1::kanMX6/sgs1ΔC500.MYC.HIS3 
KHSY2934 ura3-52/ura3-52, leu2Δ1/ leu2Δ1, trp1Δ63/trp1Δ63, his3Δ200/his3Δ200, 
lys2ΔBgl/ lys2ΔBgl, hom3-10/ hom3-10, ade2Δ1/ade2Δ1, ade8/ade8, 
YEL069C::URA3/YEL069C::ura3::TRP1, 
sgs1::kanMX6/sgs1ΔC600.MYC.HIS3 
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Table A.3: Yeast strains used in this study (Continued) 
KHSY2937 ura3-52/ura3-52, leu2Δ1/ leu2Δ1, trp1Δ63/trp1Δ63, his3Δ200/his3Δ200, 
lys2ΔBgl/ lys2ΔBgl, hom3-10/ hom3-10, ade2Δ1/ade2Δ1, ade8/ade8, 
YEL069C::URA3/YEL069C::ura3::TRP1, 
sgs1::kanMX6/sgs1ΔC700.MYC.HIS3 
KHSY2940 ura3-52/ura3-52, leu2Δ1/ leu2Δ1, trp1Δ63/trp1Δ63, his3Δ200/his3Δ200, 
lys2ΔBgl/ lys2ΔBgl, hom3-10/ hom3-10, ade2Δ1/ade2Δ1, ade8/ade8, 
YEL069C::URA3/YEL069C::ura3::TRP1, 
sgs1::kanMX6/sgs1ΔC800.MYC.HIS3 
KHSY2943 ura3-52/ura3-52, leu2Δ1/ leu2Δ1, trp1Δ63/trp1Δ63, his3Δ200/his3Δ200, 
lys2ΔBgl/ lys2ΔBgl, hom3-10/ hom3-10, ade2Δ1/ade2Δ1, ade8/ade8, 
YEL069C::URA3/YEL069C::ura3::TRP1, 
sgs1::kanMX6/sgs1ΔC1428.MYC.HIS3 
KHSY2970 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1, 
ade8, YEL069C::URA3, sgs1.MYC.HIS3 
KHSY2972 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1, 
ade8, YEL069C::URA3, sgs1ΔC200.MYC.HIS3 
KHSY2973 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1, 
ade8, YEL069C::URA3, sgs1ΔC300.MYC.HIS3 
KHSY2974 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1, 
ade8, YEL069C::URA3, sgs1ΔC400.MYC.HIS3 
KHSY2975 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1, 
ade8, YEL069C::URA3, sgs1ΔC500.MYC.HIS3 
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Table A.3: Yeast strains used in this study (Continued) 
KHSY2976 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1, 
ade8, YEL069C::URA3, sgs1ΔC600.MYC.HIS3 
KHSY2977 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1, 
ade8, YEL069C::URA3, sgs1ΔC700.MYC.HIS3 
KHSY2978 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1, 
ade8, YEL069C::URA3, sgs1ΔC800.MYC.HIS3 
KHSY2979 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1, 
ade8, YEL069C::URA3, sgs1ΔC1428.MYC.HIS3 
KHSY3181 ura3-52/ura3-52, leu2Δ1/ leu2Δ1, trp1Δ63/trp1Δ63, his3Δ200/his3Δ200, 
lys2ΔBgl/ lys2ΔBgl, hom3-10/ hom3-10, ade2Δ1/ade2Δ1, ade8/ade8, 
YEL069C::URA3/YEL069C::URA3, SGS1/sgs1ΔC1100.MYC.HIS3 
KHSY3218 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1, 
ade8, YEL069C::URA3, TRP1.PGAL1.SGS1 
KHSY3332 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1, 
ade8, YEL069C::URA3, sgs1::BLM.HIS3 
KHSY3346 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1, 
ade8, YEL069C::ura3::TRP1, BLM.MYC.kanMX6.HIS3 
KHSY3350 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1, 
ade8, YEL069C::URA3, kanMX6.PGAL1.BLM.HIS3 
KHSY3353 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1, 
ade8, YEL069C::URA3, kanMX6.PGAL1.BLM.HIS3 
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Table A.3: Yeast strains used in this study (Continued) 
KHSY3355 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1, 
ade8, YEL069C::URA3, sgs1ΔC800-blmΔN647.HIS3 
KHSY3363 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1, 
ade8, YEL069C::URA3, sgs1ΔC800-blmΔN647.HIS3, Δmec3::kanMX6 
KHSY3372 ura3-52/ura3-52, leu2Δ1/ leu2Δ1, trp1Δ63/trp1Δ63, his3Δ200/his3Δ200, 
lys2ΔBgl/ lys2ΔBgl, hom3-10/ hom3-10, ade2Δ1/ade2Δ1, ade8/ade8, 
YEL069C::URA3/YEL069C::URA3, sgs1::BLM.HIS3/sgs1::BLM.HIS3 
KHSY3409 ura3-52/ura3-52, leu2Δ/leu2Δ , trp1Δ63/ trp1Δ63, his3Δ200/his3Δ200, 
lys2ΔBgl/ys2ΔBgl, hom3-10/hom3-10, ade2Δ1/ade2Δ1, ade8/ade8, 
YEL069C::URA3/YEL069C::URA3, 
kanMX6.PGAL1.BLM.HIS3/SGS1.MYC.HIS3 
KHSY3410 ura3-52/ura3-52, leu2Δ/leu2Δ , trp1Δ63/ trp1Δ63, his3Δ200/his3Δ200, 
lys2ΔBgl/ys2ΔBgl, hom3-10/hom3-10, ade2Δ1/ade2Δ1, ade8/ade8, 
YEL069C::URA3/YEL069C::URA3, 
kanMX6.PGAL1.BLM.HIS3/sgs1ΔC200.MYC.HIS3 
KHSY3412 ura3-52/ura3-52, leu2Δ/leu2Δ , trp1Δ63/ trp1Δ63, his3Δ200/his3Δ200, 
lys2ΔBgl/ys2ΔBgl, hom3-10/hom3-10, ade2Δ1/ade2Δ1, ade8/ade8, 
YEL069C::URA3/YEL069C::URA3, 
kanMX6.PGAL1.BLM.HIS3/sgs1ΔC300.MYC.HIS3 
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Table A.3: Yeast strains used in this study (Continued) 
KHSY3414 ura3-52/ura3-52, leu2Δ/leu2Δ , trp1Δ63/ trp1Δ63, his3Δ200/his3Δ200, 
lys2ΔBgl/ys2ΔBgl, hom3-10/hom3-10, ade2Δ1/ade2Δ1, ade8/ade8, 
YEL069C::URA3/YEL069C::URA3, 
kanMX6.PGAL1.BLM.HIS3/sgs1ΔC400.MYC.HIS3 
KHSY3416 ura3-52/ura3-52, leu2Δ/leu2Δ , trp1Δ63/ trp1Δ63, his3Δ200/his3Δ200, 
lys2ΔBgl/ys2ΔBgl, hom3-10/hom3-10, ade2Δ1/ade2Δ1, ade8/ade8, 
YEL069C::URA3/YEL069C::URA3, 
kanMX6.PGAL1.BLM.HIS3/sgs1ΔC500.MYC.HIS3 
KHSY3417 ura3-52/ura3-52, leu2Δ/leu2Δ , trp1Δ63/ trp1Δ63, his3Δ200/his3Δ200, 
lys2ΔBgl/ys2ΔBgl, hom3-10/hom3-10, ade2Δ1/ade2Δ1, ade8/ade8, 
YEL069C::URA3/YEL069C::URA3, 
kanMX6.PGAL1.BLM.HIS3/sgs1ΔC600.MYC.HIS3 
KHSY3419 ura3-52/ura3-52, leu2Δ/leu2Δ , trp1Δ63/ trp1Δ63, his3Δ200/his3Δ200, 
lys2ΔBgl/ys2ΔBgl, hom3-10/hom3-10, ade2Δ1/ade2Δ1, ade8/ade8, 
YEL069C::URA3/YEL069C::URA3, 
kanMX6.PGAL1.BLM.HIS3/sgs1ΔC700.MYC.HIS3 
KHSY3420 ura3-52/ura3-52, leu2Δ/leu2Δ , trp1Δ63/ trp1Δ63, his3Δ200/his3Δ200, 
lys2ΔBgl/ys2ΔBgl, hom3-10/hom3-10, ade2Δ1/ade2Δ1, ade8/ade8, 
YEL069C::URA3/YEL069C::URA3, 
kanMX6.PGAL1.BLM.HIS3/sgs1ΔC800.MYC.HIS3 
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Table A.3: Yeast strains used in this study (Continued) 
KHSY3422 ura3-52/ura3-52, leu2Δ/leu2Δ , trp1Δ63/ trp1Δ63, his3Δ200/his3Δ200, 
lys2ΔBgl/ys2ΔBgl, hom3-10/hom3-10, ade2Δ1/ade2Δ1, ade8/ade8, 
YEL069C::URA3/YEL069C::URA3, 
kanMX6.PGAL1.BLM.HIS3/sgs1ΔC900.MYC.HIS3 
KHSY3423 ura3-52/ura3-52, leu2Δ/leu2Δ , trp1Δ63/ trp1Δ63, his3Δ200/his3Δ200, 
lys2ΔBgl/ys2ΔBgl, hom3-10/hom3-10, ade2Δ1/ade2Δ1, ade8/ade8, 
YEL069C::URA3/YEL069C::URA3, 
kanMX6.PGAL1.BLM.HIS3/sgs1ΔC1000.MYC.HIS3 
KHSY3424 ura3-52/ura3-52, leu2Δ/leu2Δ , trp1Δ63/ trp1Δ63, his3Δ200/his3Δ200, 
lys2ΔBgl/ys2ΔBgl, hom3-10/hom3-10, ade2Δ1/ade2Δ1, ade8/ade8, 
YEL069C::URA3/YEL069C::URA3, 
kanMX6.PGAL1.BLM.HIS3/sgs1ΔC1100.MYC.HIS3 
KHSY3425 ura3-52/ura3-52, leu2Δ/leu2Δ , trp1Δ63/ trp1Δ63, his3Δ200/his3Δ200, 
lys2ΔBgl/ys2ΔBgl, hom3-10/hom3-10, ade2Δ1/ade2Δ1, ade8/ade8, 
YEL069C::URA3/YEL069C::URA3, 
kanMX6.PGAL1.BLM.HIS3/sgs1ΔC1428.MYC.HIS3 
KHSY3426 ura3-52/ura3-52, leu2Δ/leu2Δ , trp1Δ63/ trp1Δ63, his3Δ200/his3Δ200, 
lys2ΔBgl/ys2ΔBgl, hom3-10/hom3-10, ade2Δ1/ade2Δ1, ade8/ade8, 
YEL069C::URA3/YEL069C::URA3, 
kanMX6.PGAL1.BLM.HIS3/kanMX6.PGAL1.BLM.HIS3 
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Table A.3: Yeast strains used in this study (Continued) 
KHSY3429 ura3-52/ura3-52, leu2Δ1/ leu2Δ1, trp1Δ63/trp1Δ63, his3Δ200/his3Δ200, 
lys2ΔBgl/ lys2ΔBgl, hom3-10/ hom3-10, ade2Δ1/ade2Δ1, ade8/ade8, 
YEL069C::URA3/YEL069C::ura3::TRP1, 
sgs1::kanMX6/sgs1ΔC1100.MYC.HIS3 
KHSY3470 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1, 
ade8, YEL069C::URA3, sgs1ΔC220.MYC.HIS3 
KHSY3473 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1, 
ade8, YEL069C::URA3, sgs1ΔC240.MYC.HIS3 
KHSY3476 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1, 
ade8, YEL069C::URA3, sgs1ΔC260.MYC.HIS3 
KHSY3479 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1, 
ade8, YEL069C::URA3, sgs1ΔC280.MYC.HIS3 
KHSY3500 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1, 
ade8, YEL069C::URA3, sgs1ΔC900.MYC.HIS3 
KHSY3502 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1, 
ade8, YEL069C::URA3, sgs1ΔC1000.MYC.HIS3 
KHSY3504 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1, 
ade8, YEL069C::URA3, sgs1ΔC1100.MYC.HIS3 
KHSY3510 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1, 
ade8, YEL069C::URA3, TRP1.PGAL1. SGS1.MYC.HIS3 
KHSY3512 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1, 
ade8, YEL069C::URA3, sgs1-C1047F.TRP1 
228 
 
Table A.3: Yeast strains used in this study (Continued) 
KHSY3516 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1, 
ade8, YEL069C::URA3, sgs1-F1056A.TRP1 
KHSY3517 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1, 
ade8, YEL069C::URA3, sgs1-C1047F.MYC.HIS3 
KHSY3520 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1, 
ade8, YEL069C::URA3, sgs1-F1056A.MYC.HIS3 
KHSY3523 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1, 
ade8, YEL069C::URA3, kanMX6.PGAL1.BLM.MYC.TRP1.HIS3 
KHSY3528 ura3-52/ura3-52, leu2Δ1/ leu2Δ1, trp1Δ63/trp1Δ63, his3Δ200/his3Δ200, 
lys2ΔBgl/ lys2ΔBgl, hom3-10/ hom3-10, ade2Δ1/ade2Δ1, ade8/ade8, 
YEL069C::URA3/YEL069C::ura3::TRP1, 
sgs1::kanMX6/sgs1ΔC1000.MYC.HIS3 
KHSY3534 ura3-52/ura3-52, leu2Δ1/ leu2Δ1, trp1Δ63/trp1Δ63, his3Δ200/his3Δ200, 
lys2ΔBgl/ lys2ΔBgl, hom3-10/ hom3-10, ade2Δ1/ade2Δ1, ade8/ade8, 
YEL069C::URA3/YEL069C::ura3::TRP1, 
sgs1::kanMX6/sgs1ΔC900.MYC.HIS3 
KHSY3536 ura3-52/ura3-52, leu2Δ1/ leu2Δ1, trp1Δ63/trp1Δ63, his3Δ200/his3Δ200, 
lys2ΔBgl/ lys2ΔBgl, hom3-10/ hom3-10, ade2Δ1/ade2Δ1, ade8/ade8, 
YEL069C::URA3/YEL069C::URA3, SGS1/sgs1ΔC1000.MYC.HIS3 
KHSY3539 ura3-52/ura3-52, leu2Δ1/ leu2Δ1, trp1Δ63/trp1Δ63, his3Δ200/his3Δ200, 
lys2ΔBgl/ lys2ΔBgl, hom3-10/ hom3-10, ade2Δ1/ade2Δ1, ade8/ade8, 
YEL069C::URA3/YEL069C::URA3, SGS1/sgs1ΔC900.MYC.HIS3 
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Table A.3: Yeast strains used in this study (Continued) 
KHSY3543 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1, 
ade8. YEL069C::URA3, sgs1ΔC800-blmΔN647.MYC.TRP1 
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APPENDIX B: 
 
NMR DATA 
 
 
 
Table B1: Peak assignments for Sgs1 N1-125 peptide 
Residue 
Number Residue H HN CA CB 
1 M 
    2 V 8.21988 122.3445 62.3294 32.91862 
3 T 8.22853 119.026 61.76092 69.8252 
4 K 8.33585 125.4552 54.21737 32.62978 
5 P N/A N/A 63.02 32.21 
6 S 8.36899 115.9146 58.29224 63.82262 
7 H 
    8 N 
    9 L 8.19468 122.5807 55.48658 42.32477 
10 R 8.28251 122.1783 56.49396 30.52714 
11 R 
    12 E 
    13 H 
    14 K 
    15 W 
    16 L 7.90041 123.5679 55.17055 42.47335 
17 K 8.06267 121.7686 56.57215 32.96658 
18 E 
    19 T 8.04 114.57 62.1205 69.6257 
20 A 8.2848 126.2067 52.82452 19.27114 
21 T 8.042 113.5352 62.00811 69.79695 
22 L 
 8.20142    
124.57117 124.5712 55.31136 42.28904 
23 Q 8.329 121.3023 56.0418 29.3875 
24 E 
  
56.8542 30.5093 
        25 D 8.335 121.6091 54.5717 41.1865 
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Table B1: Peak assignments for Sgs1 N1-125 peptide   (Continued) 
 
26 K 8.2065 121.5207 57.0863 32.7918 
27 D 8.26583 120.1133 54.91777 41.10337 
28 F 7.96111 120.5838 58.7914 39.41052 
29 V 7.83837 121.8131 63.23366 32.5935 
30 F 8.13081 122.8441 58.80898 39.36015 
31 Q 8.10104 121.0846 56.29585 29.31666 
32 A 8.0602 124.3929 53.1189 18.90968 
33 I 7.95223 119.4848 61.86297 38.55723 
34 Q 8.20301 122.9763 56.26645 29.1325 
35 K 
    36 H 
  
56.6091 30.5955 
37 I 7.98315 122.1882 61.41187 38.63476 
38 A 8.26634 127.0843 52.79229 19.19498 
39 N 
    40 K 8.12 121.49 56.2169 32.95 
41 R 8.26615 123.4053 54.00874 
 42 P N/A N/A 63.01 32.31 
43 K 8.47766 122.0044 56.45931 33.05701 
44 T 8.14235 115.244 61.56435 69.71656 
45 N 
  
52.83696 38.78605 
46 S 
  
56.50993 63.42659 
47 P 
    48 P 
    49 T 
    50 T 8.16 118.78 54.59 41.2 
51 P N/A N/A 63.04 39.01 
52 S 8.44744 116.8972 58.21897 63.95412 
53 K 8.43197 123.4124 56.67553 32.972 
54 D 8.2693 120.9317 54.6034 41.1861 
55 E 8.2659 121.222 56.6222 30.2675 
56 C 8.33404 119.5746 58.50417 28.30785 
57 G 8.2578 110.8407 44.69437 
 58 P N/A N/A 63.56 32.1 
59 G 8.51983 109.4864 45.40379 
 60 T 7.9646 113.204 
  61 T 
    62 N 
  
53.1974 
 63 F 8.0905 120.8059 57.8361 
 64 I 8.0588 122.8569 61.0498 38.7329 
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Table B1: Peak assignments for Sgs1 N1-125 peptide (Continued) 
65 T 8.13716 118.0419 61.6789 69.62651 
66 S 8.19 118.5 57.96791 64.03301 
67 I 8.14958 124.2996 58.65614 38.70634 
68 P N/A N/A 63.17 32.11 
69 A 
    70 S 8.22905 114.6649 58.1819 64.03219 
71 G 8.16959 110.6062 44.67143 
 72 P N/A N/A 
  73 T 8.28 113.97 61.86 69.7 
74 N 
    75 T 8.1234 114.4951 
  76 A 8.26019 126.4146 52.79309 19.33326 
77 T 8.06419 113.6282 62.13061 69.70393 
78 K 8.26435 123.6846 56.3553 32.92902 
79 Q 
    80 H 
    81 E 
  
56.728 30.5256 
82 V 8.17 121.25 62.6101 56.728 
83 M 
    84 Q 
    85 T 8.17685 115.9563 61.94339 69.68748 
86 L 8.25404 124.6848 55.16385 42.39013 
87 S 8.23658 116.2874 58.19368 63.84549 
88 N 8.41612 120.698 53.35475 38.95899 
89 D 8.30018 120.5722 54.77021 41.1655 
90 T 8.03624 113.6258 62.31408 69.52244 
91 E 8.32668 123.086 57.37228 29.98405 
92 W 8.01026 120.9964 57.7331 29.16892 
93 L 7.83456 122.8286 55.60242 42.37008 
94 S 7.95789 115.3333 58.62363 63.59823 
95 Y 7.96941 121.879 58.30853 38.75819 
96 T 7.92071 115.502 61.87001 69.80556 
97 A 8.12105 126.2384 52.8683 19.27598 
98 T 8.01092 112.2691 61.84889 69.65426 
99 S 
    100 N 8.23843 117.7062 53.1433 38.91206 
101 Q 8.22509 120.3727 56.30673 29.22771 
102 Y 8.07296 120.253 57.5453 38.5643 
103 A 7.93554 124.7221 52.4258 19.67012 
104 D 8.22067 119.5048 54.25103 41.13511 
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Table B1: Peak assignments for Sgs1 N1-125 peptide (Continued) 
 
 
105 V 7.90708 121.1807 59.67993 32.80018 
106 P N/A N/A 62.5757 
 107 M 8.21988 122.3445 56.36728 32.91862 
108 V 8.02629 120.714 61.93245 33.12821 
109 D 8.31981 123.9739 54.21426 41.31996 
110 I 
    111 P N/A N/A 63.09 32.15 
112 A 8.4098 124.753 52.59244 19.25044 
113 S 8.30954 114.9381 58.36703 63.77139 
114 T 8.1277 115.3548 61.7155 69.656 
115 S 8.1623 117.4504 58.3601 63.7295 
116 V 8.11231 122.2318 62.34681 32.73477 
117 V 8.17994 124.1036 62.21606 32.7663 
118 S 8.33011 119.8839 58.13893 63.73322 
119 N 
    120 P N/A N/A 63.27 32.14 
121 R 8.38416 120.6465 56.16673 30.7691 
122 T 8.08281 116.708 59.55571 69.56049 
123 P N/A N/A 63.66 32.11 
124 N 8.4193 118.3227 53.33006 39.16951 
125 G 7.84815 115.3577 46.22267 
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Table B2: Peak assignments for Sgs1 N1-80 peptide 
Residue 
Number Residue H HN CA CB 
1 M 
  
55.3785 32.8186 
2 V 8.21 122.31 62.28 32.87 
3 T 8.23151 119.0454 61.7235909 69.80896 
4 K 8.33908 125.4415 54.1603394 32.6217995 
5 P N/A N/A 63.0794182 83.009697 
6 S 8.37255 115.8686 58.2680206 63.7881699 
7 H 
    8 N 
  
53.3577805 38.7228394 
9 L 8.19247 122.5594 55.4583092 42.2596207 
10 R 8.25 121.46 56.1738 30.5 
11 R 8.27 122.21 56.26 30.68 
12 E 
    13 H 
    14 K 
   
32.7890816 
15 W 8.01492 121.0278 57.1287804 29.399929 
16 L 7.89708 123.5431 55.1884117 42.4949112 
17 K 8.05774 121.7429 56.566761 32.9739304 
18 E 8.41845 121.5595 56.8657 30.219 
19 T 8.03966 114.5798 61.9319115 69.7065277 
20 A 8.28776 126.295 52.65 19.2876396 
21 T 8.04672 113.706 61.9318314 69.7565918 
22 L 8.20583 124.5754 55.31213 42.2676888 
23 Q 8.33352 121.3175 55.8962097 29.42 
235 
 
Table B2: Peak assignments for Sgs1 N1-80 peptide (Continued) 
24 E 8.43 121.98 56.63 30.45 
25 D 8.34 121.64 54.5437508 41.1975098 
26 K 8.20896 121.5487 57.0044098 32.8010292 
27 D 8.26834 120.1106 54.9319 41.0997314 
28 F 7.96073 120.5829 58.7588997 39.3948593 
29 V 7.8332 121.7531 63.1692696 32.5655403 
30 F 8.13168 122.9027 58.7493401 39.359169 
31 Q 8.0996 121.1583 56.244709 29.3470402 
32 A 8.06327 124.4081 53.1120911 18.0088692 
33 I 7.94951 119.468 61.8188896 38.5292702 
34 Q 8.21003 123.063 56.2424812 29.1556606 
35 K 8.1676 121.789 56.89 32.9058 
36 H 
  
56.6144295 30.5993195 
37 I 7.96672 122.2637 61.3540916 38.6244011 
38 A 8.26951 127.1183 52.7955513 19.1597309 
39 N 8.2482 117.7394 53.2123 38.8374 
40 K 8.1294 121.5962 56.1281 32.9709015 
41 R 8.27519 123.4202 54.0261688 30.1029 
42 P N/A N/A 62.956459 32.2294 
43 K 8.48149 122.0392 56.4200401 33.0219688 
44 T 8.15418 115.3279 61.4978905 69.9117432 
45 N 8.32 121.0177 53.08 38.94 
46 S 8.24 117.72 56.57 63.14 
47 P N/A N/A 
  48 P N/A N/A 63.0189781 32.0674896 
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Table B2: Peak assignments for Sgs1 N1-80 peptide (Continued) 
49 T 8.23617 114.3647 61.68 69.8253784 
50 T 8.16683 118.8081 59.6694298 69.7886505 
51 P N/A N/A 63.0924911 32.2289505 
52 S 8.44991 116.8439 58.2057915 63.8908081 
53 K 8.43316 123.4211 56.6177711 32.9634895 
54 D 8.27 120.98 54.6 41.2 
55 E 8.27 121.13 56.64 30.33 
56 C 8.34 119.62 58.4585609 28.2946396 
57 G 8.26367 110.7965 43.9230804 
 58 P N/A N/A 63.5016594 32.0774689 
59 G 8.52181 109.4896 45.3688393 
 60 T 7.96866 113.2012 61.8311691 69.9331436 
61 T 8.18 115.94 61.9390488 69.6863632 
62 N 
  
53.1432495 
 63 F 8.09147 120.8253 57.8064499 39.4358597 
64 I 8.064 122.95 61.06 38.63 
65 T 8.13863 118.1441 61.7212601 69.6549683 
66 S 8.2 118.54 58.05 63.7762413 
67 I 8.15659 124.3697 58.6881409 38.7136688 
68 P N/A N/A 63.1273804 32.1472511 
69 A 8.41648 124.7613 52.5667801 19.2261391 
70 S 8.2387 114.7023 58.1207008 64.0062027 
71 G 8.1787 110.6324 83.009697 63.99 
72 P N/A N/A 63.2068481 32.2116318 
73 T 8.29179 114.0037 61.8410492 69.7118683 
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Table B2: Peak assignments for Sgs1 N1-80 peptide (Continued) 
74 N 8.43 121.4487 53.1906 38.7594 
75 T 8.12689 114.5378 61.9174118 69.5784836 
76 A 8.29 126.4438 52.7818794 19.3586197 
77 T 8.07365 113.5912 61.8951683 69.7438736 
78 K 8.25609 124.0322 56.1994705 33.1184387 
79 Q 8.39793 122.5607 55.9633102 29.68297 
80 H 7.9755 125.3586 57.1394 30.5982 
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APPENDIX C: 
 
PERMISSIONS 
 
 
Figure C3: Permissions for text content from chapter 3. 
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Figure C4: Permission for figures/tables in chapter 3. 
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Figure C5: Permissions for content in appendix A. 
 
 
 
 
 
